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A B S T R A C T
Background
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy of childhood. Untreated, this incurable disease, which
has an X-linked recessive inheritance, is characterised by muscle wasting and loss of walking ability, leading to complete wheelchair
dependence by 13 years of age. Prolongation of walking is a major aim of treatment. Evidence from randomised controlled trials (RCTs)
indicates that corticosteroids significantly improve muscle strength and function in boys with DMD in the short term (six months),
and strength at two years (two-year data on function are very limited). Corticosteroids, now part of care recommendations for DMD,
are largely in routine use, although questions remain over their ability to prolong walking, when to start treatment, longer-term balance
of benefits versus harms, and choice of corticosteroid or regimen.
We have extended the scope of this updated review to include comparisons of different corticosteroids and dosing regimens.
Objectives
To assess the effects of corticosteroids on prolongation of walking ability, muscle strength, functional ability, and quality of life in
DMD; to address the question of whether benefit is maintained over the longer term (more than two years); to assess adverse events;
and to compare efficacy and adverse effects of different corticosteroid preparations and regimens.
Search methods
On 16 February 2016 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, EMBASE, CINAHL
Plus, and LILACS. We wrote to authors of published studies and other experts. We checked references in identified trials, handsearched
journal abstracts, and searched trials registries.
Selection criteria
We considered RCTs or quasi-RCTs of corticosteroids (e.g. prednisone, prednisolone, and deflazacort) given for a minimum of three
months to patientswith a definiteDMDdiagnosis.We considered comparisons of different corticosteroids, regimens, and corticosteroids
versus placebo.
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Data collection and analysis
The review authors followed standard Cochrane methodology.
Main results
We identified 12 studies (667 participants) and two new ongoing studies for inclusion. Six RCTs were newly included at this update and
important non-randomised cohort studies have also been published. Some important studies remain unpublished and not all published
studies provide complete outcome data.
Primary outcome measure: one two-year deflazacort RCT (n = 28) used prolongation of ambulation as an outcome measure but data
were not adequate for drawing conclusions.
Secondary outcomemeasures:meta-analyses showed that corticosteroids (0.75mg/kg/day prednisone or prednisolone) improvedmuscle
strength and function versus placebo over six months (moderate quality evidence from up to four RCTs). Evidence from single trials
showed 0.75 mg/kg/day superior to 0.3 mg/kg/day on most strength and function measures, with little evidence of further benefit at 1.5
mg/kg/day. Improvements were seen in time taken to rise from the floor (Gowers’ time), timed walk, four-stair climbing time, ability
to lift weights, leg function grade, and forced vital capacity. One new RCT (n = 66), reported better strength, function and quality of
life with daily 0.75 mg/kg/day prednisone at 12 months. One RCT (n = 28) showed that deflazacort stabilised muscle strength versus
placebo at two years, but timed function test results were too imprecise for conclusions to be drawn.
One double-blind RCT (n = 64), largely at low risk of bias, compared daily prednisone (0.75mg/kg/day) with weekend-only prednisone
(5 mg/kg/weekend day), finding no overall difference in muscle strength and function over 12 months (moderate to low quality
evidence). Two small RCTs (n = 52) compared daily prednisone 0.75 mg/kg/day with daily deflazacort 0.9 mg/kg/day, but study
methods limited our ability to compare muscle strength or function.
Adverse effects: excessive weight gain, behavioural abnormalities, cushingoid appearance, and excessive hair growth were all previously
shown to be more common with corticosteroids than placebo; we assessed the quality of evidence (for behavioural changes and weight
gain) as moderate. Hair growth and cushingoid features were more frequent at 0.75 mg/kg/day than 0.3 mg/kg/day prednisone.
Comparing daily versus weekend-only prednisone, both groups gained weight with no clear difference in body mass index (BMI) or
in behavioural changes (low quality evidence for both outcomes, one study); the weekend-only group had a greater linear increase in
height. Very low quality evidence suggested less weight gain with deflazacort than with prednisone at 12 months, and no difference in
behavioural abnormalities. Data are insufficient to assess the risk of fractures or cataracts for any comparison.
Non-randomised studies support RCT evidence in showing improved functional benefit from corticosteroids. These studies suggest
sustained benefit for up to 66 months. Adverse effects were common, although generally manageable. According to a large comparative
longitudinal study of daily or intermittent (10 days on, 10 days off ) corticosteroid for a mean period of four years, a daily regimen
prolongs ambulation and improves functional scores over the age of seven, but with a greater frequency of side effects than an intermittent
regimen.
Authors’ conclusions
Moderate quality evidence from RCTs indicates that corticosteroid therapy in DMD improves muscle strength and function in the
short term (twelve months), and strength up to two years. On the basis of the evidence available for strength and function outcomes,
our confidence in the effect estimate for the efficacy of a 0.75 mg/kg/day dose of prednisone or above is fairly secure. There is no
evidence other than from non-randomised trials to establish the effect of corticosteroids on prolongation of walking. In the short term,
adverse effects were significantly more common with corticosteroids than placebo, but not clinically severe. A weekend-only prednisone
regimen is as effective as daily prednisone in the short term (12 months), according to low to moderate quality evidence from a single
trial, with no clear difference in BMI (low quality evidence). Very low quality evidence indicates that deflazacort causes less weight gain
than prednisone after a year’s treatment. We cannot evaluate long-term benefits and hazards of corticosteroid treatment or intermittent
regimens from published RCTs. Non-randomised studies support the conclusions of functional benefits, but also identify clinically
significant adverse effects of long-term treatment, and a possible divergence of efficacy in daily and weekend-only regimens in the longer
term. These benefits and adverse effects have implications for future research and clinical practice.
P L A I N L A N G U A G E S U M M A R Y
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Review question
Is there new evidence for benefit from corticosteroids for prolongation of walking, and improving muscle strength and functional
abilities in Duchenne muscular dystrophy (DMD), particularly over the long term (more than two years)? Are different corticosteroids,
or different regimens equally effective, with similar side effect profiles?
Background
DMD is an incurable disease beginning in childhood that almost exclusively affects boys. Muscle wasting and loss of walking lead to
wheelchair dependence and early death. Randomised controlled trials (RCTs) have shown that corticosteroids improve muscle strength
and function for up to six months and strength up to two years (evidence on function at two years is limited). Data from other study
types suggest that corticosteroids produce better function over a five-year period in many patients. Overall, long-term benefit remains
unclear, and has to be weighed against long-term side effects. It is also unclear whether different corticosteroids differ greatly in side
effects. Earlier versions of this review found insufficient evidence to determine whether an intermittent regimen is as effective as a daily
regime, or produces fewer side effects.
Study characteristics
We found 12 studies of corticosteroid treatment in DMD, involving a total of 667 randomised boys; two other studies are ongoing.
Among the 12 completed studies, the treatments were: a corticosteroid versus inactive medicine (placebo) (in nine trials); daily versus
weekend-only prednisone (in one trial); and deflazacort versus prednisone (in three trials). Some studies included more than one
comparison; some were not fully reported or provided results that could not be analysed.
Key results and quality of the evidence
One trial, a two-year study comparing a corticosteroid (deflazacort) with placebo, assessed the effects of corticosteroids on the ability
to continue walking, but the data were not suitable for analysis. Most studies did not report ability to continue walking.
At the usual 0.75 mg/kg/day dose, corticosteroids improved muscle strength and function over six months compared to placebo. These
results are based on combined data (up to 152 participants) from four trials, which provided moderate quality evidence. Improvements
were seen in timed tests (eg. timed walk or run, time to stand, stair climb), ability to lift weights, a leg function grade, and a measure
of the strength of muscles used in breathing. Evidence from single trials showed 0.75 mg/kg/day prednisone to be superior to 0.3 mg/
kg/day on most strength and function tests, with little evidence of greater benefit at 1.5 mg/kg/day. Changes in appearance and hair
growth were more common at 0.75 mg/kg/day than 0.3 mg/kg/day.
One RCT (n = 66) also reported better strength, function and quality of life at 12 months with daily 0.75 mg/kg/day prednisone. The
two-year RCT, which had 28 participants, showed that deflazacort stabilised muscle strength for up to two years compared to placebo.
This study did not show benefit on timed tests at two years; however, these results are imprecise and at high risk of bias, with less than
half the original participants contributing data.
One trial found that changes in muscle strength and function were similar with daily and weekend-only prednisone regimens over a
12-month period (low to moderate quality evidence).
Two small RCTs compared daily prednisone 0.75 mg/kg/day with daily deflazacort 0.9 mg/kg/day, but trial methods did not allow
comparisons of muscle strength or function.
Previous versions of this review have found adverse events such as excessive weight gain, abnormal behaviour, changes in appearance,
and abnormal hair growth to be more common with corticosteroids than with placebo.We assessed the quality of evidence for abnormal
behaviour and weight gain for this review and found it to be moderate. The newer study of daily versus weekend-only prednisone
showed that both groups gained weight. The body mass index (BMI; a measure of weight for height) did not show any clear difference
between the regimens (low quality evidence). The weekend-only group had a greater increase in height. According to very low quality
evidence from two studies, deflazacort appeared to cause less weight gain at one year than prednisone, and no significant difference in
numbers with behaviour change. Data were insufficient to assess the risk of fractures or cataracts.
The evidence is up to date to February 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Corticosteroids versus placebo for Duchenne muscular dystrophy
Patient or population: pat ients with Duchenne muscular dystrophy
Setting: outpat ient
Intervention: cort icosteroids
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk or score/ value
with placebo
Risk or score/ value
with corticosteroids
Prolongat ion of t ime to
loss of ambulat ion - not
reported
See comment See comment Not est imable - - An outcome measure in
one 2-year trial (n = 28)
. The trial reported a
13-month prolongat ion
of walking with def laza-
cort among boys who
became wheelchair-de-
pendent, but stat ist i-
cal analysis was f lawed
as it did not take ac-
count of part icipants
st ill walking at study
end
Mean change in aver-
age muscle score: pred-
nisone - daily dose reg-
imen (0.75 mg/ kg/ day)
Assessed with: MRC
scale (higher indicates
stronger)
Follow-up: 6 months
The mean change in
average muscle score
was 4.73 units1
The mean change in av-
erage muscle score in
the intervent ion group
was 0.52 units more (0.
33 more to 0.71 more)
- 147
(3 RCTs)2
⊕⊕⊕©
M oderate3
The average muscle
score (MRC scale) also
showed a clear dif f er-
ence in favour of cor-
t icosteroid at 0.3 mg/
kg/ day and 1.5 mg/ kg/
day. For other strength
outcomes see text
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Nine-metre walking/
running t ime: pred-
nisone - daily dose reg-
imen (0.75 mg/ kg/ day)
Assessed with: sec-
onds
Follow-up: 6 months
The mean nine-metre
walking/ running t ime
was 9.1 seconds4
The mean nine-metre
walking/ running t ime in
the intervent ion group
was 2.73 seconds
quicker (3.97 quicker to
1.50 quicker)
- 111
(3 RCTs)5
⊕⊕⊕©
M oderate3
For other funct ional
outcomes and cort icos-
teroid doses, see text
4-stair climbing t ime:
prednisone - daily dose
regimen (0.75 mg/ kg/
day)
Assessed with: sec-
onds
Follow-up: 6 months
The mean 4-stair climb-
ing t ime was 7.40 sec-
onds
The mean 4-stair climb-
ing t ime in the inter-
vent ion group was 3.09
seconds quicker (4.33
quicker to 1.85 quicker)
- 152
(4 RCTs)6
⊕⊕⊕©
M oderate3
For other funct ional
outcomes and cort icos-
teroid doses, see text
Mean % weight gain:
prednisone - daily dose
regimen (0.75 mg/ kg/
day)
Follow-up: 6 months8
The mean %weight gain
was 6.95 %
The mean % weight
gain in the intervent ion
group was 9.27% more
(6.87% more to 11.68%
more)
- 126
(2 RCTs)7
⊕⊕⊕©
M oderate3
For other prednisone
doses, see text. 1.
09% more weight gain
reported with def laza-
cort (2 mg/ kg alternate
days) than with placebo
(mean gain 25.5%)
Behavioural changes -
prednisone (0.75 mg/
kg/ day)
Follow-up: 6 months
500 per 1000 695 per 1000
(470 to 1000)
RR 1.39
(0.94 to 2.06)
135
(2 RCTs)
⊕⊕⊕©
M oderate3
For other doses, see
text
Fractures
Follow-up: 6 months
1 part icipant receiving def lazacort had a patho-
logical f racture of t ibia. An arm f racture occurred
in the placebo group of a prednisone trial and
a traumatic f racture of femur occurred in the
placebo phase of a cross-over prednisone trial
- 143
(3 RCTs)
- None of the included
studies measured bone
densitometry. A 6-
month trial is too short
to adequately assess
long-term side ef fects.
Other trials did not com-
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ment on the occurrence
of f ractures
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; M RC: Medical Research Council; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Mean of mean control group values.
2Two addit ional trials (6 and 12 months’ durat ion), which could not be included in the meta-analysis, also demonstrated
improvements in muscle strength over placebo with daily or interm it tent prednisone 0.75 mg/ kg/ day - see text for details
(Beenakker 2005; Hu 2015).
3Single downgrading for unclear risk of allocat ion bias and possible publicat ion bias.
4Mean of the mean control group values at 6 months f rom Griggs 1991, Hu 2015 and Mendell 1989 (data are not provided in
Rahman 2001 report).
5Two addit ional trials (6 and 12 months’ durat ion), which could not be included in the meta-analysis, also demonstrated
improvements in t imed walk over placebo with daily or interm it tent prednisone 0.75 mg/ kg/ day - see text for details (Beenakker
2005; Hu 2015).
6An addit ional 6-month trial, which could not be included in the meta-analysis, also demonstrated improvements in 4-stair
climb over placebo with interm it tent prednisone (0.75 mg/ kg/ day given for the f irst 10 days of every month for six months) -
see text for details (Beenakker 2005; Hu 2015).
7Two addit ional trials (6 and 12 months’ durat ion), which could not be included in the meta-analysis, monitored weight during
daily or interm it tent prednisone 0.75 mg/ kg/ day; no clear dif f erence was present between groups at six months (interm it tent
dosing) or a year; however these results were imprecise - see text for details (Beenakker 2005; Hu 2015).
8For details of other dosages and the def lazacort versus placebo comparison see the review text.
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B A C K G R O U N D
Description of the condition
Duchenne muscular dystrophy (DMD), which has an incidence
of 1 in 3500 to 1 in 5000 male live births (Emery 1991; Mendell
2012), is the most common muscular dystrophy of childhood.
Boys withDMD present in the first five years of life with abnormal
gait, inability to run, and difficulty in rising from the floor. Un-
treated, the combination of muscle weakness and contractures of
the tendo Achilles and iliotibial bands leads to loss of independent
walking at a mean age of 9.5 years (range 7 to 13 years). Before
corticosteroids were routinely used, once these boys become con-
stant wheelchair users, over 50% developed scoliosis. Subclinical
cardiomyopathy is very common, but this becomes symptomatic
only in about 20% of patients, often in the second decade of life
(Frankel 1976; Ishikawa 1995; Ishikawa 1999; Muntoni 2003).
The late teen years are marked by progression of respiratory mus-
cle weakness, nocturnal hypoventilation, respiratory failure, and
death in late teens or twenties in untreated patients. No curative
treatment for DMD is known, but the quality of life and com-
fort of the patient can be improved by symptomatic physiother-
apeutic and medical treatments (Bushby 2003; Dubowitz 1995;
Emery 2003; Heckmatt 1989). Provision of respiratory support,
with ventilator use at the appropriate stage, can prolong survival
into the fourth decade (Eagle 2002; Eagle 2007; Gomez-Merino
2002; Jeppesen 2003).
The DMD gene locus is at Xp21 and codes for a protein named
dystrophin (Hoffman 1987). Depending on the type of mutation
in the dystrophin gene, there may be a severe reduction or absence
of dystrophin in muscle, resulting in DMD (Koenig 1989). Dys-
trophin localises at the cytoplasmic side of the sarcolemma and
binds to a glycoprotein complex (Matsumura 1993; Matsumura
1994;Mendell 1995). This dystrophin-glycoprotein complex pro-
vides a link between the cytoskeleton of the muscle fibre and the
extracellular matrix. Lack of dystrophin compromises this link
and is postulated to lead to muscle fibre degeneration (Deconinck
2007; Petrof 1993; Petrof 1998).
Although DMD is not primarily an immune-mediated disease,
some evidence raises the possibility that humoral and cellular im-
mune responses contribute to the pathological processes. This in-
cludes invasion of necrotic muscle fibres by macrophages and cy-
totoxic T-cells (Arahata 1984), complement activation with de-
position of membrane attack complexes on necrotic fibres, and
expression of HLA class I antigens on the dystrophic muscle fi-
bres (Engel 1982), making them susceptible to T-cell mediated
damage. Initial empirical studies of prednisone in DMD (e.g.
Drachman 1974) and the above histopathological observations
led to trials of immunomodulation therapy with corticosteroids
(Angelini 1994; Bäckman 1995; Biggar 2001; Bonifati 2000;
Dubowitz 2002; Fenichel 1991a; Fenichel 1991b; Griggs 1991;
Griggs 1993;Mendell 1989;Mesa 1991; Sansome 1993), azathio-
prine (Griggs 1993), and ciclosporin (Sharma 1993). Complimen-
tary DNA (cDNA) microarray studies on the mdx mouse demon-
strated a differential gene expression in affected and non-affected
muscles (Porter 2003), and a “skeletal muscle molecular signature”
dominated by chronic inflammatory response (Porter 2002). A
study of cDNAmicroarray analysis of skeletal muscle from DMD
patients reported a variable gene expression pattern that correlated
with the severity of dystrophic changes onhistological examination
(Noguchi 2003). Pescatori 2007 undertook gene expression profil-
ing of skeletal muscle fromDMD patients and reported induction
of genes involved in the inflammatory response, extracellular ma-
trix remodeling and muscle regeneration, and reduced transcrip-
tion of genes involved in energy metabolism. Dudley 2006 inves-
tigated the interactive effect of mechanical and oxidative stresses in
pathogenesis of muscle fibre damage in dystrophin-deficient mdx
mice and normal wild-type control mice. Their experiments sug-
gested that sarcolemmal damage in dystrophin deficiency is mod-
ulated by synergistic interactions between mechanical and oxida-
tive stresses. Taken together, these quoted studies provide further
evidence that the absence of dystrophin, though necessary, is not
sufficient to cause the pattern of fibrosis, inflammation, and mus-
cle degeneration and regeneration, characteristic of DMD.
Description of the intervention
Over the last three decades, many studies of the use of prednisone,
prednisolone and deflazacort in DMD have been published. In
the neuromuscular literature, authors often described these med-
ications as “steroids” (e.g. Dubrovsky 1998) or “corticosteroids”
(e.g. Bushby 2004 andMoxley 2005).Corticosteroids (the steroids
produced by the adrenal cortex) may have a predominant glu-
cocorticoid or mineralocorticoid activity. The relevant corticos-
teroids in neuromuscular practice (prednisone, prednisolone, and
deflazacort) have a predominant glucocorticoid action, and their
dose equivalence, toxicity and possibly, at least one mode of action
relates to this glucocorticoid activity.
The commonly used corticosteroids in published trials are pred-
nisone, prednisolone, and deflazacort. The corticosteroid dose
used in various trials for prednisolone or its equivalent ranges
from 0.3 mg/kg/day to 1.5 mg/kg/day, given daily or on alter-
nate days, or in an intermittent (10 days on, 10 or 20 days off )
regimen (Angelini 1994; Beenakker 2005; Escolar 2011; Griggs
1991; Mendell 1989; Dubowitz 2002).
How the intervention might work
The precise mechanism by which corticosteroids increase strength
in DMD is not known, but their potential beneficial effects in-
clude inhibition of muscle proteolysis (Elia 1981; Rifai 1995),
stimulation of myoblast proliferation (Bal 1980), stabilisation of
muscle fibre membranes (Jacobs 1996), increase in myogenic re-
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pair (Anderson 2000), anti-inflammatory or immunosuppressive
effect (Kissel 1991), reduction of cytosolic calcium concentrations
(Metzinger 1995; Passaquin 1998; Vandebrouck 1999), up-regu-
lation of utrophin (Pasquini 1995), and differential regulation of
genes in muscle fibres (Muntoni 2002).
Why it is important to do this review
Evaluation of the role of corticosteroids in DMD by systematic
reviews, such as Wong 2002, Campbell 2003, and Moxley 2005,
helped the development of clinical practice parameters (Moxley
2005), and international workshops establishing standards for use
of corticosteroids in DMD (Bushby 2004). Although many ob-
servers claimed a beneficial effect on muscle strength, the long-
term functional benefit remained unclear, and had to be weighed
against the short-term and long-term side effects and tolerability
of these drugs.
The previous version of this review examined RCT evidence that
showed corticosteroid therapy inDMD improvedmuscle strength
and function in the short term (sixmonths), and evidence exists for
benefit on strength at two years, although no conclusions can be
drawn from two-year timed function data, which are very limited.
The most effective prednisone regimen appeared to be 0.75 mg/
kg/day given daily. In the short term, adverse effects were signifi-
cantly more common with corticosteroids than placebo, but not
clinically severe. Long-term benefits and hazards of corticosteroid
treatment could not be evaluated from the published RCTs at that
time. Since the last review, care recommendations for DMD have
been published that recommend the use of corticosteroids (Bushby
2010a; Bushby 2010b). However, additional questions important
to clinical practice about the choice of corticosteroid, optimal
dosage regimens, long-term outcomes, and age of initiation or dis-
continuation of treatment remain (Bushby 2004; Bushby 2007).
Updating systematic reviews such as this one is essential to answer
these questions and plan further studies.
O B J E C T I V E S
To assess the effects of corticosteroids on prolongation of walking
ability, muscle strength, functional ability, and quality of life in
DMD; to address the question of whether benefit is maintained
over the longer term (more than twoyears); to assess adverse events;
and to compare efficacy and adverse effects of different corticos-
teroid preparations and regimens.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised or quasi-randomised trials of cor-
ticosteroids such as prednisone, prednisolone, deflazacort, or oth-
ers, with a minimum treatment period of three months. (Quasi-
randomised trials use a method of allocating participants to dif-
ferent interventions that is not truly random, such as by date of
birth, day of the week, or medical record number).
Types of participants
We considered trials involving patients with a definite diagnosis
of Duchenne muscular dystrophy (DMD), based on either of the
following.
1. The definition of Brooke 1981.
◦ Male patient with onset of proximal weakness by five
years and elevated serum creatine kinase (CK), together with two
of the following minor criteria:
⋄ muscle hypertrophy/lower limb contractures/toe
walking, electrocardiogram (ECG) changes, myopathic
electromyogram (EMG) changes, and dystrophic change on
muscle biopsy.
2. The European Neuromuscular Centre (ENMC) DMD
diagnostic criteria (Emery 1997).
◦ Onset of proximal weakness by five years of age, loss of
unassisted walking by 13 years, 10-fold or greater elevation of
serum CK, dystrophic muscle biopsy, absent or minimal
dystrophin on muscle biopsy, and/or Duchenne-type mutation
in the dystrophin gene.
Types of interventions
We considered trials examining the effects of any corticosteroid,
including prednisone, prednisolone, and deflazacort, compared
with placebo or another corticosteroid, or comparing regimens.
The minimum treatment period was three months. For placebo
comparisons, to analyse the effect of corticosteroids on patients
with DMD, we considered the three drugs together as a group.
The corticosteroids were reviewed on the basis of their dose equiv-
alence, which is well known (BNF 2016; Frey 1990).
Types of outcome measures
Primary outcomes
Prolongation of time to loss of ambulation (independent walking
without long leg calipers) (Heckmatt 1985; Spencer 1962).
Secondary outcomes
1. Strength outcome measures (performed after an
intervention period of at least three months) assessed by manual
muscle strength testing using Medical Research Council (MRC)
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strength scores (MRC 1976), ability to lift weights, or hand-held
dynamometry (Beenakker 2001).
2. Functional outcome measures, assessed by functional rating
scores such as Motor Ability Score (Scott 1982), Functional
Grade (leg function grade) (Brooke 1981; Brooke 1983), and
North Star Ambulatory Assessment score (Ricotti 2016; Scott
2012), or functional tests, such as timed walk, time taken to rise
from the floor (Gowers’ time), and four-stair climbing time
(Brooke 1981; Brooke 1983; Scott 1982).
3. Pulmonary function - forced vital capacity (FVC)
4. Quality of life, assessed by a validated measure, such as the
Pediatric Quality of Life Inventory (PedsQL) Neuromuscular
Model (Davis 2010)
5. Adverse events (noted during treatment or up to one year
after cessation of treatment), including:
◦ deaths;
◦ life-threatening infections;
◦ abnormal behaviour, e.g. irritability, hyperactivity,
euphoria, mood lability, depression;
◦ cushingoid appearance;
◦ fractures (if data were available beyond one year after
cessation of treatment they were collected);
◦ hyperglycaemia, glycosuria;
◦ hypertension;
◦ weight gain;
◦ height restriction;
◦ cataracts
Search methods for identification of studies
Electronic searches
On 16 February 2016, we searched for eligible trials in the
CochraneNeuromuscular SpecialisedRegister, theCochraneCen-
tral Register of Controlled Trials (CENTRAL) in the Cochrane
Register of Studies Online (16 February 2016), MEDLINE (Jan-
uary 1966 to February 2016), EMBASE (January 1980 to Febru-
ary 2016), CINAHL Plus (January 1937 to February 2016), and
LILACS (January 1982 to February 2016).
On 26
April 2016 we searched ClinicalTrials.gov (www.clinicaltrials.gov)
and the World Health Organization International Clinical Trials
Registry Platform (ICTRP) (http://www.who.int/ictrp/en/).
The detailed search strategies are in the appendices: Appendix
1 (Cochrane Neuromuscular Specialised Register), Appendix
2 (CENTRAL), Appendix 3 (MEDLINE), Appendix 4 (EM-
BASE), Appendix 5 (CINAHL Plus), Appendix 6 (LILACS), and
Appendix 7 (clinical trials registers).
Searching other resources
We wrote to authors of published studies and other experts in
this disease to help identify other trials. We checked all references
in the identified trials and contacted trial authors to identify any
additional published or unpublished data, or other trials.
Data collection and analysis
Selection of studies
One review author (EM) independently screened the initial search
of all the databases and reference lists to identify citations with po-
tential relevance to the review. EMobtained the full text of selected
articles (translated into English where required) and using prede-
fined eligibility criteria, selected trials for inclusion in the review.
AM and TK checked and agreed study selection. Review authors
were not blinded to trial authors, journal or results. Discussion
between the review authors and, if necessary, the involvement of a
third party (editor in charge of the review) resolved disagreements
when they occurred.
We recorded the selection process in sufficient detail to complete
a PRISMA flow diagram (Moher 2009), and ’Characteristics of
excluded studies’ table.
Data extraction and management
For the earlier versions of this review, one review author entered
data into Review Manager 5 (RevMan) (RevMan 2014) and the
then Review Group Co-ordinator checked the data entry. For this
update two review authors (EM and RB) extracted data for the
newly included studies and RB entered data into RevMan. EM
checked the data entry.
Assessment of risk of bias in included studies
Two review authors (EM and RB) independently assessed the risk
of bias in each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion. We assessed the risk
of bias according to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgment in the ’Risk of bias’ table.We summarised the risk
of bias judgements across different studies for each of the domains
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listed. Where information on risk of bias relates to unpublished
data or correspondence with a trialist, we noted this in the ’Risk
of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contribute to that outcome.
Measures of treatment effect
For dichotomous outcomes we reported risk ratios (RRs) with a
95% confidence interval (CI). For continuous outcomes we re-
ported mean differences (MDs) with a corresponding 95% CI
when the outcomes were measured in the same units in each trial.
We reported calculations of MD and 95% CI from Review Man-
ager 5 in preference to values given in trial reports, where different
(e.g. because of rounding), for consistency of approach across the
review
Unit of analysis issues
We used the generic inverse variance (GIV) method in RevMan
when analyses included cross-over studies.
Dealing with missing data
We sought full reports from authors where trials were published
in abstract form, presented at meetings or presented as posters,
and we contacted trial authors to obtain missing or ambiguously
reported data. Because a number of the published papers gave only
P values and means or differences (Griggs 1991; Mendell 1989),
we inferred the standard deviations (SDs) and other quantities
required for the RevMan meta-analysis by inverting the P value
calculations. Care was required by a statistician to obtain reason-
able values from what were sometimes very small and ’rounded’
P values. One study reported the difference (and P values) in re-
sponses as daily rate of change, obtained from a regression using
data from a six-month follow-up period (Beenakker 2005). We
scaled up the response to 24 weeks (six months) equivalent, and
deduced the standard error (SE) from the P values, assuming they
had been obtained using a normal (the 1.96 cut-off ) rather than
a t-test, because RevMan assumes normality, and any other ap-
proach would give conflicting results. However, the P values were
sometimes very small and rounding errors may make the results
very approximate, so results using these inferred SEs have to be
interpreted cautiously.
Assessment of heterogeneity
We conducted meta-analysis only when clinically appropriate. We
assessed statistical heterogeneity using the I2 statistic (Higgins
2011). We used a random-effects meta-analysis in all cases, even
when the heterogeneity was low.
Assessment of reporting biases
The review included too few trials in any one analysis to reliably
assess small study effects using funnel plots. The Cochrane Hand-
book for Systematic Reviews of Interventions recommends that tests
for funnel plot asymmetry are only used when at least 10 studies
are included in a meta-analysis (Higgins 2011).
Data synthesis
Where appropriate, we pooled estimates from individual studies
to obtain overall estimates and 95% CIs. For continuous outcome
measures we did this using the MD with corresponding 95% CIs.
TheMD is a method of meta-analysis used to combine differences
between treatment effects from different studies when the out-
comes are measured in the same units in each trial. It averages the
differences from the studies involved in the meta-analysis, weight-
ing them according to precision of the effect estimate.
If any of the studies using a common outcome measure did not
report the SD or we could not deduce it, we deduced the SE and
pooled estimates from the individual studies using the Revman
GIV facility to obtain overall estimates and 95% CIs. By this
method, the weight given to each study is chosen to be the inverse
of the variance of the effect estimate (i.e. one over the square of
its standard error). Thus, larger studies, which have smaller SEs,
receive more weight than smaller studies, which have larger SEs.
This choice of weight minimises the imprecision (uncertainty) of
the pooled effect estimate. For dichotomous outcomes, we used
RRs with corresponding 95% CI. To include an additional study
in GIVmeta-analyses at this update, we entered available data into
the calculator tool available in RevMan to produce a mean and SE
with 95% CI.
’Summary of findings’ tables
We included ’Summary of findings’ tables for each main compar-
ison. We assessed the evidence for key outcomes using the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness, and publication bias). We graded the
evidence as high, moderate, low, or very low quality using these
criteria, providing a rationale for any decisions to downgrade the
evidence. We included the following outcomes in these tables.
1. Prolongation of time to loss of ambulation (independent
walking without long leg calipers).
2. Strength outcome measures (performed after an
intervention period of at least three months).
3. Functional outcome measures: walking times, such as time
taken to walk 30 feet (Brooke 1981; Brooke 1983; Scott 1982),
and four-stair climbing time.
4. Adverse events:
◦ weight gain;
◦ fractures (if data were available beyond one year after
cessation of treatment they were collected);
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◦ abnormal behaviour such as irritability, hyperactivity,
euphoria, mood lability, and depression.
Where data for several prednisolone/prednisone doses were re-
ported, we reported the data for 0.75mg/kg/day daily in the ’Sum-
mary of findings’ tables, as this dose ismost commonly used in clin-
ical practice. We limited the adverse events reported in the ’Sum-
mary of findings’ tables to those that commonly cause patients
to cease treatment with corticosteroids. For efficacy outcomes, in
addition to the primary outcome (prolongation of walking), we
chose strength and functional outcomes that reflect daily activities
most closely (speed of walking and climbing stairs).
Subgroup analysis and investigation of heterogeneity
We investigated the possibility of heterogeneity of treatment effect
differences among studies with appropriate tests.
It was not possible to carry out subgroup analyses (e.g. for age at
initiation of corticosteroid: less than seven years old or seven years
or older) as these data were not available for individual studies.
Sensitivity analysis
Weperformed a sensitivity analysis removing trials assessed at high
risk of bias for any domain.
R E S U L T S
Description of studies
Results of the search
The number of papers found by the first electronic searches for this
update in April 2015 were: Cochrane Neuromuscular Specialised
Register 57, CENTRAL 68, MEDLINE 221 (65 new papers),
EMBASE 95 (36 new papers), CINAHL Plus 39 (16 new papers),
and LILACS 3, with a further 84 references (57 after removal
of duplicates) from a late search in February 2016 (Register 17,
CENTRAL 18, MEDLINE 10, EMBASE 29, CINAHL 10, and
LILACS 0). We identified two additional records from reference
lists of included studies.
Simple searches of clinical trials registries in April 2016 revealed
13 references in ClinicalTrials.gov and 16 references in the Inter-
national Clinical Trials Registry Platform. From these we identi-
fied two trial reports: CTRI/2009/091/000738, which is an ongo-
ing trial, and ACTRN12605000075684, which did not provide
enough information for eligibility to be assessed. Although listed
as recruiting (as of April 2016), this trial was registered on ICTRP
in 2005.
After deduplicating the new references above in the Cochrane
Register of Studies software or manually, we obtained 163 new
references.
For the previous version of the review, six studies met the inclusion
criteria and had been published in full in peer reviewed journals
(Angelini 1994; Bäckman 1995; Beenakker 2005; Griggs 1991;
Mendell 1989; Rahman 2001). All six trials randomised partic-
ipants to corticosteroids against placebo (five to prednisolone or
prednisone for six months and one to deflazacort for two years).
In this update, we identified six additional trials for inclusion:
• three new randomised studies published since the last
version of the review (Escolar 2011; Hu 2015; Karimzadeh
2012);
• one previously excluded study comparing deflazacort and
prednisone (Bonifati 2000), now eligible because of the
expanded scope of the review to evaluate evidence from
comparative trials of corticosteroids;
• two previously excluded studies published only as abstracts,
as this is current Cochrane practice (Brooke 1996; Todorovic
1998). However, we were unable to obtain further data from the
trial authors.
Two additional studies are ongoing (CTRI/2009/091/000738;
Guglieri 2015).
In summary therefore, we included 12 studies (667 partici-
pants) at this update (Angelini 1994; Bäckman 1995; Beenakker
2005; Bonifati 2000; Brooke 1996; Escolar 2011; Griggs 1991;
Hu 2015; Karimzadeh 2012; Mendell 1989; Rahman 2001;
Todorovic 1998), additionally listing CTRI/2009/091/000738
and Guglieri 2015 as ongoing.
See Figure 1 for a flow chart illustrating the study selection process.
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Figure 1. Study flow diagram.
Included studies
Corticosteroids versus placebo
See Characteristics of included studies.
We included data from five randomised, parallel-group, double-
blind studies of corticosteroids versus placebo (Angelini 1994;
Griggs 1991; Hu 2015; Mendell 1989; Rahman 2001), and
one randomised, placebo-controlled, cross-over trial (Beenakker
2005). Overall, these studies comprised 332 participants. The 315
participants in the randomised parallel-group trials involved 88 in
the placebo groups and 161 in the corticosteroid treatment groups
(Angelini 1994; Griggs 1991; Hu 2015; Mendell 1989; Rahman
2001).One hundred and one of the 218 participants in the control
groups and 164 of the 197 in the corticosteroid groups were walk-
ing, either independently or with the help of long leg braces. The
corticosteroid treatment groups included prednisone (n = 170),
prednisolone (n = 10), and deflazacort (n = 17). Beenakker 2005
was a cross-over study comprising 17 boys, all walking indepen-
dently, who received prednisone during the six-month active treat-
ment period.
In three of the included studies, all lasting six months, treatment
groups received prednisone or prednisolone in a daily dose regi-
men (Griggs 1991; Mendell 1989; Rahman 2001). These studies
included a total of 144 participants in the treatment group and
77 in the placebo group. Prednisone is broken down in the body
to prednisolone and they are equipotent in glucocorticoid effect
(Azarnoff 1975; Frey 1990).
Beenakker 2005, used an intermittent regimen, prednisone 0.75
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mg/kg/day given for the first 10 days of every month, in the active
treatment phase. The participants were 17 independently ambu-
lant boys. One study (n = 28) used deflazacort (2 mg/kg body
weight on alternate days for two years) in the treatment group
(Angelini 1994). This was the only study to address the primary
outcome measure of prolongation of walking.
Hu 2015 was a placebo-controlled study of 66 independently am-
bulant boys and the only placebo-controlled corticosteroid study
published since the previous update of this review. The interven-
tion was prednisone 0.75 mg/kg/day given daily for a year.
The secondary outcome measures of this review were assessed by
different parameters and assessment tools in the five prednisolone/
prednisone studies that were published in full and which pro-
vided data for our secondary outcomes. However, Mendell 1989
and Griggs 1991, the two studies that comprised 80% of the
participants for all the four included and analysed studies, used
the same outcome measures, as described in Brooke 1981 (see
Characteristics of included studies). Beenakker 2005, Hu 2015,
and Rahman 2001, the other three published studies of pred-
nisolone or prednisone, also used some of these outcomemeasures.
Bäckman 1995, a cross-over trial, reported efficacy as the numbers
improving (improved or unchanged across two-thirds or more of
the tested measures) and numbers deteriorating during treatment
with prednisolone (0.35 mg/kg/day) or placebo. The participants
were 37 boys with Duchenne muscular dystrophy (DMD) (22 of
whom were ambulant) and four with Becker muscular dystrophy.
Although outcome data were not adequate for inclusion in the
review, the trial provided some adverse event data.
Todorovic 1998 was a 20-month study involving 34 boys, who
received prednisone 2mg/kg alternate days (high dose) or placebo.
No results have been published.
Brooke 1996 was a 12-month randomised, double-blind compar-
ative trial with four arms: placebo, prednisone 0.75 mg/kg, de-
flazacort 0.9 mg/kg, and deflazacort 1.2 mg/kg, published in ab-
stract form. We presume, although the abstract does not specify,
that these were daily doses. After three months, participants in the
placebo group were randomised to one of the three active treat-
ment arms and followed up for a further nine months. The ab-
stract presents data for the average muscle score (the method of
measurement is not defined), and for weight gain as a percent-
age of baseline weight. This study was large, at 196 randomised
participants, but we were unable to obtain data to allow for any
analysis.
Weekend-only versus daily prednisone
Only one randomised study provided data for a comparison of dif-
ferent prednisone dosing regimes. Escolar 2011 performed a dou-
ble-blind placebo-controlled randomised study comparing daily
prednisone 0.75 mg/kg/day (and weekend placebo) with week-
end-only prednisone 5 mg/kg/weekend day (and daily placebo),
taken over a 12-month period. The study comprised 64 eligible
participants with a mean age of 7.3 years (range 4 to 10), all of
whom were ambulant at the start. The study did not measure the
primary outcome of this review, prolongation of time to loss of
ambulation, but assessed secondary outcomes at 12 months using
multiple measures, including the change from baseline of quanti-
tative muscle testing (QMT) arm and leg scores, and mean body
mass index (BMI).
Deflazacort versus prednisone
Bonifati 2000, a double-blind study, randomised 18 participants
to treatmentwith 0.75mg/kg/day prednisone (mean age 7.5 years,
range, 5.1 to 10) or 0.9 mg/kg/day deflazacort (mean age 8.6
years, range 5.3 to 14.6) for 12 months. Investigators assessed
muscle strength and function using a summed Medical Research
Council (MRC) score of four muscles (two right upper limb, two
right lower limb) and a summed functional score comprising sev-
eral timed assessments including a 10-metre walk, rise from chair
and floor, and four-stair climbing. Mean weight increase after 12
months was expressed as a percentage of initial weight. The trial
authors presented outcomedata forMRCscores, functional scores,
and weight increase graphically, limiting full analysis. They tab-
ulated adverse events. We requested further data but received no
response from study authors.
Karimzadeh 2012 initially randomised 34 participants to either
prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day. Eight
early dropouts occurred, but the trial continued for 12 months
with 14 participants in the deflazacort group (mean age 7.1 years,
range 3.2 to 10.5) and 12 in the prednisone group (mean age
7.37 years, range 6 to 10). In total, the study ran for 18 months,
but at 12 months a further four participants were excluded from
the prednisone group due to unacceptable weight gain; these four
also had poor motor function scores. The report presented limited
outcome data at 12 and 18 months. We contacted study authors
for more data but did not receive a reply.
As noted above, Brooke 1996 also studied this comparison but did
not provide data for analysis.
Excluded studies
Non-randomised excluded studies
See Characteristics of excluded studies.
We excluded three RCTs. These were: a comparison of pred-
nisone and azathioprine with no placebo group (Griggs 1993), a
study of deflazacort versus prednisolone inwhich the high dropout
rate invalidated results (Pradhan 2006), and a study of ayurvedic
medicine, prednisone and placebo in which investigators modified
the design mid-trial (Vasanth 1996).
We also listed non-randomised studies in the excluded studies.
Thirty-eight of these were fully published (Alman 2004; Balaban
2005; Biggar 2001; Biggar 2004; Biggar 2006; Bonifati 2006;
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Bothwell 2003; Brooke 1987; Connolly 2002; Daftary 2007;
DeSilva 1987; Drachman 1974; Dubowitz 2002; Fenichel 1991a;
Fenichel 1991b; Henricson 2013; Houde 2008; Kinali 2002;
Kinali 2007;King2007;Markham2005;Mayhew2013;Mazzone
2013; Merlini 2003; Mesa 1991; Parreira 2007; Reitter 1995;
Ricotti 2013; Sansome 1993; Schara 2001; Schram 2013; Siegel
1974; Silva 2012; Silversides 2003; Simon 2011; Takeuchi 2013;
Yilmaz 2004). Eight non-randomised studies were published in
abstract format only (Ahlander 2003; Angelini 1995; Aviles 1982;
de Groot 2002; Dubrovsky 1999; Pandya 2001; Resende 2001;
Tunca 2001). One paper was a discussion of corticosteroid use
(Griggs 2013). We identified and excluded six review articles
reporting the various studies (Angelini 2007; Angelini 2012;
Campbell 2003; Flanigan 2012; McAdam 2012; Wong 2002).
Ongoing studies
See Characteristics of ongoing studies.
Guglieri 2015 is a large ongoing randomised double-blind study
taking place at 40 centres throughout the US, UK, Canada, Ger-
many, Italy, and Spain. This study is comparing three corticos-
teroid regimens for efficacy and adverse events: prednisone 0.75
mg/kg/day, prednisone 0.75 mg/kg/day switching between 10
days on and 10 days off treatment, and deflazacort 0.9 mg/kg/
day daily. The planned follow-up period is three to five years. No
outcome data are yet available.
Risk of bias in included studies
Figure 2 illustrates the review authors’ ’Risk of bias’ assessments
of included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Although all the studies were described as randomised, most re-
ports did not provide enough detail to assesswhether themethodof
randomisation was adequate.We were able to determine that three
studies were at low risk of bias (Angelini 1994; Hu 2015; Escolar
2011), and one was at high risk of bias (Karimzadeh 2012). For al-
location concealment, we assessed three trials at low risk of bias on
the basis of information provided by the trial authors (Beenakker
2005; Escolar 2011; Rahman 2001), eight studies at unclear risk of
bias, as the reports provided no information, and one study at high
risk of bias (Karimzadeh 2012) (see Characteristics of included
studies).
Blinding
Trial authors described eight of the 12 studies as double blind, but
we considered only six of them at low risk of both performance
and detection bias (Angelini 1994; Bäckman 1995; Bonifati 2000;
Escolar 2011; Griggs 1991; Mendell 1989). Hu 2015 blinded
participants but it is unclear whether blinding of outcome assessors
or investigators was attempted. Three studies provided too little
information to form a judgement (Brooke 1996; Beenakker 2005;
Todorovic 1998). We judged both Rahman 2001, which used
a vitamin control intervention, and Karimzadeh 2012, a single-
blind study, at high risk of bias.
Incomplete outcome data
Six of the 12 studies described withdrawals and dropouts and we
judged these studies at low risk of bias (Beenakker 2005; Bonifati
2000; Griggs 1991; Hu 2015;Mendell 1989; Rahman 2001). Tri-
alists described dropouts from Griggs 1991 in a subsequent se-
quential study (Griggs 1993). Rahman 2001 reported one dropout
and described it in response to the Cochrane authors’ request.
The risk of attrition bias was unclear in four studies (Bäckman
1995; Brooke 1996; Escolar 2011; Todorovic 1998). . Karimzadeh
2012 was at high risk of attrition bias, as dropouts were those
with worse outcomes. Most two-year analyses in Angelini 1994
included fewer than 50% of the randomised participants and we
judged it at high risk of attrition bias.
Selective reporting
Reporting bias was difficult to assess as trial registration records
and protocols are not available for earlier trials, and outcomes were
rarely fully defined in methods. Our assessment of bias was ’high’
for six trials and ’unclear’ for two. Only Beenakker 2005, Griggs
1991, Hu 2015, and Mendell 1989 had a ’low risk’ assessment.
Other potential sources of bias
Brooke 1996 and Todorovic 1998 were reported in abstracts and
provided no information to assess the presence of other bias. Our
assessment was ’unclear’ for these trials and low risk for others.
Effects of interventions
See: Summary of findings for the main comparison
Corticosteroids versus placebo for Duchenne muscular dystrophy;
Summary of findings 2 Weekend-only versus daily prednisone
for Duchenne muscular dystrophy; Summary of findings 3
Deflazacort versus prednisone for Duchenne muscular dystrophy
Corticosteroids versus placebo
Six studies provided data for this comparison (Angelini 1994;
Beenakker 2005; Griggs 1991; Hu 2015; Mendell 1989; Rahman
2001). Bäckman 1995, a cross-over trial, reported efficacy as the
numbers improving (improved or unchanged across two-thirds or
more of the testedmeasures) and numbers deteriorating. Although
these data were not adequate for inclusion in the comparison of
outcome measures, the trial did provide adverse event data. The
two studies reported in abstract form provided only limited in-
formation: Todorovic 1998 reported no usable results and Brooke
1996 provided some numerical data, but with insufficient detail
for analysis.
See Summary of findings for the main comparison.
Primary outcome measure: prolongation of time to loss of
ambulation
Only Angelini 1994 (n = 28), a two-year study, used prolongation
of time to loss of ambulation as an outcome measure. The other
studies were of short duration (six months or one year), and not
designed to demonstrate prolongation of walking.
Angelini 1994 reported that deflazacort (2 mg/kg on alternate
days) prolonged ambulation by 13months, but the statistical tech-
nique used to infer this result was not appropriate. Four of the
17 participants in the deflazacort group became wheelchair de-
pendent, at a mean interval of 33.2 months after randomisation,
versus six of 11 placebo participants, at a mean interval of 20.5
months. The trial authors reported the difference of 13 months
between these two sets of participants who lost walking ability as
“mean prolongation of walking”, ignoring the 13 participants in
the deflazacort group and five in the placebo group who were still
walking at the end of the study. The trialists did not report the
age of boys who remained ambulant at the end of the study and
this information was not available on contacting the lead investi-
gator. We therefore were not able to construct Kaplan-Meier sur-
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vival curves for evaluating prolongation of walking as an outcome
measure.
Secondary outcome measures
(1) Muscle strength
(a) Average muscle score
Griggs 1991, Mendell 1989 and Rahman 2001 reported muscle
strength as an average muscle score (as described in Brooke 1981
and Brooke 1983). The two large studies had one placebo arm
and two treatment arms (Griggs 1991; Mendell 1989). Mendell
1989 studied two prednisone dose regimens (0.75 mg/kg/day and
1.5 mg/kg/day), comparing them with a placebo group. Griggs
1991 compared 0.3 mg/kg/day and 0.75 mg/kg/day prednisone
regimens with placebo. Hu 2015 studied a 0.75 mg/kg daily pred-
nisone regimen, reporting scores for lower limb muscle strength
(right hip flexion and right knee extension) according to the
MRC scale expanded to a 10-point scale, at six and 12 months.
These data were not suitable for meta-analysis with Griggs 1991,
Mendell 1989 and Rahman 2001. Bäckman 1995 evaluated mus-
cle strength in three ways: (a) average muscle strength from 26
muscle groups on the MRC zero to five grading system and the
performance scores were added and divided by the number ofmus-
cle groups to get the average muscle strength; (b) isometric muscle
strength, measured in 24 muscle groups with a Penny and Giles
myometer; and (c) hand-grip strength measured bilaterally with a
strain gauge. The publication did not report data, nor could the re-
view authors obtain data from the surviving study author. Angelini
1994 measured muscle strength in two ways: (a) MRC index cal-
culated by assessing four limbmuscle groups using theMRC scale;
and (b) myometry (but the number of muscle groups tested and
the myometer used were not described). Beenakker 2005 assessed
changes in muscle force in nine muscle groups with hand-held
dynamometry (Beenakker 2001; Beenakker 2005b). Brooke 1996
was a four-way comparison of two doses of deflazacort (0.9 mg/kg
and 1.2 mg/kg), prednisone (0.75 mg/kg), and placebo, which re-
ported average change in muscle strength at three months (“based
on a standardised method used in several previous trials”).
Analysis of pooled data from three trials (n = 147) demonstrated
a statistically significant improvement in average muscle score in
the prednisone 0.75 mg/kg/day group versus placebo, with a mean
difference (MD) of 0.52 (95% confidence interval (CI) 0.33 to
0.71) after six months of treatment; moderate quality evidence
(Griggs 1991; Mendell 1989; Rahman 2001) (see Analysis 1.2;
Figure 3; Summary of findings for themain comparison). Removal
of Rahman 2001, the trial at high risk of bias, had no substantial
effect on the result (MD 0.47, 95% CI 0.32 to 0.63).
Figure 3. Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.1 MRC -
Average muscle score after 6 months of treatment - prednisone.
17Corticosteroids for the treatment of Duchenne muscular dystrophy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Griggs 1991 (n = 61) also compared prednisone 0.3 mg/kg/day
with placebo and after six months of treatment there was statisti-
cally significant improvement in average muscle score in favour of
the prednisone group, with a MD of 0.34 (95% CI 0.17 to 0.51)
(see Analysis 1.2).
Mendell 1989 (n = 65) also compared prednisone 1.5 mg/kg/
day with placebo and after six months of treatment there was a
statistically significant improvement in average muscle score in the
prednisone group, with a MD of 0.45 (95% CI 0.23 to 0.67) (see
Analysis 1.2).
Beenakker 2005 (n = 16), a cross-over study, compared an inter-
mittent regimen of prednisone (0.75 mg/kg/day given for the first
10 days of every month for six months) with placebo. There was
a statistically significant difference in the muscle force during the
prednisone phase compared to the placebo phase. Using the stan-
dard errors (SEs) inferred from the quoted P values, the RevMan
GIV facility gave a difference in favour of prednisone of 99.2 N
(95% CI 15.63 to 182.81) (see Analysis 1.20).
Brooke 1996 (n = 196) reported an average change in muscle
strength (“based on a standardised method used in several previ-
ous trials”) after three months. Reported changes were -0.1 with
placebo, +0.27 with prednisone 0.75 mg/kg, +0.8 with deflazacort
0.9 mg/kg, and +0.26 with deflazacort 1.2 mg/kg. For all compar-
isons versus placebo, P < 0.0001. The abstract provided no par-
ticipant numbers for intervention groups, or standard deviation
(SD).
Hu 2015 reported that lower limb muscle strength grade “re-
mained stable” in the prednisone group, whereas it declined in
the placebo group. The MD between groups favoured prednisone
over placebo for both hip flexion and knee extension at six months
(MD 0.64, 95% CI 0.20 to 1.08 and MD 0.71, 95% CI 0.27 to
1.15, respectively; n = 63) and at 12 months (MD 1.27, 95% CI
0.74 to 1.80 and MD 1.23, 95% CI 0.71 to 1.75, respectively; n
= 58) (Analysis 1.4; Analysis 1.5).
Angelini 1994 was a 24-month trial comparing deflazacort (2 mg/
kg administered on alternate days) with placebo. Treatment con-
tinued until the participants became wheelchair dependent. After
six months, the MD for change in MRC index (%) was similar in
the deflazacort and placebo groups (MD 1.97, 95% CI -1.79 to
5.73, n = 26); after 24 months the difference favoured deflazacort
(MD 6.60, 95% CI -3.79 to 16.99, n = 13) (Analysis 1.3).
(b) Ability to lift weights
Ability to lift standardised weights (as described in Brooke 1981)
was assessed and reported in two studies (Griggs 1991; Mendell
1989). Analysis of pooled data from these studies demonstrated
a statistically significant improvement in lifting weights in the
prednisone 0.75 mg/kg/day group after six months of treatment
as compared to placebo, with aMD of 0.75 (95%CI 0.50 to 0.99,
n = 94) (see Analysis 1.15).
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo, and after six months of treatment there was a statisti-
cally significant improvement in lifting weights in the prednisone
group, with a MD of 0.38 (95% CI 0.13 to 0.63, n = 39) (see
Analysis 1.15).
Mendell 1989 compared prednisone 1.5 mg/kg/day with placebo
and after sixmonths of treatment therewas a statistically significant
improvement in lifting weights in the prednisone group, with a
MD of 0.96 (95% CI 0.52 to 1.40, n = 57) (see Analysis 1.15).
(2) Functional outcome measures
(a) Time taken to rise from the floor (Gowers’ time)
Five studies provided six-month data on time taken to rise to
the standing position (as described in Brooke 1981) (Beenakker
2005; Griggs 1991; Hu 2015; Mendell 1989; Rahman 2001). A
decrease in Gowers’ time indicates better ability to rise from the
floor, representing improvement.
Beenakker 2005, a cross-over study in which 16 participants were
analysed (17 randomised), compared an intermittent regimen of
prednisone (0.75 mg/kg/day given for the first 10 days of ev-
ery month, for six months) with placebo. There was a statisti-
cally significant difference in the time taken to rise from the floor
during the prednisone phase compared to the rising time in the
placebo phase. Using the SEs inferred from the quoted P values,
the RevMan GIV facility gave a difference in favour of prednisone
of -1.08 seconds (95% CI -2.51 to 0.35) (see Analysis 1.6).
Analysis of pooled data from Griggs 1991, Mendell 1989, Hu
2015, and Rahman 2001 demonstrated statistically significant im-
provement in the prednisone 0.75 mg/kg/day group compared
with placebo after six months of treatment. Using the SEs inferred
from the quoted P values for the older studies, or derived using
the RevMan calculator function from the Hu 2015 group means,
SD and N, the RevMan GIV facility gave a difference in favour of
prednisone of -2.28 seconds (95%CI -3.12 to -1.44) (see Analysis
1.6). Removal of Rahman 2001 had no substantial effect on the
result (MD -2.22, 95% CI -3.17 to -1.26),
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo. The GIV analysis showed that after six months of treat-
ment, there was a difference in favour of prednisone of -1.59 sec-
onds (95% CI -3.75 to 0.57) (see Analysis 1.6).
Mendell 1989 also compared prednisone 1.5 mg/kg/day with
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placebo. The GIV analysis showed that after six months of treat-
ment, there was a difference in favour of prednisone of -2.74 sec-
onds (95% CI -3.98 to -1.50) (see Analysis 1.6).
Hu 2015 compared the effects of daily 12-month treatment with
0.75 mg/kg/day prednisone to placebo (n = 60). The results in-
dicated a MD in Gowers’ time post treatment in favour of pred-
nisone of -2.21 seconds (95% CI -3.88 to -0.54) (see Analysis
1.6).
Angelini 1994 reported change in Gowers’ time (units assumed to
be seconds) with no significant difference between deflazacort (2
mg/kg alternate days) and placebo at 6 months (MD -2.06, 95%
CI -6.70 to 2.58, n = 19) or 24 months (MD -4.86, 95% CI -
11.01 to 1.29, n = 10) (Analysis 1.7; Analysis 1.9).
(b) Timed walk
The time taken to walk nine metres (as described in Brooke
1981) was reported in four studies (Beenakker 2005; Griggs 1991;
Mendell 1989; Rahman 2001). A decrease in walking time indi-
cates ability to walk faster, representing improvement.
Beenakker 2005 compared an intermittent regimen of prednisone
(0.75 mg/kg/day given for the first 10 days of every month, for
six months) with placebo, in a cross-over design study. There was
a statistically significant difference in nine metres running time
during the prednisone phase compared to the running time in the
placebo phase. Using the SEs inferred from the quoted P values,
the RevMan GIV facility gave a difference in favour of prednisone
of -0.68 seconds (95% CI -1.15 to -0.21, n = 16) (see Analysis
1.10).
Analysis of pooled data from Griggs 1991, Mendell 1989, and
Rahman 2001 demonstrated a statistically significant improve-
ment in nine-metre walking time in the prednisone 0.75 mg/kg/
day group after six months of treatment. Using the SEs inferred
from the quoted P values, the RevMan GIV facility gave a dif-
ference in favour of prednisone of -2.73 seconds (95% CI -3.97
to -1.50, n = 111; moderate quality evidence) (see Analysis 1.10;
Figure 4; Summary of findings for themain comparison). Removal
of Rahman 2001 had no substantial effect on the result (MD -
2.39 seconds, 95% CI -3.50 to -1.27).
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Figure 4. Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.7 Nine-
metre walking/running time after 6 months of treatment - prednisone.
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo. The GIV analysis showed that after six months of treat-
ment, there was a difference in favour of prednisone of -1.18 (95%
CI -2.65 to 0.29, n = 40) (see Analysis 1.10).
Mendell 1989 also compared prednisone 1.5 mg/kg/day with
placebo. The GIV analysis showed that after six months of treat-
ment, there was a difference in favour of prednisone of -2.64 sec-
onds (95% CI -4.45 to -0.83, n = 57) (see Analysis 1.10).
Hu 2015 reported time to walk 10 metres, which prevented inclu-
sion of data in the meta-analysis. The trial reported a post treat-
mentMD (seconds) in favour of daily prednisone 0.75 mg/kg/day
over placebo; at six months, the MD was -0.94 (95% CI -1.73 to
-0.15, n = 63), and at one year -1.71 seconds (95% CI -2.74 to -
0.68, n = 58) (see Analysis 1.12; Analysis 1.13.
Angelini 1994 reported change in timed walk (we assume in sec-
onds); the MD favoured deflazacort (2 mg/kg alternate days) at
six months (MD -3.01, 95% CI -4.76 to -1.26, n = 23), but no
clear difference was present at 24 months (MD -0.67, 95% CI -
2.37 to 1.03, n = 12) (see Analysis 1.11; Analysis 1.14).
(c) Four-stair climbing time
Five studies reported the time taken to climb four standardised
stairs (as described in Brooke 1981) at six months (Beenakker
2005; Griggs 1991; Hu 2015; Mendell 1989; Rahman 2001).
A decrease in four-stair climbing time indicates ability to ascend
stairs faster, representing improvement.
Beenakker 2005 compared an intermittent regimen of prednisone
(0.75 mg/kg/day given for the first 10 days of every month for six
months) with placebo, in a cross-over design study. There was a
statistically significant difference in four-stair climbing time dur-
ing the prednisone phase compared to the placebo phase. Using
the SEs inferred from the quoted P values the RevMan GIV fa-
cility gave a difference in favour of prednisone of -1.93 seconds
(95% CI -3.56 to -0.30, n = 16) at 6 months (see Analysis 1.16).
Analysis of pooled data from Griggs 1991, Mendell 1989, Hu
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2015, and Rahman 2001 demonstrated a statistically significant
benefit over placebo in four-stair climbing time in the prednisone
0.75 mg/kg/day group after six months of treatment. Using the
SEs inferred from the quoted P values for the older studies, and
using the RevMan calculator tool to derive SE from the Hu 2015
(final values) data, the RevMan GIV facility gave a difference in
favour of prednisone of -3.09 seconds (95% CI -4.33 to -1.85, n
= 135; moderate quality evidence) (see Analysis 1.16; Summary
of findings for the main comparison). Removal of Rahman 2001
had no substantial effect on the result (MD -2.98, 95% CI -4.43
to -1.53), and increased heterogeneity (I2 = 66%).
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo. The GIV analysis showed that after six months of treat-
ment, there was a difference in favour of prednisone of -2.68 sec-
onds (95% CI -4.06 to -1.30, n = 32) (see Analysis 1.16; Figure
5).
Figure 5. Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.11 Four-
stair climbing time after 6 months of treatment - prednisone.
Mendell 1989 compared prednisone 1.5 mg/kg/day with placebo.
The GIV analysis showed that after six months of treatment, there
was a difference in favour of prednisone of -3.05 seconds (95%
CI - 4.41 to -1.69, n = 42) (see Analysis 1.16).
Hu 2015 compared daily prednisone 0.75 mg/kg/day with
placebo. After a year of treatment, the mean difference in four-
stair climb time favoured prednisone, at -1.63 seconds (95% CI -
3.07 to -0.19, n = 52) (see Analysis 1.18).
Angelini 1994 reported change in “time, stairs” (not further speci-
fied), comparing deflazacort (2mg/kg alternate days) and placebo.
The results (we assume in seconds) were imprecise, allowing for
the possibility of effects in either direction, MD -2.96, 95% CI -
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7.02 to 1.10, n = 23 at six months, and MD 0.63, 95% CI -4.29
to 5.55, n = 11 at 24 months (see Analysis 1.17; Analysis 1.19).
(d) Leg function grade
Leg function grade (as described inBrooke 1981 andBrooke 1983)
was assessed in two studies (Griggs 1991; Mendell 1989). The leg
function grade is assessed on a 10-point scale: grade 1 representing
ability to walk and climb stairs without assistance; and grade 10
representing confinement to bed. Analysis of pooled data from
these studies demonstrated a statistically significant improvement
in the prednisone 0.75 mg/kg/day group versus placebo after six
months of treatment, with a MD of -0.41 points (95% CI -0.73
to -0.09, n = 129) (see Analysis 1.21).
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo. After six months of treatment the mean improvement in
leg function grade was 0.39 points (95% CI 0.01 to 0.79, n = 58)
less than in the placebo group (see Analysis 1.21).
Mendell 1989 also compared prednisone 1.5 mg/kg/day with
placebo and after six months of treatment the mean improvement
in the prednisone group was 0.49 points (95% CI 0.05 to 0.93, n
= 68) less than in the placebo group (see Analysis 1.21).
(3) Pulmonary function - forced vital capacity (FVC)
FVC (as described in Brooke 1981) was measured in two studies
(Griggs 1991; Mendell 1989). Analysis of pooled data from these
studies demonstrated a mean improvement in FVC in the pred-
nisone 0.75 mg/kg/day group, after six months of treatment of
0.17 L more than in the placebo group (95% CI 0.10 to 0.24, n
= 127) (see Analysis 1.22).
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo. After six months of treatment the improvement in FVC
in the prednisone group was 0.16 L (95% CI 0.05 to 0.27, n =
59) more than in the placebo group (see Analysis 1.22).
Mendell 1989 also compared prednisone 1.5 mg/kg/day with
placebo. After six months of treatment the mean improvement in
FVC in the prednisone group was 0.14 L (95% CI 0.05 to 0.23,
n = 62) more than in the placebo group (see Analysis 1.22).
(4) Quality of life (QoL)
Measured in Beenakker 2005 and Hu 2015.
Beenakker 2005 measured QoL with the DUX-25 at the start
and end of both six-month trial periods. This questionnaire covers
four domains: physical, emotional, social, and home functioning.
The items are scored using a five-point scale. The raw data or
statistical analysis of QoL were not available. The QoL did not
change significantly during the prednisone period. With every
newmeasurement, however, participants reported a slightly higher
QoL, irrespective of themedication given, resulting in a significant
improvement in the last measurement on two scales (emotional
functioning and the total scale); Beenakker et al considered this to
be possibly related to the attention of being involved in a trial.
Hu 2015 assessed child self reported and parent proxy reported
quality of life using the Chinese version of PedsQTLM 3.0 NMM
(total score). Items are rated on a five-point scale, and transformed
linearly to a zero to 100 scale. “Scores were computed as the sum
of items divided by the number of items answered.” Higher scores
indicated better quality of life.
Twenty-nine boys were too young to complete the questionnaire
at baseline, being under seven years old. Clear differences in favour
of prednisone 0.75 mg/kg/day were present at six and 12 months
in self reported and proxy reported quality of life. At six months,
the MD for the self reported questionnaire was 10.87, 95% CI
0.64 to 21.10, n = 38 and 9.97, 95% CI 1.96 to 17.98, n = 63, for
the proxy reported measure. At 12 months, corresponding values
were MD 16.05, 6.46 to 25.64, n = 41 and MD 14.42, 95% CI
5.85 to 22.99, n = 58 (Analysis 1.23; Analysis 1.24).
(5) Adverse events
Adverse events were evaluated by the different investigators as fol-
lows.
Mendell 1989 examined the participants for adverse effects in an
area separate from that of clinical evaluation at baseline and at one,
two, three, and six months after the start of prednisone treatment.
Trialists reported data for both treatment and placebo groups.
Griggs 1991 examined the participants and interviewed the par-
ents for adverse effects at baseline and at one, two, three, and six
months of treatment. Trialists reported data for both treatment
and placebo groups.
Rahman 2001 did not report adverse effect data.
Hu 2015 measured and reported body weight, height, body mass
index (BMI) and diastolic blood pressure in prednisone (0.75 mg/
kg/day) and control groups at six and 12 months. The report did
not provide data on the incidence of other adverse effects for the
placebo group; adverse effects occurred in 16 of the 31 children
receiving prednisone who completed the 12-month study.
Angelini 1994 monitored the participants every two months of
the study for adverse effects. Trialists reported weight gain data for
treatment (deflazacort) and placebo groups, but incidence of the
other adverse effects only for the deflazacort group.
Bäckman 1995 asked the parents of participants at the end of
the study to report any signs or symptoms that could possibly be
related to the treatment.
Beenakker 2005 evaluated the adverse effects at each visit by using
a standard list that described the corticosteroid-related adverse
effects. This included patient and parent interview for symptoms
and examination for physical signs relating to adverse effects.
(a) Weight gain
Mendell 1989 and Griggs 1991 reported this adverse event as per
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cent weight gain at last visit above baseline (first visit), on the
presumption of six months of treatment. As per cent weight gain
was only available as the number of participants in each of a set of
intervals on the per cent weight gain scale, we derived the mean
and SD for each group assuming each individual had the mid-
value of the interval in which they fell. The review authors did
not use Sheppard’s correction for bias in variances obtained using
grouped data because the interval widths were variable and the
magnitude of the correction for bias in the SDswas found to be less
than 2%. Analysis of pooled data from Mendell 1989 and Griggs
1991 demonstrated a statistically significant weight gain in the
prednisone 0.75 mg/kg/day group after six months of treatment
as compared to placebo, with a MD of 9.27% (95% CI 6.87% to
11.68%, n = 126; moderate quality evidence) (see Analysis 1.25;
Summary of findings for the main comparison).
Hu2015 reported that one participant in the prednisone (0.75mg/
kg/day) group showed obvious weight gain at 12 months (placebo
group not reported). However, no clear difference in weight was
present between the prednisone and placebo groups at six and 12
months, with wide CIs (Analysis 1.28; Analysis 1.29). Similarly,
BMI (kg/m2) showed no clear difference at six or 12 months, with
wide CIs (Analysis 1.30; Analysis 1.31).
Beenakker 2005 compared an intermittent regimen of prednisone
(0.75 mg/kg/day given for the first 10 days of every month, for
six months) with placebo, in a cross-over design study. They re-
ported the difference and P value in weight as daily rate of change,
obtained from a regression using data from a six-month follow-
up period. We scaled up the response to 24 weeks (six months)
equivalent, and deduced the standard error (SE) from the P val-
ues. The mean weight gain during the prednisone phase (2.37 kg)
was greater than in the placebo phase (1.47 kg), but the analysis
using the SEs inferred from the quoted P values and the RevMan
GIV facility showed that the difference, 0.84 kg (95% CI -0.04
to 1.72), did not quite reach statistical significance (see Analysis
1.26).
Angelini 1994 compared deflazacort with placebo and presented
weight gain data for 11 deflazacort and five placebo patients as per
cent weight change. As per cent weight change was only reported
as the number of participants in each of a set of intervals on the
per cent weight gain scale, the mean and SD for each group were
derived as described above for Mendell 1989 and Griggs 1991.
After two years of treatment, the degree of weight gain in the
deflazacort group was slightly greater than that in the placebo
group, but as CIs include the possibility of large effects in either
direction (MD 1.09%, 95% CI -13.92 to 16.10, n = 16) (see
Analysis 1.27), we can draw no conclusions.
(b) Behavioural changes
Three studies reported the number of patients with behavioural
changes in treatment and placebo groups (Beenakker 2005;Griggs
1991; Mendell 1989).
Analysis of pooled data from these studies demonstrated a statisti-
cally non-significant risk of behavioural changes in the prednisone
0.75 mg/kg/day group after six months of treatment as compared
to placebo, with a RR of 1.39 (95% CI 0.94 to 2.06; moderate
quality evidence) (see Analysis 1.33; Summary of findings for the
main comparison).
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo. After six months of treatment there was no statistically
significant difference in behavioural changes in the prednisone and
placebo groups, with a RR of 1.02 (95% CI 0.67 to 1.56) (see
Analysis 1.33).
Mendell 1989 compared prednisone 1.5 mg/kg/day with placebo.
After six months of treatment there was a trend to increased risk
of behavioural changes in the prednisone group but this was not
statistically significant, with a RR of 1.43 (95% CI 0.92 to 2.24)
(see Analysis 1.33).
Beenakker 2005 compared an intermittent regimen of prednisone
(0.75 mg/kg/day given for the first 10 days of every month, for six
months) with placebo, in a cross-over design study. The study re-
ported the number of patients with behavioural side effects (hyper-
activity, irritability, euphoria) in prednisone-treated and placebo-
treated participants, but data on occurrence of these adverse effects
during all four phases of the cross-over trial were not presented or
available, and because of this, the review authors could not under-
take appropriate statistical analysis.
Angelini 1994 reported behavioural changes in six of 11 partic-
ipants in the deflazacort group at six months but did not report
the data for the placebo group.
(c) Cushingoid appearance
Three studies reported the number of participants with cushingoid
appearance in treatment and placebo groups (Beenakker 2005;
Griggs 1991; Mendell 1989).
Beenakker 2005 compared an intermittent regimen of prednisone
(0.75 mg/kg/day given for the first 10 days of every month, for six
months) with placebo, in a cross-over design study. Four partici-
pants were noted to have cushingoid appearance during the pred-
nisone treatment period as compared to one in the placebo period.
Data on occurrence of this adverse effect during all four phases of
the cross-over trial were not presented or available, and because of
this, we could not undertake appropriate statistical analysis.
Analysis of pooled data from Griggs 1991 and Mendell 1989
demonstrated a significant risk of cushingoid appearance in the
prednisone 0.75 mg/kg/day group after six months of treatment
as compared to placebo, with a RR of 2.37 (95% CI 1.53 to 3.67)
(see Analysis 1.34).
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo. After six months of treatment there was no significant
difference in cushingoid appearance in the prednisone and placebo
groups, with a RR of 1.15 (95% CI 0.60 to 2.17) (see Analysis
1.34).
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Mendell 1989 also compared prednisone 1.5 mg/kg/day with
placebo, and after six months of treatment there was a significant
risk of cushingoid appearance in the prednisone group, with a RR
of 4.36 (95% CI 2.04 to 9.33) (see Analysis 1.34).
Angelini 1994 reported a cushingoid appearance in two of 11
participants in the deflazacort group at six months but did not
report data for the placebo group.
Hu 2015 reported a cushingoid appearance in three of 31 partic-
ipants in the prednisone (0.75 mg/kg/day) group at 12 months
but did not report data for the placebo group.
(d) Excessive hair growth (hirsutism)
Two studies reported the number of participantswith excessive hair
growth in treatment and placebo groups (Griggs 1991; Mendell
1989). Analysis of pooled data from these studies demonstrated
a statistically significant risk of excessive hair growth in the pred-
nisone 0.75 mg/kg/day group after six months of treatment as
compared to the placebo group, with a RR of 2.60 (95% CI 1.47
to 4.60) (see Analysis 1.32).
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo. After six months of treatment there was no significant
difference in excessive hair growth in the prednisone and placebo
groups, with a RR of 0.73 (95% CI 0.18 to 3.0) (see Analysis
1.32).
Mendell 1989 also compared prednisone 1.5 mg/kg/day with
placebo, and after six months of treatment there was a significant
increase in the number of boys with excessive hair growth in the
prednisone group, with a RR of 2.32 (95% CI 1.16 to 4.64) (see
Analysis 1.32).
Angelini 1994 reported excessive hair growth in none of the 11
participants at six months and in three out of eight patients at
two years in the deflazacort group, but did not report data for the
placebo group.
Hu 2015 reported hair growth in two of 31 participants in the
prednisone group at 12 months, but did not report data for the
placebo group.
(e) Acne
Two studies reported the number of participants with acne in treat-
ment and placebo groups (Griggs 1991; Mendell 1989). Analysis
of pooled data from these studies demonstrated a trend to develop
acne in the prednisone 0.75 mg/kg/day group after six months
of treatment as compared to placebo but this was not statistically
significant, with a RR of 1.78 (95% CI 0.96 to 3.32) (see Analysis
1.35).
Griggs 1991 also compared prednisone 0.3 mg/kg/day with
placebo and after six months of treatment there was no significant
difference in acne in the prednisone and placebo groups, with a
RR of 0.73 (95% CI 0.18 to 3.0) (see Analysis 1.35).
Mendell 1989 compared prednisone 1.5 mg/kg/day with placebo
and after six months of treatment there was a trend to develop acne
in the prednisone group, but this was not statistically significant,
with a RR of 1.77 (95% CI 0.84 to 3.73) (see Analysis 1.35).
Hu 2015 reported acne in two of 31 participants in the prednisone
group at 12months, but did not report data for the placebo group.
(f) Osteoporosis, fractures
None of the included studies performed bone densitometry stud-
ies. Two studies instructed the participants in the study to take 0.3
g calcium carbonate with eachmeal (Griggs 1991;Mendell 1989).
Two of the included studies commented upon fractures (Angelini
1994; Beenakker 2005). Angelini 1994 reported pathological frac-
ture of the tibia in one participant in the deflazacort-treated group.
There was no description of the timing of the fracture in relation
to duration of deflazacort treatment, circumstances leading to the
fracture, or results of any bone density studies. One participant,
randomised to the placebo group in the first phase of Beenakker
2005, developed a traumatic fracture of the femur 10 days into the
study and dropped out. One participant in the placebo treatment
group in Griggs 1991 dropped out of the study because of an arm
fracture; Griggs 1993 subsequently reported this incident.
(g) Hyperglycemia/glycosuria
Angelini 1994 and Bäckman 1995 checked blood glucose, and
another two studies checked urine dipstix (Griggs 1991; Mendell
1989). Griggs 1991 reported glycosuria in one participant, who
was on prednisone 0.75 mg/kg/day. The report did not state the
severity of glycosuria and its impact.
(h) Hypokalemia
Only Angelini 1994 and Bäckman 1995 performed blood tests
for electrolyte surveillance. Angelini 1994 reported “mild hy-
pokalemia” in three of 11 deflazacort-treated participants but this
was “easily correctable” with oral potassium supplements.
(i) Hypertension
Griggs 1991 reported hypertension with a blood pressure of 130/
110 in one participant taking prednisone 0.75 mg/kg/day.
Hu 2015 did not report any hypertension.Monitoring of diastolic
blood pressure revealed no statistically significant differences at six
or 12 months between the group treated with prednisone 0.75
mg/kg/day and the group receiving placebo.
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(j) Gastrointestinal side effects
Gastrointestinal side effects were defined differently and inconsis-
tently in the included studies.
Mendell 1989 grouped increased appetite, nausea and stom-
ach discomfort under the umbrella of gastrointestinal symptoms;
these, as a whole, were not significantly different between the
placebo and prednisone treatment groups. Griggs 1991 reported
increased appetite as a separate side effect and this was significantly
more frequent in the prednisone 0.75 mg/kg/day group as com-
pared to the placebo group (P = 0.02). Angelini 1994 reported
that in their two-year study, none of the participants developed
gastrointestinal disturbances on deflazacort 2 mg/kg on alternate
days; they had, however, treated all the children with antacids
(drug name not specified). Parents of the participants in Bäckman
1995, the study of prednisolone 0.35 mg/kg/day, did not report
gastrointestinal side effects.
(k) Increased appetite
Two studies reported the number of participants with increased
appetite in treatment and placebo groups or phases (Beenakker
2005; Griggs 1991).
Beenakker 2005 compared an intermittent regimen of prednisone
(0.75 mg/kg/day given for the first 10 days of every month, for
six months) with placebo, in a cross-over design study. Four of
the 16 participants were noted to have increased appetite during
the prednisone treatment period as compared to one out of 16
in the placebo period. Data on occurrence of this adverse effect
during all four phases of the cross-over trial were not presented or
available, and because of this, review authors could not undertake
appropriate statistical analysis.
Griggs 1991 compared prednisone 0.3 mg/kg/day with placebo.
After six months of treatment, there was no significant difference
in the prednisone and placebo groups with a RR of 1.54 (95% CI
0.90 to 2.62) (see Analysis 1.36).
Griggs 1991 also compared prednisone 0.75 mg/kg/day with
placebo. After six months of treatment, there was no significant
difference in the prednisone and placebo groups, with a RR of
1.80 (95% CI 1.09 to 2.99) (see Analysis 1.36).
Hu 2015 reported increased appetite in six of 31 participants in
the prednisone (0.75 mg/kg/day) group at 12 months, but did not
report data for the placebo group.
(l) Cataracts
The participants were evaluated for cataracts in four of the six
included studies (Angelini 1994; Beenakker 2005; Griggs 1991;
Mendell 1989), but the studies did not describe the precise exami-
nation (slit lamp or red reflex) performed for detection of cataracts.
No cataracts were reported.
(m) Death
Bäckman 1995 reported two deaths during the study. A 16-year-
old boy died of pneumonia and a four-year-old died during an
appendectomy. The authors did not report whether the deaths
occurred during the prednisolone or the placebo phases.
(n) Life-threatening infections
Two studies described specific monitoring to document episodes
of intercurrent infection (Griggs 1991; Mendell 1989). None of
the studies described the treatment strategy for exposure to chicken
pox (varicella zoster). Apart from the 16-year-old boy who died of
pneumonia described above (Bäckman 1995), the trials reported
no other episodes of infection.
(o) Height restriction
Griggs 1991 and Mendell 1989 stated that they measured height,
but presented no data. Bäckman 1995, Beenakker 2005, and
Rahman 2001 did not describe height measurement.
Hu 2015 measured height (cm) at 6 and 12 months, reporting no
clear difference in height between prednisone-treated and placebo-
treated boys, although the results were imprecise, and allowed for
effects in either direction (MD -0.88, 95 CI -6.89 to 5.13, n = 63
at 6 months and MD -2.62, 95% CI -8.66 to 3.42; n = 58, at 12
months) (see Analysis 1.37; Analysis 1.38).
Angelini 1994 monitored height every 2 months. By two years,
growth was 11.4 ± 2.7 cm in the treated group and 11.2 ± 2.2
cm in the placebo group; however, the report does not state the
numbers of boys measured at this time point.
Observations on prednisone dose-response relationship and
adverse events
A full investigation of the prednisone dose-response relationship
to identify the optimum dose would need individual patient data
within-study analyses, and the included studies reported no such
analyses. We consider this further in the Discussion.
Two studies made direct comparisons of prednisone doses (Griggs
1991; Mendell 1989).
Griggs 1991 compared 0.3 mg/kg/day prednisone to 0.75 mg/
kg/day prednisone, finding statistically significant differences in
favour of the higher dose in average muscle strength scores (5.82
versus 6.00, P = 0.026, n = 65), time (seconds) to climb stairs (5.76
versus 4.23, P = 0.0014, n = 37), time (seconds) to stand (6.64
versus 4.56, P = 0.004, n = 33), and lifting weights (kg) (1.64
versus 2.04, P = 0.0006, n = 43), but no statistically significant
differences in leg function grade (4.07 versus 4.19, P = 0.53, n =
63), time (seconds) to travel nine metres (7.33 versus 6.37, P =
0.127, n = 44), or measures of pulmonary function.
Mendell 1989 compared 0.75mg/kg/day prednisonewith 1.5mg/
kg/day prednisone, finding no statistically significant differences
in strength or functional outcomes between the two doses: muscle
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strength score (6.23 versus 6.5, P = 0.84, n = 60), leg function
grade (3.25 versus 3.36, P = 0.67, n = 64), time (seconds) to climb
stairs (3.87 versus 4.00, P = 0.74, n = 47), time (seconds) to travel
nine metres (6.81 versus 7.04, P = 0.77, n = 55), time (seconds)
to stand (4.15 versus 3.43, P = 0.055, n = 34), lifting weights
(1.88 versus 2.13, P = 0.06, n = 55), or in measures of pulmonary
function.
From the forest plots showing studies grouped by dosage of pred-
nisone on several outcome variables, the confidence in effect esti-
mates for the efficacy of prednisone doses of 0.75 mg/kg/day or
above appears fairly secure. There was no evidence from Mendell
1989 of further benefit at 1.5 mg/kg/day.
Comparing adverse event rates at the 0.3 mg/kg/day (n = 33) and
0.75 mg/kg/day (n = 34) prednisone doses, the only statistically
significant differences between groups were in numbers reporting
hair growth (9% versus 41%, P = 0.006) and cushingoid features
(41% versus 71%, P = 0.02) (Griggs 1991). The between-group
difference in number of participants with over 20% weight gain
(11% versus 31%) was not statistically significant (P = 0.18), and
this was also the case for differences in ankle oedema (3% versus
6%, P = 0.60), acne (9% versus 26%, P = 0.08), insomnia (9%
versus 18%, P = 0.33), anorexia (3% versus 3%, P = 0.97), hy-
peractivity (16% versus 26%, P = 0.42), irritability (34% versus
50%, P = 0.20), increased appetite (59% versus 68%, P = 0.49),
and glycosuria (0% versus 3%, P = 0.71). No cataracts occurred.
Mendell 1989 reported no statistically significant differences in
rates of individual adverse events between a 0.75 mg/kg/day daily
prednisone dose (n = 33) and a 1.5 mg/kg/day daily dose (n = 33).
Adverse events reported were: behavioural change (48% versus
64%, P = 0.22), cushingoid appearance (55% versus 73%, P =
0.13), gastrointestinal symptoms (55% versus 61%, P = 0.62),
excessive hair growth (52%versus 52%, P = 1.0), acne (36% versus
39%, P = 0.80), and easy bruising (3% versus 6%, P = 0.56). No
participants had glycosuria or cataracts.
Weekend-only versus daily prednisone
Studied in Escolar 2011. See Summary of findings 2.
Primary outcome measure: prolongation of time to loss of
ambulation
Not reported.
Secondary outcome measures
(1) Muscle strength
Analysis 2.1.
(a) Average muscle score
Escolar 2011 measured upper and lower extremitymuscle strength
using QMT scores (“the summation of maximal isometric volun-
tary contraction force of flexors and extensors of elbow and knee”)
as primary outcomes. The trialists also conducted manual muscle
testing (MMT) using the modified MRC scale.
The mean change from baseline to month 12 in the MMT score
(SD) in 54 participants was 4 (24.3) in the weekend-only dosing
group and -0.6 (23.2) in the daily dose group, with a MD of 4.60
(95% CI -8.07 to 17.27); low quality evidence. The trial authors
defined an ’equivalence limit’ for MMT as one point on the 10-
point scale for each of the 34 muscles tested, which was ± 17
points; by this test, the upper CI just allows for the possibility of
a difference between weekend-only and daily dosing.
Results forQMTscores all included data from57 participants. For
theQMT arm score andQMT leg score, the trial authors reported
an equivalent improvement in the two groups (with equivalence
defined as approximately 1 SD of the baseline distribution, which
was ± 2 lb for all muscle strength tests). Themean change inQMT
arm score from baseline (SD) was 0.70 lb (1.7) in the weekend-
only dosing group and 1.3 lb (2.4) in the daily dose group. This
was a MD of -0.60 lb (95% CI -1.67 to 0.47); moderate quality
evidence (Summary of findings 2). The change in QMT leg score
was 2.2 lb (3.7) in the weekend-only dosing group and 2.10 lb
(3.4) in the daily dosing group, with aMD of 0.10 (95% CI -1.75
to 1.95; moderate quality evidence; Summary of findings 2).
QMT scores for elbow flexors (MD -0.4, 95% CI -1.60 to 0.80)
and elbow extensors (MD -0.9, 95% CI -2.00 to 0.20) also met
the test for equivalence. However, knee flexors (MD 1.40, 95%
CI -0.50 to 3.30), knee extensors (MD -1.20, 95% CI -3.52 to
1.12), and grip score (MD -1.70, 95% CI -3.22 to -0.18) did not,
with the CIs allowing for the possibility of a difference between
groups.
(b) Ability to lift weights
Not reported.
(2) Functional outcome measures
Analysis 2.2.
In Escolar 2011, the trial authors defined an ’equivalence limit’
for timed functional tests of ± 0.4 seconds.
(a) Time taken to rise from the floor (Gowers’ time)
Using the trial authors’ definition of equivalence, we found no
evidence of difference betweenweekend-only anddaily prednisone
in change in mean Gowers’ time (seconds) at 12 months (MD
0.15, 95% CI -0.02 to 0.32, n = 46).
26Corticosteroids for the treatment of Duchenne muscular dystrophy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(b) Timed walk
Using the trial authors’ definition of equivalence, we found no evi-
dence of a difference between weekend-only and daily prednisone
on change in the 10-metre walking time (seconds) between week-
end-only and daily prednisone groups (MD 0.00, 95% CI -0.21
to 0.21, n = 56; moderate quality evidence; Summary of findings
2).
(c) Four-stair climbing time
Using the trial authors’ definition of equivalence, we found no
evidence of a difference between weekend-only and daily pred-
nisone on change inmean four-stair climbing time (seconds) (MD
0.0, 95% CI -0.22 to 0.22, n = 55; moderate quality evidence;
Summary of findings 2).
(d) Leg function grade
Analysis 2.3.
We found no difference between weekend-only and daily pred-
nisone in change on the Vignos scale (MD 0.04, 95% CI -0.7 to
0.8, n = 58). This is a 10-point lower extremity mobility function
scale, grade 1 representing ability to walk and climb stairs with-
out assistance and grade 10 representing confinement to bed. The
trial authors defined equivalence as ± 0.6, so the results are too
imprecise to rule out difference on this measure.
(e) Arm function grade
Analysis 2.4.
We foundno significant difference in arm function grademeasured
using the Brooke scale, a six-point scale in which grade 1 represents
full straight arm abduction (to touch above the head) and grade 6
represents no useful function of the hands (MD 0.10, 95% CI -
0.62 to 0.82). The trial authors defined equivalence as ± 0.3, so the
results are too imprecise to rule out a difference on this measure.
(3) Pulmonary function - forced vital capacity (FVC), forced
expiratory volume in one second (FEV1)
Analysis 2.5; Analysis 2.6; Analysis 2.7; Analysis 2.8.
In 31 participants, the FVC% and the FEV1% (n = 31) predicted
showedno clear difference between the two treatments (MD4.4%,
95% CI -9.79 to 18.59, and MD 6.0%, 95% CI -9.15 to 21.15,
respectively). For pulmonary function tests the authors defined
equivalence as ± 10% of the per cent predicted. The CIs therefore
do not rule out the possibility of a difference between the groups.
Maximal voluntary ventilation (MVV) was measured in 27 par-
ticipants. There was not a clear difference between weekend-only
and daily prednisone (MD 4.00, 95% CI -1.68 to 9.68).
Maximal inspiratory pressure (MIP) was measured in 42 people.
We did not find evidence of a difference between the two treat-
ments in this comparison (MD 0.00, 95% CI -7.63 to 7.63).
(4) Quality of life (QoL)
Not assessed.
(5) Adverse events
(a) Weight gain
Analysis 2.9; Analysis 2.10.
We found no clear evidence of a difference in mean body mass
index (BMI) (mg/m2) with weekend-only versus daily dosing at 12
months (MD -1.8 kg/m2, 95% CI -3.74 to 0.14, n = 58). Weight
in kg after 12 months of treatment showed no clear difference
between the groups (MD -2.5 kg, 95% CI -7.54 to 2.54, n = 58;
low quality evidence; Summary of findings 2).
Dosage reductions because of BMI increases were necessary in
three participants in the daily group and one participant in the
weekend-only group.
(b) Behavioural changes
Analysis 2.11; Analysis 2.12; Analysis 2.13; Analysis 2.14; Analysis
2.15; Analysis 2.16; Analysis 2.17; Analysis 2.18.
Escolar 2011 measured behavioural changes using the Child Be-
havior Checklist, a rating scale on which higher scores indicate
more severe behavioural changes. There was no clear difference
between weekend-only and daily prednisone on any of the scales:
total problems (MD 1.00, 95% CI -4.34 to 6.34, n = 54; low
quality evidence; Summary of findings 2), internalising (MD 4.0,
95% CI -0.8 to 8.8, n = 54), externalising (MD -1.0, 95% CI
-6.62 to 4.62, n = 54), anxious/depressed (MD -1.0, 95% CI -
4.99 to 2.99, n = 55), somatic complaints (MD 2.0, 95% CI -
2.24 to 6.24, n = 55), withdrawn/depressed (MD 4.0, 95% CI -
0.3 to 8.3, n = 55), attention problems (MD 2.0, 95% CI -2.4 to
6.4, n = 56), or aggressive behaviour (MD 1.0, 95% CI -3.52 to
5.52, n = 55).
One participant in the daily group had a dosage reduction because
of behaviour problems, but there were no withdrawals.
(c) Cushingoid appearance
One participant on weekend-only dosing had dosage reduction
for the development of cushingoid features.
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(d) Excessive hair growth (hirsutism)
Not reported.
(e) Acne
Not reported.
(f) Osteoporosis, fractures
Analysis 2.19.
In 53 participants, there was no significant difference between
groups in lumbar spine Z scores (SD) at 12months: weekend-only
dose -0.88 (0.85); daily dose -1.33 (0.91), P = 0.06. However, the
change in Z score from baseline to 12 months favoured weekend-
only dosing, with a small increase in the weekend-only dosing
group (change of +0.26), compared with a small decline with daily
prednisone (change of -0.30), P = 0.001.
(g) Hyperglycemia/glycosuria
Not reported.
(h) Hypokalemia
Not reported.
(i) Hypertension
Not reported.
(j) Gastrointestinal side effects
One participant in the weekend-only group withdrew from the
study because of severe vomiting.
(k) Increased appetite
Not reported.
(l) Cataracts
Not reported.
(m) Death
Not reported.
(n) Life-threatening infections
One participant in the weekend-only group had a severe case of
flu and fever and one participant in the daily group had acute
appendicitis necessitating discontinuation (events graded by the
trialists as 3 or 4 on theNational Cancer Institute (NCI)Common
Toxicity Criteria).
(o) Height restriction
Analysis 2.20; Analysis 2.21.
At 12 months, height was measured in 58 participants in Escolar
2011 and was not significantly different in the weekend-only dos-
ing group than the daily dosing group (MD 1.00 cm, 95% CI -
4.67 to 6.67). The trial authors report a “significant increase in
linear growth in the weekend-only compared to the daily dosing
group (mean change 6.6 cm versus 4.1 cm, P = 0.002). We cal-
culated SD (assuming they were the same in each group) of 2.93,
producing a MD of 2.5 cm (95% CI 0.99 to 4.01), favouring
weekend-only dosing.
Deflazacort versus prednisone
Studied in Brooke 1996, Bonifati 2000 and Karimzadeh 2012.
See Summary of findings 3.
Bonifati 2000 was a one-year study of 18 randomised participants
with DMD.
Although Karimzadeh 2012 was an 18-month study that initially
randomised 34 participants to deflazacort or prednisone, we dis-
carded the 18-month data as invalid; at one year the investigators
excluded four prednisone participants from the study because of
uncontrollable weight gain, and these participants also had a re-
duction in motor function.
Brooke 1996 was a larger trial involving 196 participants, reported
only in an abstract. The only reported efficacy outcomewas average
change in strength at three months.
Primary outcome: prolongation of time to loss of
ambulation
Not measured.
Secondary outcome measures
(1) Muscle strength
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(a) Average muscle score
Bonifati 2000 measured muscle strength using the MRC scale
in four muscles: right deltoid, triceps, iliopsoas, and quadriceps
femoris. The authors compared the differences in summed MRC
scores at 3, 6, 9, and 12 months compared to baseline. The results
were presented graphically without measures of variability and are
not suitable for analysis. The authors reported that there were no
between-group differences inMRC score at one year, andmeasures
at 3, 6, and 9 months were ”similar“ between groups.
Karimzadeh 2012 did not measure muscle strength.
Brooke 1996 reported an average change in muscle strength
(”based on a standardised method used in several previous trials“)
after three months of +0.8 with deflazacort 0.9 mg/kg, +0.26 with
deflazacort 1.2mg/kg, and +0.27with prednisone, but the abstract
provided no participant numbers, SD or P values for comparisons.
(b) Ability to lift weights
Notmeasured inBonifati 2000 orKarimzadeh 2012. Brooke 1996
provided no information.
(2) Functional outcome measures
Bonifati 2000 reported a composite score that was a sum of the
grades in functional scores (10-metre walk, rising from a chair and
from the floor, and four-stair climb) and also measured the time
taken to perform each test. The report did not provide data from
each individual test. We contacted the trial authors for details, but
received no response.
Karimzadeh 2012 measured movement function every three
months using the same three modalities as in Bonifati 2000, grad-
ing each modality in three levels (performed without assistance,
performed with assistance, or not able to perform the task) at 3,
6, 9, 12, and 18 months. We were unable to reliably interpret the
data because of inconsistencies between text and tables in the trial
report.
Brooke 1996 provided no information.
(a) Leg function grade
Notmeasured inBonifati 2000 orKarimzadeh 2012. Brooke 1996
provided no information.
(3) Pulmonary function - forced vital capacity (FVC)
Not measured in Bonifati 2000. Karimzadeh 2012 reported that
none of the groups had an abnormal vital respiratory capacity (less
than 80% normal based on age and gender) during the study, and
that there were no between-group differences, without providing
numerical data.
Brooke 1996 provided no information on pulmonary function.
(4) Quality of life (QoL)
Not measured in Bonifati 2000, Karimzadeh 2012, or Brooke
1996.
(5) Adverse events
(a) Weight gain
Data for 3-, 6- and 9-month time points were not provided by
Karimzadeh 2012, and were presented graphically in Bonifati
2000, without any measures of variability. For Bonifati 2000, we
read the data from the graph using the rulermethod, andfigures are
therefore very approximate. The percentage body weight increase
in the deflazacort and prednisone groups respectively were 2.5%
and 6% at three months, 3% and 10% at six months, and 5.8%
and 18% at nine months. The reported P value for the difference
between groups was < 0.05 at six months and ”the difference
remained statistically significant at 9 and 12 months“.
Bonifati 2000 reported the mean increase from initial weight at
12 months to be 9% (2.17 kg) in the deflazacort group (n = 9) and
21.3%(5.08kg) in the prednisone group (n =8)without providing
SD. This was reported as a significant difference at an assumed
significance threshold of P < 0.05 (the stated significance threshold
for the difference at 6 months). Using the most conservative value
of P = 0.05 for the between-group difference at one year, and
assuming that the SD of outcome measurements were the same
in each group, the estimated SD was 11.88. This gave a MD of -
12.30% (95% CI -23.61 to -0.99) (Analysis 3.1).
Karimzadeh 2012 did not clearly report the numbers in which
weight gain was measured at 12 months. However, authors state
that the study was continued after early dropouts with 14 patients
taking deflazacort, and 12 using prednisone. The MD between
groups assuming these sample sizes was -8.70% (95% CI -14.84
to -2.56) (Analysis 3.1).
This trial reported a mean change of weight of 12.95% (SD 9.23,
95%CI 7.6 to 18.3) in the deflazacort group (n = 14) and 21.65%
(SD 6.68, 95%CI 16.1 to 27.2) in the prednisone group (n = 12).
Combining the one-year weight gain data from Bonifati 2000 and
Karimzadeh 2012 (n = 43), the MD was -9.52% (95% CI -14.91
to -4.12; very low quality evidence) in favour of deflazacort (see
Figure 6; Analysis 3.1; Summary of findings 3). These data must
be interpreted with caution.
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Figure 6. Forest plot of comparison: 3 Deflazacort versus prednisone, outcome: 3.1 Weight gain (%).
The Brooke 1996 abstract reported weight gain as a percentage
of baseline weight at 12 months as follows: deflazacort 0.9 mg/
kg = 16.8%, deflazacort 1.2 mg/kg = 18.3%, and prednisone =
26.7%; P < 0.1 for comparisons of deflazacort versus prednisone.
The abstract did not give the number of participants in each group
or SD. Brooke 1996 also reported the percentage of participants
with moderate or severe obesity: 24% in the deflazacort 0.9 mg/
kg group, 11% in the deflazacort 1.2 mg/kg group, and 41% in
the prednisone group; without sufficient detail for analysis.
Bonifati 2000 reported the number of participantswith an increase
in body weight of over 20% at one year. This was 1/9 (11%) in
the deflazacort group and 4/8 (50%) in the prednisone group.
(b) Behavioural changes
The number of children with behavioural changes in Bonifati
2000 was four participants (44%) in the deflazacort group and
four participants (50%) in the prednisone group at six months
(RR 0.89, 95%CI 0.32 to 2.43; Analysis 3.2), and six participants
(66%) in the deflazacort group and five participants (62%) in the
prednisone group at one year (RR 1.07, 95%CI 0.53 to 2.17; very
low quality evidence; Analysis 3.3; Summary of findings 3). The
changes were reportedly ”slight“.Karimzadeh 2012 and Brooke
1996 provided no information on behavioural changes.
(c) Cushingoid appearance
The number of children with Cushingoid appearance in Bonifati
2000 was two (22%) in the deflazacort group and five (55%) in
the prednisone group at six months (RR 0.59; 95% CI 0.13 to
2.70; Analysis 3.2) and five (55%) in the deflazacort group and
four (50%) in the prednisone group at one year (RR 1.11; 95%CI
0.45 to 2.75; Analysis 3.3). These changes were also reported as
”slight“. Cushingoid appearance was not evaluated in Karimzadeh
2012.
Brooke 1996 reported the percentage of participants with moder-
ate or severe moon face: 36% in the deflazacort 0.9 mg/kg group,
32% in the deflazacort 1.2 mg/kg group, and 43% in the pred-
nisone group. The report did not give SD or the numbers of par-
ticipants in each group.
(d) Excessive hair growth (hirsutism)
In Bonifati 2000, hirsutism occurred in five participants (55%)
in the deflazacort group and four participants (50%) in the pred-
nisone group at six months (RR 1.11, 95% CI 0.45 to 2.75;
Analysis 3.2), and five participants (55%) in the deflazacort group
and three participants (37%) in the prednisone group at one year
(RR 1.48, 95% CI 0.51 to 4.31; Analysis 3.3). Karimzadeh 2012
did not report on the presence of hirsutism. Brooke 1996 provided
no information.
(e) Acne
Bonifati 2000 reported that no case of acne occurred. Karimzadeh
2012 didnot report on the presence of acne. Brooke 1996 provided
no information.
(f) Osteoporosis, fractures
Participants in Bonifati 2000 underwent an x-ray of the hand
at baseline and after one year of corticosteroid treatment. The
authors do not report the results other than that during the year
of treatment, bone age was similar in the two groups. One boy
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in the deflazacort group had a traumatic bone fracture after four
months of treatment.
Karimzadeh 2012 and Brooke 1996 did not report the occurrence
of fractures or osteoporosis.
(g) Hyperglycemia/glycosuria
Bonifati 2000 measured glucose. The trial authors reported no
significant change in laboratory parameters, without providing
further details. Karimzadeh 2012 reported that no glucosuria was
detected in either treatment group ”in the 3-month evaluation“ -
we thought this likely to mean at the three-monthly evaluations.
Brooke 1996 provided no information on this adverse event.
(h) Hypokalaemia
Bonifati 2000 measured electrolytes. The trial authors reported
no significant change in laboratory parameters, without providing
further details. Karimzadeh 2012 and Brooke 1996 did not report
on the presence of hypokalaemia.
(i) Hypertension
No study reported blood pressure data in detail. In Karimzadeh
2012 blood pressure wasmeasured every threemonths, with no in-
crease in either group according to the age-specific standard curve.
Bonifati 2000 reported that no case of hypertension occurred.
Brooke 1996 provided no information on this adverse event.
(j) Gastrointestinal side effects
Bonifati 2000 reported ’Gastric symptoms’ in one participant
(11%) in the deflazacort group and two participants (25%) in the
prednisone group at six months (RR 0.44, 95% CI 0.05 to 4.02;
Analysis 3.2), and one participant (11%) in the deflazacort group
and one participant (12%) in the prednisone group at one year
(RR 0.89, 95% CI 0.07 to 12.00; Analysis 3.3). Antacid treat-
ment produced complete resolution of pain. Karimzadeh 2012
and Brooke 1996 did not report on gastrointestinal effects.
(k) Increased appetite
In Bonifati 2000, appetite increase occurred in two participants
(22%) in the deflazacort group and six participants (75%) in the
prednisone group at six months (RR 0.30, 95% CI 0.08 to 1.07;
Analysis 3.2) and three participants (33%) in the deflazacort group
and six participants (75%) in the prednisone group at one year
(RR 0.44, 95% CI 0.16 to 1.22; Analysis 3.3). The trial authors
reported the change in appetite as ”slight“. Karimzadeh 2012 and
Brooke 1996 did not report on appetite change.
(l) Cataracts
Participants in Bonifati 2000 underwent a slit lamp examination
of the eye at baseline and after one year of corticosteroid treatment;
a ”slight cataract“ was found in two boys in the deflazacort group
and one in the prednisone group. Karimzadeh 2012 reported no
cataracts at the one-year evaluation. Brooke 1996 provided no
information.
(m) Death
None reported in Bonifati 2000, Brooke 1996 or Karimzadeh
2012.
(n) Life-threatening infections
The occurrence of sepsiswas not reported inBonifati 2000, Brooke
1996, or Karimzadeh 2012.
(o) Height restriction
Bonifati 2000 monitored height but did not provide any infor-
mation on it in the results. Karimzadeh 2012 reported height and
growth ”at the end of the study“ (18 months), but we discarded
these data for reasons given above. Brooke 1996 did not report
height data.
(p) Others
Bonifati 2000 reported that adverse event monitoring identified
no ankle oedema, insomnia, or anorexia.
Karimzadeh 2012 reported no cardiomyopathy (measured by de-
crease in ejection fraction at one year). One participant had sco-
liosis at the start of the study and was treated with a brace, and
had no increase in scoliosis at one-year follow-up. No scoliosis was
otherwise detected.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Weekend-only versus daily prednisone for Duchenne muscular dystrophy
Patient or population: pat ients with Duchenne muscular dystrophy
Setting: outpat ient
Intervention: weekend prednisone
Comparison: daily prednisone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Score/ value with daily
prednisone
Score/ value with week-
end-only prednisone
Prolongat ion of t ime to
loss of ambulat ion - not
reported
- - - - - Not an outcome in the
single included study
for this comparison
Change in muscle
strength - QMT arm
score (lb)
follow-up: 12 months
(higher indicates
stronger)
The mean change in
QMT arm score in the
control group was 1.3
lb
The mean change in
QMT arm score in the
intervent ion group was
0.6 lb lower (1.67 lower
to 0.47 higher)
- 57
(1 RCT)
⊕⊕©©
M oderate
1
-
Change in muscle
strength - QMT leg
score (lb)
follow-up: 12 months
(higher indicates
stronger)
The mean change in
QMT leg score in the
control group was 3.4
lb
The mean change in
QMT leg score in the in-
tervent ion group was 0.
1 lb more (1.75 lower to
1.95 higher)
- 57
(1 RCT)
⊕⊕©©
M oderate1
-
Change in muscle
strength - MMT score
Follow-up: 12 months
(higher indicates
stronger)
The mean change in
MMT score in the con-
trol group was -0.6
The mean change in
MMT score in the in-
tervent ion group was 4.
6 higher (8.07 lower to
17.27 higher)
- 54
(1 RCT)
⊕⊕©©
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Change in 10-metre
walking t ime
Follow-up: 12 months
The mean change in 10-
metre walking t ime in
the control group was
0.1 seconds
The mean change in 10-
metre walking t ime in
the intervent ion group
was 0 (0.21 quicker to
0.21 slower)
- 56
(1 RCT)
⊕⊕©©
M oderate3
-
Change in 4-stair climb-
ing t ime
Follow-up: 12 months
The mean change in 4-
stair climbing t ime in
the control group was -
0.06 seconds
The mean change in 4-
stair climbing t ime in
the intervent ion group
was 0 (0.22 quicker to
0.22 slower)
- 55
(1 RCT)
⊕⊕©©
M oderate3
-
BMI (kg/ m2) at end of
study
Follow-up: 12 months
The mean BMI (kg/ m2)
in the control group was
19.6
The mean BMI kg/ m2 in
the intervent ion group
was 1.8 lower (3.74
lower to 0.14 higher)
- 58
(1 RCT)
⊕⊕©©
Low4
Mean % weight gain not
reported. Mean dif fer-
ence in weight (kg) did
not show a clear dif -
ference at 12 months,
being 2.5 kg lower; 7.
54 lower to 2.54 higher
with weekend-only dos-
ing
Behavioural changes
assessed with Child Be-
haviour Checklist total
prob-
lems (higher scores in-
dicate more severe be-
havioural changes)
Follow-up: 12 months
The mean behavioural
change score in the
control group was 48
The mean behavioural
change score in the in-
tervent ion group was 1
higher (4.34 lower to 6.
34 higher)
- 54
(1 RCT)
⊕⊕©©
Low4
-
Fractures - not reported See comment See comment Not est imable 53
(1 RCT)
- No f ractures reported.
Change in lumbar spine
Z scores favoured
weekend-only dosing
(increase in the week-3
3
C
o
rtic
o
ste
ro
id
s
fo
r
th
e
tre
a
tm
e
n
t
o
f
D
u
c
h
e
n
n
e
m
u
sc
u
la
r
d
y
stro
p
h
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
end group +0.26, com-
pared with -0.30 decline
with daily prednisolone
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
BM I: body mass index; CI: conf idence interval; M M T : manual muscle test ing; QM T : quant itat ive muscle test ing; RCT : randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Trial authors def ined equivalence lim its (lim its within which the regimens can be considered of equivalent ef f icacy) of ± 2 lb
for QMT. We downgraded once as although serious imprecision is present, the CIs fall within the equivalence lim its.
2We downgraded the quality of evidence twice for serious imprecision due to small sample size; trial authors def ined
equivalence lim its (lim its within which the regimens can be considered of equivalent ef f icacy) of ± 17 points and the CIs allow
for the possibility of non-equivalence.
3Trial authors def ined equivalence lim its (lim its within which the regimens can be considered of equivalent ef f icacy) of ± 0.4
seconds for t imed tests. We downgraded once; although serious imprecision is present, the CIs fall within the equivalence
lim its.
4 We downgraded the evidence for very serious imprecision (due to small sample sizes, plus the CI includes appreciable
dif f erences in favour of either intervent ion).
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Deflazacort versus prednisone for Duchenne muscular dystrophy
Patient or population: pat ients with Duchenne muscular dystrophy
Setting: outpat ient
Intervention: def lazacort
Comparison: prednisone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk or score/ value
with prednisone or
prednisolone
Risk or score/ value
with deflazacort
Prolongat ion of t ime to
loss of ambulat ion - not
reported
See comment See comment Not est imable - - None of the studies in-
vest igat ing this com-
parison assessed pro-
longat ion of t ime to
loss of ambulat ion
Muscle strength - not
reported
See comment See comment - - - One study measured
summed MRC scores
f rom 4 muscles at 3, 6,
9, and 12 months, but
presented data graphi-
cally without measures
of variability
Change in 10-metre
walking t ime
Follow-up: 12 months
- - - - Two studies (n =
43) reported composite
scores of t imed func-
t ion tests, but did not re-
port the scores for each
test separately
3
5
C
o
rtic
o
ste
ro
id
s
fo
r
th
e
tre
a
tm
e
n
t
o
f
D
u
c
h
e
n
n
e
m
u
sc
u
la
r
d
y
stro
p
h
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Change in 4-stair climb-
ing t ime
Follow-up: 12 months
- - - - - Two studies (n =
43) reported composite
scores of t imed func-
t ion tests, but did not re-
port the scores for each
test separately
Weight gain (%)
Follow-up: 12 months
The mean weight gain
(%) was 21.48%
The mean weight gain
(%) in the intervent ion
group was 9.52% lower
(14.91 lower to 4.12
lower)
- 43
(2 RCTs)
⊕©©©
Very low 1,2,3
-
Behavioural changes
Follow-up: 12 months
500 per 1000 445 per 1000 (160 to
1000)
RR 1.07 (0.53 to 2.17) 17
(1 RCT)
⊕©©©
Very low 1,2,4
-
Fractures
Follow-up: 12 months
1 traumatic f racture occurred af ter 4 months’
def lazacort treatment in one study (n = 26). No
other f ractures reported
Not est imable - - -
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; M RC: Medical Research Council; RCT : randomised controlled trial; RR: risk rat io; SD: standard deviat ion
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1We downgraded the quality of evidence twice for a high risk of bias in most domains.
2We downgraded the quality of evidence once for possible publicat ion bias - a large study remains unpublished (Brooke 1996).
3Analysis involved some stat ist ical assumptions in calculat ing SD.
4CIs include the possibility of both a large ef fect and a clinically unimportant ef fect (i.e. imprecision).
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D I S C U S S I O N
Summary of main results
We identified 50 studies of corticosteroids in Duchenne muscular
dystrophy (DMD) conducted over the last four decades. From
these, 12 randomised controlled trials (RCTs), with a total of 667
participants, were eligible for inclusion in this review based on our
predefined criteria.
Among these studies, six (n = 332) were RCTs comparing corticos-
teroids against placebo; five studied prednisolone or prednisone
andone studied deflazacort.With regard to ambulatory status, 282
participants were walking, either independently or with the help of
long leg braces. Two large studies contributed the majority of the
patients (202 of 332) to the corticosteroid versus placebo compar-
ison (Griggs 1991; Mendell 1989). The treatment groups within
this comparison included prednisone (n = 217), prednisolone (n
= 10) and deflazacort (n = 17). Unfortunately, two large studies
of deflazacort in DMD comprising 206 participants in total have
not been published beyond abstract form and their final data are
not available (Brooke 1996; Reitter 1995).
We identified one RCT of daily prednisone versus weekend-only
prednisone in 64 ambulant boys and two RCTs (n = 52) of pred-
nisone versus deflazacort. A further largemulticentre international
RCT comparing daily prednisolone (0.75 mg/kg/day), daily de-
flazacort (0.9 mg/kg.day), and intermittent prednisolone (0.75
mg/kg/day 10 days on, 10 days off ) is of major interest, but still
in progress at the time of this review (Guglieri 2015). A further
potentially eligible RCT is in progress in India, comparing daily
prednisolone 0.75 mg/kg/day given for 10 consecutive days per
month versus daily dosing (CTRI/2009/091/000738).
Corticosteroids versus placebo
Primary outcome measure: prolongation of time to loss of
ambulation
Loss of ambulation is the key milestone in the natural history of
DMD, and is of maximal functional significance. Prevention or
postponement of this event is the key aim of therapeutic interven-
tions in the first decade of life, and a desired outcome measure.
Prolongation of time to loss of ambulation was not the stated pri-
mary outcomemeasure ofmost RCTs, probably because to achieve
sufficient power to demonstrate this effect, studies would require a
large sample size and long duration (Muntoni 2002). As progres-
sive muscle weakness is the major contributor to loss of walking,
trialists have used measurements of muscle strength as a surrogate
marker, enabling clinical trials to be completed in as little as six
months. These short-term studies do not demonstrate prolonga-
tion of time to loss of ambulation or allow evaluation of adverse
effects that develop after long-term use of corticosteroids (Griggs
1991; Mendell 1989; Rahman 2001).
Although Angelini 1994 assessed our primary outcome measure,
the data available did not allow us to create survival curves for
prolongation of walking. Some disparities that cannot be read-
ily explained further highlight the need for appropriate statisti-
cal analysis. Deflazacort and placebo groups were evenly matched
at randomisation, and among participants who lost ambulation
during the study, the mean age at which boys became wheelchair-
dependent was very similar in the two groups (deflazacort group,
108 months; and placebo group, 104 months). Comparing these
groups, the significance of the difference of 13 months in duration
of walking between randomisation and becoming wheelchair-de-
pendent cannot be ascertained without knowing the ages of the
ambulant children at the end of the study.
Secondary outcome measures
Strength
Strength parameters in the corticosteroid treatment groups
demonstrated statistically significant improvement comparedwith
placebo. All seven of the included studies measured muscle
strength usingMRC-based scores (Angelini 1994; Bäckman 1995;
Griggs 1991; Hu 2015; Mendell 1989; Rahman 2001; Todorovic
1998).
Pooled data from Griggs 1991, Mendell 1989, and Rahman 2001
demonstrated a statistically significant improvement in muscle
strength over six months (reported as muscle strength score) with
prednisone/prednisolone treatment versus placebo. Beenakker
2005 reported data on muscle strength as muscle force assessed
by hand-held dynamometry, which could not be pooled with data
from the above three studies; nevertheless, this trial demonstrated
improvement in muscle force during the six-month prednisolone
treatment phase over the placebo phase. The improvement inmus-
cle strength or force occurred with all four treatment regimens
(0.75 mg/kg/day for the first ten days of every month, 0.3 mg/kg
daily, 0.75 mg/kg daily and 1.5 mg/kg daily). Data from the other
trials were lacking or not suitable for analysis.
Hu 2015 was a 12-month study and demonstrated improvements
in lower limb muscle strength at both six and 12 months. We
could not include the data in meta-analysis because although in-
vestigators used MRC-based scores, they tested two muscles and
did not combine results into a single score.
The two-year study of deflazacort (2 mg/kg on alternate days)
versus placebomeasured change inMRC index (%) over the initial
score, demonstrating a difference in favour of deflazacort at 24
months, but not at 6 months (Angelini 1994).
Function
Functional parameters showed statistically significant improve-
ment over the short term (up to a year) in corticosteroid-treated
groups. The functional parameters showing improvement in-
cluded time taken to rise from the floor, time taken to walk nine
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metres, time taken to climb four stairs, and the leg functional
grade. It is, however, important to note that none of the included
studies reported any non-ambulant (wheelchair-dependent) par-
ticipants regaining the ability to walk on treatment with pred-
nisone.
Data from Beenakker 2005, Griggs 1991, Hu 2015, Mendell
1989, and Rahman 2001 demonstrated a statistically significant
improvement in time taken to rise from the floor in the prednisone/
prednisolone treatment groups on all dose regimens (0.3 mg/kg/
day, 0.75 mg/kg/day, and 1.5 mg/kg/day in daily dose regimens
or 0.75 mg/kg/day on the first 10 days of every month, in an
intermittent regimen). The muscle weakness in DMD leads to
increasing difficulty in rising from the floor at around five years of
age, with loss of this ability towards the end of the first decade of
life.
Time taken to walk nine (or ten) metres showed a statistically
significant improvement in all prednisone/prednisolone treatment
groups versus placebo in five trials (Beenakker 2005; Griggs 1991;
Hu 2015; Mendell 1989; Rahman 2001). Leg function grades
also showed a statistically significant improvement in all pred-
nisone/prednisolone treatment groups versus placebo in three tri-
als (Griggs 1991; Mendell 1989; Rahman 2001).
Angelini 1994, a comparisonof alternate day deflazacort (2mg/kg)
versus placebo, demonstrated a difference in favour of deflazacort
in timed gait at six months. but no significance difference on our
analyses in other functional parameters at the six-month or two-
year time points. The study measured outcomes until participants
became wheelchair dependent and had a high dropout rate at two
years.
Pulmonary function
One of the desired effects of any successful treatment in DMD is
the preservation of respiratory muscle strength, thereby preserv-
ing pulmonary function and postponing or removing the risk of
nocturnal hyperventilation and respiratory failure. A good marker
of respiratory reserve is forced vital capacity (FVC) and two of
the large included studies measured this outcome (Griggs 1991;
Mendell 1989). A statistically significant improvement in the FVC
in all prednisone treatment groups versus placebo was present after
sixmonths of treatment. Parallel results are available fromnon-ran-
domised cohort studies (Biggar 2001; Biggar 2004; Biggar 2006;
Silversides 2003), which showed strength improvement and sta-
bilisation of FVCover the long term in deflazacort-treated patients
(see below).
Quality of life
Two trials measured quality of life (Beenakker 2005; Hu 2015),
with only Hu 2015 providing numerical data. Self reported and
proxy reported quality of lifemeasures were better with prednisone
0.75 mg/kg/day than with placebo.
Adverse events
Caution is required in extrapolating the adverse effects of corticos-
teroid therapy reported in these included studies to circumstances
of long-term clinical use. Five of the seven included studies used
daily doses of prednisone/prednisolone over a six-month period;
one used a daily dose for a year. The longest included study, of
two years’ duration, used deflazacort 2 mg/kg on alternate days
(Angelini 1994).We would expect the side effects observed during
these studies to be much less than those likely to occur during
five years or longer use, as may be anticipated in clinical practice.
These short-term studies would be unlikely to detect long-term
adverse effects, especially loss of bone mineral density, increased
bone fracture incidence, cataracts, and growth failure with short
stature.
The propensity for excessive weight gain on corticosteroid treat-
ment was clear. This did not appear to adversely affect strength or
function in these short-term studies, except for one participant (in
the prednisone 0.3 mg/kg/day group), who at the end of the six
months of the Griggs 1991 study refused to continue to another
subsequent study of prednisone versus azathioprine (Griggs 1993).
Behavioural changes and cushingoid side effects were statistically
significant in the corticosteroid treatment groups, but were not
considered important enough for treatment to be discontinued in
these short-term studies.
Participants treated with prednisone 0.75 mg/kg/day over the six-
month period were at significant risk of excessive hair growth.
Participants and their families appear to have tolerated this side
effect, which caused no participants to drop out of the study.
Combined data from Mendell 1989 and Griggs 1991 demon-
strated more acne in the prednisone 0.75 mg/kg/day group during
the six months of treatment compared to six months of placebo,
but this difference was not statistically significant.
As the intermittent corticosteroid regimens are postulated to have
a better adverse effect profile, we wanted to compare the daily dose
regimen (studied in Mendell 1989, Griggs 1991, and Rahman
2001) with the intermittent regimen (studied in Beenakker 2005).
We were not able to make a comparison, as adverse effects data
from the only RCT of intermittent prednisone were not available
in a format that would allow statistical analysis (Beenakker 2005).
In this six-month randomised, controlled, cross-over trial of in-
termittent prednisone (0.75 mg/kg/day for the first 10 days each
month), increased appetite and behavioural side effects occurred
more frequently during the prednisone period than during the
placebo period, but these effects appear to have been mild, as they
required no dose adjustment or drug discontinuation.
Only one included study reported a pathological fracture (of the
tibia) while on corticosteroid (deflazacort 2mg/per kg on alternate
days) (Angelini 1994). The report did not describe the duration of
treatment prior to the occurrence of fracture or the circumstances
of the fracture. One participant in the placebo treatment group in
Griggs 1991 dropped out of the study because of an arm fracture
(reported in Griggs 1993).
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None of the studies assessed bone mineral density by dual energy
x-ray absorptiometry (DEXA) scans. This relates to the age ofmost
of the studies and their short-term nature. However, in view of the
benefit of corticosteroid therapy in DMD, the treatment regimen
is routinely continued in these patients over a decade or longer. In
these circumstances, the development of osteoporosis is a major
risk, and future studies should consider bone health assessment
and systematic DEXA scanning in their protocol for adverse event
monitoring (Biggar 2005; Quinlivan 2005).
Corticosteroid dose-response relationship
Clinically, it is important to use the minimum effective dose of
corticosteroid. To answer the question of what this may be, we
reviewed the forest plots showing studies grouped according to
dosage of prednisone/prednisolone. On the basis of the evidence
available for analysis, our confidence in the effect estimate for pred-
nisone/prednisolone at doses of 0.75 mg/kg/day is fairly secure.
There is little evidence of an increase in benefit when the dose is
further increased from 0.75 to 1.5 mg/kg daily (Mendell 1989).
This suggests that the daily dose regimen of 0.75 mg/kg/day is
adequate to achieve what benefit prednisone can provide.
Differences in the proportion of boys experiencing hair growth
and cushingoid features was significantly greater on a daily pred-
nisone dose of 0.75 mg/kg/day than on 0.3 mg/kg/day, but the
higher dose did not significantly increase rates of other common
adverse events (Griggs 1991). Mendell 1989 found no statistically
significant increases in frequency of any adverse event when com-
paring 1.5 mg/kg/day with 0.75 mg/kg/day prednisone.
A proper investigation of the prednisone dose-response relation-
ship to identify the optimum dose would need individual patient
data within study analyses. We recommend that future studies
make arrangements for provision of individual patient data for
these analyses.
Co-interventions
The co-interventions identified included daily calcium carbonate
(Griggs 1991; Mendell 1989), antacids given routinely to all par-
ticipants (Angelini 1994), and dietetic advice to avoid weight gain
(Angelini 1994; Griggs 1991; Mendell 1989). In Hu 2015, con-
comitant interventions included a calcium-rich diet, medications
(vitamin D, calcium, ranitidine, over-the-counter antacid), a high
protein, low carbohydrate, low fat diet, and respiratory, cardiac,
and rehabilitative interventions (Hu 2015). These co-interven-
tions, however, are clinically extremely unlikely to be responsible
for the benefits observed. None of the studies assessed physical
activity levels as a potentially confounding factor.
Weekend-only versus daily prednisone
Escolar 2011 was the only published RCT of weekend-only versus
daily prednisone. No appreciable difference was present in the
primary outcomes of upper and lower limb strength or the safety
outcome of body mass index (BMI) between the two groups at
12 months. We did find a difference with faster times to rise from
the floor in the daily group, but no clear differences were seen for
any other functional outcomes measured. The trial identified no
clear difference in weight gain, as the result had wide confidence
intervals that include the possibility of no benefit from weekend-
only over daily treatment. The weekend-only treatment group had
a larger increase in linear height.
Deflazacort versus prednisone
Of the three RCTs of deflazacort versus prednisone, only Bonifati
2000 and Karimzadeh 2012 have been published in detail, while
Brooke 1996 (n = 106) has been published only as an abstract.
Bonifati 2000 was a study with only 18 participants, comparing
the adverse effects of prednisone with those of deflazacort, both
given in a daily dose regimen over one year. The trialists did not
present power calculations. The two corticosteroids demonstrated
similar benefit on strength and functional tests, but the difference
in weight gain was statistically significant, being more marked in
the prednisone treatment group. One of the nine participants in
the deflazacort group, in comparison to four of the nine in the
prednisone group, experienced a weight gain of more than 20%
over baseline. Karimzadeh 2012 randomised 34 participants to
either daily prednisone 0.75 mg/kg/day or daily deflazacort 0.9
mg/kg/day. After early dropouts the trial continued for 12 months
with 26 participants. At 12 months there was no appreciable dif-
ference in motor function scores between the two drug regimens.
There was a clear difference in weight gain combining data from
the two trials, with the greatest gain seen in the prednisone group,
although this evidence is very low quality.
Brooke 1996 and Reitter 1995 (which is not stated to be ran-
domised) are of major clinical interest because they involved a
large number of participants. These trials compared prednisone
with deflazacort and, in addition, compared prednisone and de-
flazacort with a contemporaneous placebo control group. The re-
view authors contacted the authors of these studies for an earlier
version of this review, but data were not available. Campbell 2003
reported similar difficulties in obtaining these data for their sys-
tematic review of deflazacort in DMD.
Evidence from excluded randomised studies
Pradhan 2006 explored the possibility that daily prednisolone ini-
tiated in the late ambulant phase of DMDwould delay loss of am-
bulation, while also aiming to shorten the period of corticosteroid
exposure and thereby diminish adverse effects. The investigators
calculated the power of this study to detect a significant difference
between the control and treatment groups, not on the basis of time
to loss of ambulation, but on muscle power. This open, controlled
trial assessed the effect of prednisolone 0.75 mg/kg daily, started
at a stage when the participants had started falling several times in
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a day. The investigators randomly allocated 67 serially seen boys
into a prednisolone treatment group (44 participants, mean age
8.83 ± 1.25 years) or control group (23 participants, mean age
8.18 ± 0.64 years). Both groups also received vitamin E. The trial-
ists followed up participants for two years, and thereafter until the
boys reached a ”chair bound stage“. Of the 44 participants in the
prednisolone treatment group, 24 dropped out because of adverse
effects and treatment was stopped in a further five because of no
improvement in power. Fifteen of the remaining 19 in the treat-
ment group could be followed up regularly for two years, and then
up to ”chair bound stage“; only data from these 15 participants
were used for comparison with the control group. Pradhan 2006
reported that in this subgroup of 15, the mean age of becoming
wheelchair-dependent was 169 ± 9 months compared to 132 ± 8
months in the control group. As the statistical analysis was based
only on the 15 participants who responded without significant
adverse effects, and does not take into account dropouts or non-
responders in the prednisolone treatment group, we did not in-
clude Pradhan 2006 in the review.
Though the trialists did not analyse the data in this study on an
intention-to-treat basis, the results may be of clinical significance,
as there appears to be a subgroup of boys withDMDwho achieved
prolongation of time to loss of ambulation by three years, without
significant adverse effects. Caution is required in interpretation of
these results as they cannot be generalised to the whole population
of boys affected by DMD.
The variability in response to corticosteroid treatment amongst
individuals affected by DMD in this and other studies, remains
unexplained and is likely to be multifactorial. Bonifati 2006 sug-
gested glucocorticoid receptor polymorphisms to be one of the
possible factors modulating the long-term response to corticos-
teroids.
Evidence from non-randomised studies
Though non-randomised, these studies listed in Table 1 still con-
stitute an important body of evidence.
The initial studies
Early, open studies aiming to document some benefit of corticos-
teroid therapy in DMD used prednisone in high doses ranging
from 1.5 mg/kg/day to 5 mg/kg on alternate days (Brooke 1987;
DeSilva 1987; Drachman 1974; Siegel 1974). DeSilva 1987, an
open study, used loss of ambulation as its primary endpoint and
reported prolongation of walking by approximately two years. The
adverse effects of corticosteroid treatment in this study were sig-
nificant and included excessive weight gain, which occurred in the
majority of the participants, and hyperactivity, cataracts, hyper-
tension, and stress fractures. These initial studies led to RCTs and
further open cohort studies to assess efficacy, and to find optimal
dose regimens to minimise adverse effects (Griggs 1991; Mendell
1989).
Alternate day prednisone therapy
Fenichel 1991a compared alternate-day dosing regimens of pred-
nisone 1.25 mg/kg or 2.5 mg/kg over a six-month period. The
study recruited the same 103 patients who had just completed the
Mendell 1989 randomised study.The placebo group fromMendell
1989 received prednisone 1.25 mg/kg on alternate days; they im-
proved in strength at three months of treatment, but showed a
decline in strength over the subsequent three months. The partici-
pants inMendell 1989 whowere treatedwith prednisone 0.75mg/
kg/day or 1.5 mg/kg/day were changed to 2.5 mg/kg on alternate
days for six months in Fenichel 1991a; they showed a decline in
muscle strength. Comparing the 1.25 mg/kg alternate day group
of Fenichel 1991a with the contemporaneous 2.5 mg/kg alternate
day group, and also with the placebo control group of the previous
Mendell 1989 study, the trial authors concluded that daily dose
prednisone was more effective than the alternate-day regimen.
Yilmaz 2004 treated 66 boys with prednisolone 0.75 mg/kg on
alternate days (plus vitamin D 600 to 1200 units/day) and com-
pared this group with a control group of 22 boys who had been
followed up in the same centre in the past (”pre-steroid era“). The
controls were reportedly chosen at random, but no details were
given regarding this process. Duration of follow-up was 2.75 ± 0.1
years. Age at loss of walking ability was 10.0 ± 1.5 (range 7 to 14)
years in the prednisolone group, compared to 8.6 ± 2.6 (range 6 to
11) years in the control group. Amongst the prednisolone-treated
boys, 14 walked independently beyond the age of 12 years and
three beyond 13 years, but all lost the ability to walk by the end of
14 years of age. At the end of the study, none of the prednisolone
treatment group developed scoliosis during the follow-up period
(by a mean age 10.8 ± 1.2 years), whereas seven boys in the control
group had scoliosis by a mean age of 11.7 ± 2 years.
Daily prednisone therapy
At the end of Fenichel 1991a, 93 of the 103 participants entered
an open study in which they were given prednisone 0.75 mg/kg/
day for two years, the results of which were published in Fenichel
1991b. Muscle strength, described as average muscle score (previ-
ously described as muscle strength score) stabilised over a two-year
period. Over the two-year period, the prednisone dose had to be
decreased because of adverse effects, to as low as 0.15 mg/kg/day.
Prednisone 0.65 mg/kg/day was considered to be the minimum
effective dose, but only half of the participants could tolerate this
dose by the end of the study.
Long-term daily prednisone therapy
Pandya 2001 reported the long-term outcome of 30 participants
who had received prednisone for a mean period of 10 years. This
cohort comprised a subgroup of participants treated with pred-
nisone 0.75 mg/kg/day in Mendell 1989, who were followed up
at the University of Rochester. At the initiation of prednisone,
18 of the 30 participants were ambulant: 13 independently and
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five walking with long leg braces. At the time of the final visit,
one participant was still walking independently at age 18 years,
one participant was lost to follow-up, and three participants had
discontinued prednisone because of weight gain. The average age
of loss of independent ambulation was 14.5 years. This repre-
sents significant improvement in comparison to previous natural
history studies, which reported loss of walking in untreated boys
with DMD at mean ages of 8.8 years (Dubowitz 1978), 9.5 years
(Gardner-Medwin 1980), and 10.5 years (Allsop 1981). The pred-
nisone dose had to be decreased because of systemic side effects; in
this cohort of 30 participants the mean prednisone dose tolerated
was 0.35 mg/kg/day.
Studies comparing prednisone with corticosteroid-naïve
patients (but drug regimen not specified)
Takeuchi 2013 utilised the national registry of Japanese DMD/
Becker muscular dystrophy (BMD) patients set up in 2009 to
report the age at loss of ambulation only between those treated
with prednisone and those who were corticosteroid-naïve. The
registry includes prednisone use status as current, past, or never,
but does not record details of dose regimen, age at commencement,
duration, or side effects. The study authors considered 245patients
in the prednisone-treated group (171 current, 74 past), and 315
who had never been treated. Ultimately, loss of ambulation data
were available on 242 treated and 311 untreated boys, with loss
of ambulation reported in 123 and 190, respectively. The median
age at loss of ambulation in the untreated group was 10.1 years
(interquartile range (IQR) 10 years to 10.5 years) compared to 11
years (IQR 10.5 years to 11.5 years) in the treated group.
Henricson 2013 was a multicentre, international, prospective co-
hort study assessing 340 patients with DMD, ranging in age from
2 to 28 years, at three-monthly (ambulant) or six-monthly (non-
ambulant) intervals. Participants were divided into three groups:
82 corticosteroid-naïve patients (never treated or treated for less
than one month total), 210 current corticosteroid users, and 48
past corticosteroid users (treated for more than one month previ-
ously, but not currently receiving corticosteroids). The study au-
thors did not specify the preparation of corticosteroid, the regimen
(daily versus intermittent), and whether these were the same for all
patients studied. They additionally considered and tabulated out-
comes by age group. Main outcomes focused on ambulation and
functional milestones: each visit attempted to assess timed tests
for standing from supine, climbing four standard stairs, walking
or running 10 metres, upper limb function (Brooke scale), and
lower limb function (Vignos). Over the age of six years, current
corticosteroid users consistently demonstrated greater functional
abilities than past users or naïve patients. Past users had less ability
than current users, but performed better than the naïve group.
None of the naïve boys walked beyond age 12, compared to the
8% of past users and 45% of current users still able to walk in-
dependently between 13 and 15 years of age. In 16- to 18-year-
olds, only in the group currently taking corticosteroids were any
members ambulant (12%). In the upper limbs, 37% of current
corticosteroid users, aged 18 years or above, could still lift hand
to mouth to feed independently, compared to none of the past
user or corticosteroid-naïve groups. MRC manual muscle testing
(MMT) scores did not significantly differ between the corticos-
teroid-treated group and the cohort as a whole. Pulmonary func-
tion as measured by FVC and FEV1 (forced expiratory volume in
one second) was comparatively better in the corticosteroid-treated
group between the ages of 10 to 15 years. In terms of bone health,
the trial authors reported a similar incidence of fractures between
corticosteroid-users and the other groups among those more than
13 years old, although the need for surgical spinal stabilisation was
reduced in the corticosteroid group between the ages of 13 and 15
years.
Daily dose deflazacort studies
Schara 2001, a retrospective study, reported 19 ambulant boys
with DMD who were treated with deflazacort 0.9 mg/kg/day for
more than two years (mean 65 months, range 49 to 79 months).
Fourteen of the 19 boys aged 9.4 to 13.8 years were able to rise
from a supine position. Five boys lost this function at a mean age
of 13.5 years (range 10 to 16 years, which is a marked improve-
ment as compared to natural history controls (mean 8.2 ± 1.9
years). All deflazacort-treated boyswere able towalk independently
during the study period to a mean age of 13 years (range 9.4 to
18.11 years). The key side effects reported were short stature and
cataracts. Fourteen of the 19 deflazacort-treated boys developed
cataracts; one patient’s progressive cataracts led to implantation of
lenses 56 months into the treatment.
Among the non-randomised studies, the most impressive func-
tional results of corticosteroid therapy in DMD have been re-
ported from Bloorview MacMillan Children’s Centre in Toronto,
Canada in a series of five publications: Alman 2004, Biggar 2001,
Biggar 2004, Biggar 2006, and Silversides 2003. All five studies
describe the use of daily dose deflazacort in clinical practice at the
Bloorview MacMillan Children’s Centre from January 1990 on-
wards, and they report an overlapping cohort of patients.
Biggar 2001 used a starting dose of deflazacort 0.9 mg/kg daily
in 30 boys with DMD (age 7 to 15 years) over 3.8 years (SD
1.5) and compared this group with 24 boys who were followed
up at the same clinic contemporaneously, who did not take up
the option of deflazacort treatment because of parental choice
(most commonly, fear of side effects). Seven of the 30 boys in the
deflazacort group stopped walking at a mean of 12.3 (SD 2.7)
years, and this contrasted with the non-treated participants, all
24 of whom stopped walking at a mean of 9.8 (SD 1.8) years.
The FVC in the deflazacort-treated group was significantly greater
at 15 years (P < 0.001), but the trial authors did not report the
number of participants at 15 years. Ten of the 30 boys in the
deflazacort treatment group developed asymptomatic cataracts.
The two groups were significantly different in height; mean height
in the deflazacort-treated group continued along the 3rd centile,
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compared to mean height between the 25th and 50th centiles for
the non-treated group.
The primary outcome of interest in Silversides 2003 was cardiac
function. The trialists reported a cohort of 33 Duchenne patients
who underwent echocardiographic evaluation. Twenty-one par-
ticipants had been on deflazacort, for a mean duration of 5.1 years
± 2.4, and trialists compared this group with the other 12 who had
not accepted the option of deflazacort treatment. The mean age at
final follow-up was 14 (± 2) years for the deflazacort-treated group
and 16 (± 2) years for the non-treated group. This age difference in
the two groups was not statistically significant (P = 0.08), but the
biological significance cannot be discounted. Cardiomyopathy, as
indicated by left ventricular ejection fraction less than 45%, was
demonstrated in only one of the 21 deflazacort-treated partici-
pants, compared to seven out of 12 non-treated participants (P =
0.001). The mean ejection fraction reduction was 33% (± 7) in
the deflazacort group and 21% (± 8) in the non-treated group (P
= 0.002).
Alman 2004 focused on the development of scoliosis in the cohort
of 54 boys followed up at the Bloorview Macmillan Centre and
initially reported in Biggar 2001. The mean age at follow-up was
16 years. Only five of the 30 deflazacort-treated boys developed
scoliosis of more than 20°. In comparison, 16 of the 24 untreated
boys developed scoliosis of more than 20°. Deflazacort treatment
was associated not only with a reduced incidence of scoliosis, but
also delayed the onset and/or development of scoliosis; of the boys
who developed scoliosis of > 20°, the five deflazacort-treated boys
required spinal surgery at a later age of 15.1 ± 2.0 years, compared
with the 16 non-treated boys who underwent spinal surgery at
12.9 ± 2.4 years.
Biggar 2006 reported the updated and cumulative results of the
overlapping cohorts fromAlman 2004, Biggar 2001, Biggar 2004.
and Silversides 2003. The included participants were 74 boys with
DMD between 10 and 18 years old who could co-operate for re-
producible muscle and pulmonary function testing and were fol-
lowed up in Neuromuscular Clinics, Toronto, Canada between
January 1990 and December 2004. (Investigators excluded four
boys who stopped taking deflazacort within two to three years,
before they were 10 years old; they are not included in these 74
patients). Boys were offered deflazacort treatment while they were
still ambulant but had clinical evidence of worsening muscle func-
tion, as evidenced by frequent falls and difficulty in rising from the
floor or climbing stairs. Of the 74 boys, 40 were treated with de-
flazacort; the remaining 34 who did not accept deflazacort (mainly
due to fear of side effects, or family cultural or religious reasons)
were used as the comparison group. Boys treated with deflazacort
(and most boys not treated with deflazacort) received oral daily
supplements of vitamin D (1000 units) and calcium (750 mg).
Mean age at starting deflazacort was 7.7 ± 1.2 years. The deflaza-
cort starting dose was 0.9 mg/kg daily, which gradually declined
over the years as boys grew and gained weight, or was reduced
because of side effects. By 10 years of age, the mean dose was 0.8
± 0.18 mg/kg/day, by 15 years it was 0.55 ± 0.09 mg/kg/day, and
by 18 years 0.5 ± 0.2 mg/kg/day. Mean age at the end of the study
period was 15.2 ± 2.7 years in the deflazacort-treated group and
15.2 ± 2.5 years in the non-treated group. Mean time on deflaza-
cort was 5.5 years. The key results are listed as follows.
Walking (10 metres): In the deflazacort-treated group, 25 of 31
(81%) could walk at 12 years, 13 of 17 (76%) at 15 years, and
two of six boys walked independently at 18 years. By contrast, all
34 boys not treated stopped walking by 12 years of age (mean age
9.8 ± 1.8 years).
Scoliosis: Scoliosis is a frequent complication of DMD in the sec-
ond decade of life, occurring in up to 90% of affected boys, and
in the huge majority, is clinically evident in the 13 to 15 year
age group. In the Biggar 2006 cohort, by 18 years of age (mean
13.8 ±1.6 years), 30 of 34 (90%) boys who were not treated de-
veloped a spinal curve of more than 20°. In contrast, only four
of 40 (10%) deflazacort-treated boys developed scoliosis of more
than 20° during the study period. The possible explanations for
this could be deflazacort-related prolongation of the ambulatory
phase, improvement in paraspinal and truncal muscle strength, or
both.
Cardiac function: Moderate or severe left ventricular systolic dys-
function (ejection fraction below 45%) was noted in only four out
of 40 boys in the deflazacort-treated group as compared with 20
of 34 boys in the not treated group.
Pulmonary function: FVC, reported as per cent predicted (for age
andheight) (FVC-PP), was remarkably preserved in the deflazacort
treated group. Both groups of boys, treated and untreated, were
reported to have similar FVC-PP before 10 years of age, but the
report did not present the data. As anticipated, in line with the
natural history of DMD, in the no treatment group, FVC-PP
showed a gradual decline with age (65 ± 13% at 10 years, 47 ±
19% at 15 years, and 34 ± 10% at 18 years). In contrast, in the
deflazacort-treated group, the FVC-PP was 95 ± 17% at 10 years,
88 ± 12% at 15 years, and 81 ± 13% at 18 years. The clinically-
important implication was that by 18 years of age, 46% of the boys
not treated required nocturnal ventilatory support, compared to
none in the deflazacort-treated group.
Survival: To our knowledge, Biggar 2006 was the first study re-
porting the impact of corticosteroid therapy on survival in DMD.
Twelve of the 34 (35%) boys not treated died at mean age 17.6 ±
1.7 years, of cardiorespiratory complications (details not reported).
Only two of the 40 deflazacort-treated boys died; cause of death
was left ventricular failure, and age at death was 13 years and 18
years.
Adverse events: The growth suppression effect of long-term gluco-
corticoid treatment was evident in short stature in the deflazacort-
treated group; at age 15 years, the height of deflazacort-treated
boys was 143 ± 9 cm, compared to 164 ± 8 cm for boys not treated.
Twenty-two of the 40 deflazacort-treated boys developed bilateral
cataracts, though they were asymptomatic for the duration of the
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study.
Biggar 2006 gave dietary recommendations to all boys on each
hospital visit, and referred boys to a nutritionist if weight exceeded
expected weight by 5% to 10%, or if weight loss exceeded 10%.
With this approach, excessive weight gain, which is a common side
effect of corticosteroid therapy, was not noted to be a significant
clinical problem amongst these 40 deflazacort-treated boys, over
a mean treatment period of five years. Trialists reported only one
boy from the Bloorview Macmillan Centre to have discontinued
deflazacort because of excessive weight gain, and this boy was not
included in the 74 participants reported in Biggar 2006. Three
boys in the deflazacort-treated group developed fragility vertebral
fractures compared with none in the non-treated group. Long-
bone fractures were documented in 25% of boys in both groups,
with no difference between groups.
Houde 2008 retrospectively analysed the medical charts of 105
boys with DMD over an eight-year period. The boys were divided
into those receiving deflazacort for more than one year (treated)
and those not receiving the drug or who had received it for less
than six months (untreated). The trialists excluded five boys in
the treated group; four because they had stopped taking the drug
after two years, and one because he had received prednisone for six
years before switching to deflazacort. Among the untreated group,
they excluded 21 because of missing data or because boys were too
young to participate in all regular assessments. Overall, 37 boys
received deflazacort, and 42 were untreated. The starting dose was
0.9 mg/kg/day, adjusted according to progression or side effects,
with a maximum of 1 mg/kg. The mean length of treatment was
66 months, with 70% taking deflazacort for more than five years,
and 22% for more than eight years. The mean age on beginning
treatment was 7.6 ± 1.7 years and themean dose at themost recent
clinic visit recorded was 0.69 ± 0.2 mg/kg. All boys, treated and
untreated, were offered review every three months. The mean age
of the treated group was 13.1 ± 3.2 years. Among the untreated
patients, 24 were over 18 and no longer actively followed at the
clinic. Of the 18 who were still under regular clinic review, the
mean age was 9.5 ± 2.9 years. Key findings were as follows.
Ambulation: The trialists reported loss of ambulation as when a
boy could no longer walk, even with help. For those who used
long leg braces, it was recorded as the time when natural walking
stopped or when the use of braces began. Twelve of 37 boys in
the treated group had lost ambulation at a mean age of 11.5 ±
1.9 years, compared with 32/42, mean age of 9.6 ± 1.4 years (P <
0.05) in the untreated group. Of boys aged 12 years or more, 13/
23 (53%) of the treated group could still walk compared to none
of the untreated group.
Muscle strength: MRC score of 34 muscles was recorded every six
months. Scores were cumulated and converted to a percentage of
normal (where 100% = normal). Muscle strength at age 16 was
63%±4 in the treated group compared to 31%±3 in the untreated
group, P < 0.003.
FVC: The treated group improved in FVC: 66% ± 14 treated
versus 48% ± 22 untreated, P < 0.007.
Cardiac function: The deflazacort group improved in cardiac func-
tion, with significantly better values for fractional shortening and
ejection fraction, and a lower incidence of dilated cardiomyopa-
thy. Of note, angiotensin converting enzyme inhibitors were used
more frequently in the treated group but their effect could not be
isolated from those of deflazacort. The older age of the untreated
group may also have biased the incidence of cardiomyopathy.
Scoliosis development: Fewer boys developed scoliosis in the treated
group 10/37 (27%) than in the untreated group 28/42 (67%).
Scoliosis when it did occur also tended to be less severe; none of
the treated boys required corrective surgery in the treated group,
compared with 12/28 (43%) of the untreated group.
Adverse events: All adverse events weremore common in the treated
group. Fractures occurred in both groups, with a similar incidence
of long-bone fractures (24% treated group, 26% untreated group)
but the incidence of vertebral fractures was greater in the treated
group (20% versus 0%), although none contributed to any func-
tional decline. Nineteen of the 37 participants in the treated group
required bisphosphonates compared with none in the untreated
group. Excess weight (BMI > 85% percentile) was present in both
groups; 13/21 (62%) of the treated group versus 6/11 (55%) of the
untreated group. Evidence of growth suppression and short stature
was also seen in the treated group, with mean height gain being
three times as much in the untreated group at age 12 years. Height
values were not available for all children and some were younger
than 12 years old, but the available data showed that only 3/20
(15%) of the treated group grew 4 cm per year or more, compared
to 19/19 of the untreated group at age 12. Cataracts developed in
18/37 (49%) of the treated group; in 17 of 18 (94%) this was after
more than five years of treatment. One patient required surgery.
Studies comparing deflazacort with prednisone daily dose
regimens
Balaban 2005 reported a retrospective study of the long-term effect
of daily dose corticosteroids in a cohort of 49 boys with DMD
between the ages of 12 and 15 years. Eighteen boys were treated
with prednisone, 12 with deflazacort, and 19 had no treatment.
Parents had been informed about treatment alternatives and were
offered the option of corticosteroid medication, and the choice of
deflazacort or prednisone. The study site was inDenver, Colorado,
USA; the authors report that the cost of deflazacort was much
greater than prednisone (USD 3 per day versus USD 0.50 per
day), and some families chose on the basis of cost.
The mean age of starting deflazacort was 7.45 ± 0.97 years, mean
duration of treatment was 5.85 ± 1.5 years, and the starting dose
was 0.9 mg/kg/day. The mean age of starting prednisone was 6.90
± 1.0 years, mean duration of treatment 5.49 ± 1.98 years, and
the starting dose 0.75 mg/kg/day. The benefits, including prolon-
gation of the ability to walk 30 feet on level ground, were similar
in groups treated with deflazacort or prednisone, as compared to
the untreated boys. Excessive weight gain was more common in
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prednisone-treated boys, leading to discontinuation of prednisone
in three of the 18 boys in this group. Two of the 12 deflazacort-
treated boys developed asymptomatic cataracts.
Intermittent corticosteroid regimens
Dubowitz regimen - prednisolone 10 days on, 10/20 days off
In order to lessen the adverse effects of long-term corticosteroid
treatment, Dubowitz recommended an intermittent regimen of
prednisolone 0.75 mg/kg/day for the first 10 days of every calen-
dar month (treatment cycles of 10 days on prednisolone, 20 days
off; Dubowitz 1991). An open study of 32 patients demonstrated
that this intermittent regimen had a positive influence on strength
at six months, followed by a slow decline at 12 and 18 months
(Sansome 1993); weight gain and other side effects were much less
than would be expected with continuous therapy. Subsequently,
to increase efficacy, the investigators modified the regimen to a
10 days on prednisolone 0.75 mg/kg/day and 10 days off treat-
ment cycle. The same research group highlighted the long-term
tolerability of the intermittent (10 days on treatment, 10 days off )
regimen of prednisolone (Dubowitz 2002; Kinali 2002). The four
boys reported in these studies were started on prednisolone be-
tween four and five years of age, and followed up over a period
of between 3.75 and over five years. These boys showed ”remark-
able improvement“ (described by authors as gaining the ability
to rise from the floor without Gowers’ manoeuvre, hop on one
or both legs, and run without waddle) and the functional bene-
fit was partly sustained without the evidence of abnormal weight
gain, demineralisation of bone, or other signs of chronic pred-
nisolone toxicity. These studies, though including small numbers,
also suggested that the beneficial effects of corticosteroids appear
to be greater when treatment is initiated at a younger age, in the
early ambulant phase (Dubowitz 2002; Kinali 2002). No long-
term data exist reporting prolongation of ambulation with this
intermittent regimen.
Kinali 2007 retrospectively analysed predictive factors for devel-
opment of scoliosis in DMD in 123 DMD boys, aged 17 years or
older. Thirty-seven of the 123 boys (30%) had received intermit-
tent prednisolone (0.75 mg/kg/day, 10 consecutive days/month)
for a median time of one year (two months to nine years), starting
between 7.7 and 12.4 years (mean 9.5 years). The study authors
used univariate analysis to relate age at onset of scoliosis and scol-
iosis severity at 17 years with glucocorticoid treatment and other
factors. There was a positive relationship between age at scoliosis
onset (later) and duration (longer) of prednisolone treatment (r =
0.44, P = 0.01, n = 36). Severity of scoliosis at 17 years and dura-
tion of prednisolone treatment showed no relationship (P = 0.64).
The intermittent prednisolone regimen in Kinali 2007 appeared
to be associated with a later onset of scoliosis; the trial author con-
cluded that the observation of unchanged scoliosis severity at 17
years probably reflected the shorter overall glucocorticoid expo-
sure in this cohort.
Parreira 2007 ”sought to select a sequence of tests which can be
applied in a practical and swift fashion in an outpatient setting
to assess patients’ response to steroid therapy“ and reported its
application to 32 boys with DMD who were treated with inter-
mittent prednisolone (0.75 mg/kg/day in an intermittent course
of 10 days on, 10 days off ), or deflazacort (1 mg/kg/day). The
trialists did not report the number of boys using prednisolone or
deflazacort regimens. Age range at the start of treatment was 5
years 8 months to 8 years 8 months, and the boys were assessed
on 10 visits, monthly for the first six months and then every two
months until the 14-month end point. Of the 26 boys who com-
plied with the medication and assessment regimen, eight lost am-
bulation during the study period. The benefit appeared modest.
Over the 14-month period, muscle strength assessment showed
worsening of MRC indices, but there was a statistically signifi-
cant improvement in weight lifting test results (P < 0.001), and
improvement in time taken to walk nine metres. The data pre-
sented did not allow comparison of the effect of intermittent pred-
nisolone with that of daily dose deflazacort. The study authors did
not describe adverse effects. Parreira 2007 emphasised that muscle
strength measurements alone are not sufficient for evaluating the
results of corticosteroid treatment, and that tests analysing func-
tion and execution should also be performed.
Connolly regimen - twice weekly prednisolone (5
mg/kg/dose)
In a further attempt to decrease long-term adverse effects,
Connolly 2002 devised a twice-weekly regimen of prednisone
given every Friday and Saturday (5 mg/kg/dose). Twenty treated
boys (with an average age of eight years) were compared to his-
torical controls. Strength, evaluated with hand-held manometer
and grip meter, improved over six to 12 months. At least six of
the 20 boys developed irritability, which led to discontinuation
of treatment in two, and a 25% to 30% dose reduction in four
patients. Long-term results for this treatment regimen have not
been reported.
Nigro regimen - Deflazacort 0.6 mg/kg/day 20 days on, 10
days off
Professor Nigro’s group in Naples, Italy, who studied 56 boys,
utilised this intermittent regimen of deflazacort; Biggar 2004 re-
ported the results, and compared them with the daily dose de-
flazacort regimen used in 32 of 60 boys in Toronto, Canada.
(The Toronto patients were part of the overlapping patient co-
horts described in Alman 2004, Biggar 2001, Bonifati 2006, and
Silversides 2003).
In Professor Nigro’s Naples group, 56 boys at mean age 6.0 ± 1.5
years, were started on the intermittent regimen of deflazacort 0.6
mg/kg given on the first 20 days of each month. Nineteen of the
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56 stopped deflazacort within one month because of ”economical
and/or environmental reasons“, and they served as a control group
for comparison. The deflazacort-treated boys were also given daily
supplements of vitamin D (880 iu) and calcium (1000 mg). Dura-
tion of deflazacort treatment was more than four years in all boys.
In the control group of 19 boys fromNaples, Italy, only four (21%)
were able to walk 10 metres at nine years and none at 12 years. Of
the 37 boys treated with intermittent deflazacort (0.6 mg/kg/day
for the first 20 days of each month), 97% (36/37) could walk 10
metres at nine years, 35% (9/26) at 12 years and 25% (3/12) at 15
years. This represents significant improvement in comparison to
the previous natural history studies, which reported loss of walking
in untreated boys with DMD at mean ages of 8.8 years (Dubowitz
1978), 9.5 years (Gardner-Medwin 1980), and 10.5 years (Allsop
1981). However, in comparison, the daily dose deflazacort 0.9
mg/kg/day regimen used to treat the 32 boys in Toronto, Canada,
appears to have a bigger impact onwalking; all 32were able towalk
10 metres at 9 years, 83% (19/23) at 12 years, and 77% (10/33)
at 15 years. The key difference in side effects was with regards to
cataracts. No cataracts were noted in the 37 patients treated with
the intermittent 20 days on, 10 days off Nigro regimen, compared
with the 30% who developed asymptomatic cataracts among 32
patients treated with daily dose deflazacort.
Long-term studies comparing daily prednisolone with
intermittent prednisolone (10 days on, 10 days off)
Ricotti 2013 was anobservational study utilising longitudinal clin-
ical data entered into the UK North Star database from 17 partic-
ipating paediatric neuromuscular centres. The investigators anal-
ysed data on 360 boys (age range 3 to 17 years) who had received
prednisolone (191 on an intermittent regimen of 10 days on, 10
days off, and 169 on a daily dose regimen). The mean duration of
treatment and follow-up was 3.9 years. The median time to loss of
ambulation was 12 years in the intermittent treatment group and
14.5 years in the daily treatment group; the hazard ratio (HR) for
intermittent treatment was 1.57 (95% CI 0.87 to 2.82). Longi-
tudinal analysis of the North Star Ambulatory Assessment (a val-
idated composite scale to measure function in ambulant DMD
boys) showed a faster rate of decline after age seven in those on the
intermittent versus the daily regimen, with the difference between
the two regimens increasing by 1.58 units per year (95% CI 1.04
to 2.11, P < 0.001), although respiratory and cardiac outcomes did
not differ between the two groups. Side effects were more com-
mon in the daily treatment group, including cushingoid features
(33% versus 15%), hyperactivity (23% versus 15%), and hyper-
tension (22% versus 5%). Both groups gained excessive weight.
The daily group had a lower mean height, MD 1.09 (95% CI
0.78 to 1.40, P < 0.001). Overall increase in BMI was greatest in
the daily treatment group: MD 0.43 (95% CI 0.11 to 0.74, P <
0.01). Ricotti 2013 reported vertebral fractures (vertebral wedging
on lateral spine radiography) in 4% of boys on the intermittent
regimen and 8% of boys on the daily regimen.
Studies selectively focusing on cardiac outcome
Markham 2005 reported cross-sectional echocardiographic short-
ening fraction data in a retrospective review of 111 subjects with
DMD who had been followed up in two centres. Forty-eight sub-
jects had been treated (29 with prednisolone, 19 with deflazacort)
for six months or longer, and they were compared with the 63
untreated subjects. The dose regimen was not reported. Age range
was three to 11 years (treated 11 ± 4, untreated 12 ± 5), and mean
length of treatment was 3 ± 2.5 years. Of the 48 treated subjects,
10 had been treated with corticosteroids for 4.2 ± 1.6 years, but
the treatment had been stopped because of adverse effects at the
time of echocardiography.
The shortening fraction was lower in the untreated group than in
the corticosteroid-treated group (30% ± 7% versus 36% ± 5%;
P < 0.001). The difference in shortening fraction between the
two groups was most obvious in subjects over 10 years of age: in
comparison with the corticosteroid-treated subjects, the untreated
subjects older than 10 years were 15 times more likely to have a
shortening fraction less than 28% (P < 0.01). Though the two
groups were similar with regards to baseline age, body mass and
left ventricular indices, the retrospective design of this study carries
the implicit risk of biased treatment allocation.
In this update we did not select any further studies selectively fo-
cusing on cardiac outcome, as a separate Cochrane review address-
ing this issue is in development (Quinlivan 2012).
Studies selectively focusing on cough efficiency and
respiratory muscle strength
Daftary 2007 studied 10 corticosteroid-treated and25non-treated
patients in a retrospective case-control study. The age range of
the treated group was seven to 21 years (median 10 years). Three
patients were treated exclusively with prednisone, five exclusively
with deflazacort, and two were started on intermittent prednisone
but later switched to daily deflazacort. Prednisone was started at a
dosage of 0.75 mg/kg/day and deflazacort at 0.9 mg/kg/day. The
mean duration of corticosteroid therapy was 8.2 years (range 1 to
14 years). Peak cough flow (PCF) and maximum expiratory pres-
sure were significantly higher in the corticosteroid-treated group.
Median PCF was 215.0 L/min in the treated group compared
with 177.5 L/min in the non-treated group (P ≤ 0.05). Median
maximum expiratory pressure (MEP) was 62.5 cm H2O in the
treated group as compared with 44.5 cm H2O in the non-treated
group (P ≤ 0.05). These results are suggestive that corticosteroid
therapy is beneficial in preserving respiratory muscle strength and
cough efficiency in DMD, and are in concordance with previous
randomised (Griggs 1991; Mendell 1989) and non-randomised
studies (Biggar 2006), which reported preservation of FVC. Of
note, Daftary 2007 observed that patients with DMD were weak
and therefore often unable to sustain exhalation for six seconds,
as required by the American Thoracic Society to meet pulmonary
function test acceptability criteria, and arbitrarily chose a three
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second (or more) exhalation criterion for acceptability. This indi-
cates the need for consensus on customisation of the test protocols,
taking into consideration the marked respiratory muscle weakness
in DMD.
In this update we did not select any further non-randomised stud-
ies selectively focusing on cough efficiency and respiratory mus-
cle strength as these outcomes are not the primary focus of this
review. A Cochrane review of Mechanical insufflation-exsuffla-
tion for people with neuromuscular disorders has been published
(Morrow 2013).
Vertebral fractures with daily dose corticosteroid regimens
Bothwell 2003 highlighted the need for caution with the long-
term use of corticosteroids. Twenty-five boys with DMD were
treated with daily corticosteroids (one prednisolone, 13 deflaza-
cort, and 11 prednisolone before switching to deflazacort) for a
median duration of 4.5 years (inter-quartile range (IQR) 3 to 10
years). The dosage used was 1 mg/kg/day. The trial authors do
not describe whether the dose was reduced over time, for exam-
ple in response to excessive weight gain. All boys were prescribed
calcium supplements and 22 of the 25 boys were also on vitamin
D. Ten of the 25 boys (40%) sustained vertebral fractures; eight
were symptomatic with backache and two had fractures detected
on spinal radiographs taken because of low bone mineral density
results. The first fracture occurred 40 months into treatment. Ex-
trapolating from the 10 boys who sustained a vertebral fracture,
Kaplan-Meier analysis predicted that 50% of treated boys would
have a vertebral fracture by 53.5 months, and 75% by 100 months
of treatment.
King 2007 reported vertebral and long-bone fractures among 75
boys in the course of long-termdaily dose corticosteroid treatment,
comparing them with 68 boys who had not been treated or had
received brief submaximal doses. Themean age of treated boys was
16.9 ± 5.6 years (range 6.1 to 30.5 years) compared to 14.4 ± 8.1
years (range 1.1 to 39.6 years) in the non-treated group. Thirty-
six boys were treated with prednisone, 25 with deflazacort, and 14
had been on both. The daily dose regimen starting dose was pred-
nisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day. At the final
clinic visit prior to data collation, the average corticosteroid dose
of the treated group was 0.55 mg/kg (range 0.10 to 0.78 mg/kg).
The mean duration of corticosteroid treatment was 8.04 years (±
5.2 years, range 0.5 to 18.5 years). The boys who began treatment
were also prescribed calcium supplements, either as calcium car-
bonate 350 mg three times daily or a calcium tablet with vitamin
D supplement (750 to 1200 mg daily), but the trialists did not
report the degree of compliance with these supplements. Treated
boys walked independently 3.3 years longer, had lower prevalence
(31% versus 91%) and severity (Cobb angle 11 versus 33 ) of
scoliosis as compared to the non-treated boys, but 32% of these
75 corticosteroid-treated boys developed a compression vertebral
fracture. Eighty per cent of vertebral fractures were identified in-
cidentally during routine scoliosis screening radiographs, and not
because of patient complaint. Vertebral fractures were reported
not to be a motivation for discontinuing corticosteroids. Vertebral
compression fractures are not a feature in the natural history of
DMD, and none were found in the 68 non-treated boys in this
study (King 2007). A higher percentage of corticosteroid-treated
boys experienced long-bone fractures, with a risk 2.6 times greater
than boys on no treatment. Whether the long-bone fractures were
more frequent in the boys who suffered vertebral fractures was not
reported, and how these complications might best be prevented
or treated was not discussed. The percentage of vertebral fractures
with a long-term intermittent, versus a daily prednisolone regimen
is discussed above.
Controversy in clinical role of corticosteroids in DMD
The 124th European Neuromuscular Centre (ENMC) Interna-
tional Workshop on treatment of DMD agreed ”that the evi-
dence for the use of daily steroids in DMD is now established and
that trials of other treatments should be against this ’gold stan-
dard’“ (Bushby 2004). The Quality Standards Subcommittee of
the American Academy of Neurology and the Practice Commit-
tee of the Child Neurology Society recommended that boys with
DMD should be offered prednisone (at a dose of 0.75 mg/kg/day)
as treatment, and that ”the offer of treatment with corticosteroids
should include a balanced discussion of potential risks“ (Moxley
2005) . Dubowitz 2005 expressed concern regarding the adverse
effects of long-term daily dose corticosteroid treatment and con-
cluded, ”What is now urgently needed is a prospective, collabo-
rative, multicentre, comparative study of the time-honoured, and
somewhat entrenched, daily regimen against some of the alterna-
tive schedules, in order to compare both efficacy and side-effects“.
He further recommended that ”in the meantime, paediatricians
as well as parents should be offered the choice of either the con-
tinuous or the intermittent schedule. Hopefully we shall not be
having the same debate in another 10 years time“.
For this review we were only able to identify one RCT comparing
daily with intermittent prednisolone regimens over a 12-month
period (Escolar 2011). This study, performed in boys with a mean
age of 7.3 years, found no difference in efficacy between the reg-
imens or overall side effect profile, with the notable exception
of greater weight gain and lower linear height in the daily treat-
ment group. A non-randomised longitudinal study over four years
demonstrated consistent findings in terms of weight and height
but also a divergence in efficacy for time to loss of ambulation
and functional ability, favouring a daily regimen after the age of
seven years. In this study, other side effects, including hyperten-
sion, were also more common on the daily regimen. Overall, the
long-term (more than 12 months) risk/benefit ratio of daily versus
intermittent prednisolone regimens remains unclear.
The FOR-DMD Study is currently open and aims to find the
optimum corticosteroid regimen for DMD (Guglieri 2015). It is
an international trial enrolling patients at 40 sites in five countries,
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randomising them to one of three regimens: daily prednisolone,
daily deflazacort or intermittent prednisolone (10 days on and 10
days off ). It aims to follow participants for three to five years and
may address remaining questions over the long-term outcomes of
intermittent regimens.
Costs
The oral corticosteroids, including prednisone/prednisolone and
deflazacort are not expensive. In the United Kingdom, the annual
cost of prednisolone (soluble tablets) for a 30 kg boy is estimated
at GBP 133 and the corresponding figure for deflazacort at the
equivalent dosage of 0.9 mg/kg/day is GBP 480 (BNF 2016).
The much bigger costs are those for drug administration and the
surveillance required to monitor both benefits and adverse effects,
and these have not been calculated. The issue of cost should not be
underestimated, as in countries where the parent or patient has to
buy medication, cost of the corticosteroid preparation may force
the patient’s choice in favour of the cheaper drug (Balaban 2005).
The major aim of corticosteroids in the ambulant phase of DMD
is to prolong the ability to walk. In the natural course of DMD,
loss of walking ability at the mean age of 9.5 years (range 6
to 13) is followed by development of scoliosis, which is rapidly
progressive during pubertal growth spurt years. This complica-
tion requires treatment with bracing, surgery, or both. Scoliosis
and its treatment have implications for patients’ quality of life
and involve anaesthetic hazards and the surgical risks of exten-
sive spine surgery. Data from non-randomised studies suggest that
prolongation of ambulation, either with rehabilitation in calipers
(Rodillo 1988), or pharmacologically with prednisolone (Tunca
2001; Yilmaz 2004), or deflazacort (Biggar 2006), reduces the risk
of development and progression of scoliosis. The decrease in inci-
dence and severity of scoliosis in corticosteroid-treated individuals
has been postulated in part to the possible increase in paraspinal/
axial muscle strength (Muntoni 2006). A decrease in incidence of
scoliosis and avoidance of scoliosis surgery as a result of corticos-
teroid therapy would reduce the financial cost of managing these
patients, but evidence for this from randomised studies is lacking.
The same optimism and caution can be extended to respiratory
and cardiac complications of DMD.
Overall completeness and applicability of
evidence
DMDhas a uniform course with regards to evolution ofmotor and
function disabilities. Most of the participants in the included stud-
ies were between eight and 15 years old. There were not enough
data available to stratify the participants according to age and to
observe the response to corticosteroids in relation to age. Future
updates could consider subgroup analysis by genotype or pheno-
type, although trials may be too small for this to be possible.
Data from the included studies and the non-randomised and co-
hort studies converge in suggesting a similar improvement in re-
sponse to corticosteroids in DMD. It is very likely that the re-
sults are applicable to all boys with DMD, especially in their am-
bulant phase. We would not anticipate that in non-ambulant,
wheelchair-dependent patients with DMD who have been corti-
costeroid-naïve in the past, corticosteroid treatment would restore
the ability to walk. However, the benefit to upper limbs, cardiac
and respiratory function remains a possibility, and this area needs
further study.
The option of treatment with corticosteroids should be discussed
in detail with the carers of ambulant boys with DMD. It would be
prudent to undertake this treatment only in centres with expertise
and facilities for comprehensive multidisciplinary pre-treatment
assessment and regular long-term monitoring of benefits and ad-
verse effects. Protocols of management, with close monitoring for
adverse effects and adjustment of corticosteroid dose would be an
essential prerequisite for patient safety.
Quality of the evidence
Corticosteroids versus placebo
Trials included in the meta-analyses for this comparison pro-
vided moderate quality evidence for effectiveness outcomes (mus-
cle strength and functional tests) (Summary of findings for the
main comparison). We downgraded the quality of evidence once
because the risk of allocation bias was unclear in all studies that
provided data for the analyses and for potential publication bias.
Removal of a trial at high risk of bias did not substantially change
the results of meta-analyses. Two studies were not fully published
or did not report results in a form suitable for reporting (Brooke
1996; Todorovic 1998). Bäckman 1995 provided only adverse
event data.
Angelini 1994 was a small two-year study (n = 28) with design
limitations, and a very high dropout rate at two years. Although the
trial assessed prolongation of ambulation, the statistical technique
used to analyse the data was not appropriate. The change in MRC
index favoured deflazacort over placebo at two years, but timed
function test results at 24 months were very imprecise, allowing
for the possibility of effects in either direction.
Weekend-only versus daily prednisone
Escolar 2011 (n = 64) was a year-long equivalence trial comparing
weekend-only anddaily dosing of prednisone.We judged the study
to be at a low risk of bias other than for attrition and reporting
bias. Results were very imprecise, producing a low quality of evi-
dence for manual muscle testing (MMT), body mass index (BMI)
and behavioural change. As CI fell within equivalence limits for
muscle strength measured by quantitative muscle testing (QMT),
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10-metre walk and four-stair climb, we considered the quality of
evidence for these outcomes moderate (Summary of findings 2).
Deflazacort versus prednisone
For all assessed outcomes, the evidence comparing prednisone
with deflazacort at one year was very low quality (Summary of
findings 3). Two newly included studies comparing different cor-
ticosteroids did not fully report data, making only limited analy-
sis possible (Bonifati 2000; Karimzadeh 2012). Karimzadeh 2012
was at a high risk of bias in most domains and Bonifati 2000 was
at unclear risk of selection bias and high risk of selective report-
ing. We downgraded evidence from these studies twice for serious
limitations in trial design and implementation. Brooke 1996, a
large four-arm study (n = 196) comparing two doses of deflazacort,
prednisone and placebo, also represented a risk of publication bias,
being available only as an abstract, providing little useful data.
Potential biases in the review process
Searches were comprehensive, and studies we identified were con-
sistent with other reviews of these interventions in DMD. We at-
tempted to contact study authors for clarification or missing data;
some responded but others did not. Methods have not substan-
tially changed from previous versions of the review. We added
some additional detail to complywith currentCochrane standards;
however, the new trials presented few opportunities for meta-anal-
ysis.
Agreements and disagreements with other
studies or reviews
The American Academy of Neurology (AAN) produced practice
guidelines on corticosteroid treatment of Duchennemuscular dys-
trophy (DMD) following a systematic review of the literature from
January 2004 to July 2014, and identification of 34 studies (Gloss
2016). The conclusions of this Cochrane review are compatible
with the recommendations of the AAN committee, who found
evidence that:
• prednisone and deflazacort should both be offered for
improving muscle strength;
• prednisone and deflazacort are possibly equally efficacious
in improving motor function;
• prednisone may be associated with greater weight gain than
deflazacort;
• deflazacort may be associated with a higher risk of cataracts
than prednisone;
• a weekend-only regimen of prednisone 10 mg/kg/weekend
day may be equivalent to prednisone 0.75 mg/kg/day over a 12-
month period;
• prednisone 0.75mg/kg/day is associated with significant
risk of weight gain, hirsutism and cushingoid changes.
The AAN guidelines also examined other outcomes - cardiac and
respiratory outcomes, and scoliosis that we did not address in this
update.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Randomised controlled trials (RCTs) providemoderate quality ev-
idence that treatment with corticosteroids in Duchenne muscu-
lar dystrophy (DMD) compared with placebo improves muscle
strength and function, including respiratory muscle strength and
function, for six months. There is evidence of continuing bene-
fit on muscle strength and function at one year. On the basis of
the evidence available, our confidence in the effect estimate for
the efficacy of a 0.75 mg/kg/day dose of prednisolone or above
is fairly secure. Little RCT evidence is available on longer-term
effects of corticosteroids versus placebo; one small longer-term
RCT found an improvement in muscle strength at two years with
deflazacort, with imprecise results on function at two years. Not
enough data were available to adequately compare the efficacy of
prednisone and deflazacort, although there is very low quality data
favouring deflazacort for less weight gain. In the short term (12
months), a weekend-only prednisolone regimen is as effective as
daily prednisolone according to low to moderate quality evidence
from a single trial. Low quality evidence did not show a differ-
ence between the regimens on change in body mass index (BMI).
A greater increase in linear height occurred in the weekend-only
regimen, but no appreciable difference in other side effects. The
long-term benefits and harms of daily corticosteroids or daily ver-
sus intermittent regimens are not clear. Non-randomised studies
suggest that clinically significant prolongation of time to loss of
ambulation is possible with daily corticosteroids, though poten-
tial harms, including weight gain, behavioural changes, vertebral
fractures, and cataracts, are significant. Non-randomised studies
also suggest there may be a divergence in efficacy between daily
and intermittent prednisolone regimens beyond the age of seven
years, with greater side effects from daily regimens in the longer
term.
Implications for research
Many issues, including the ideal age or functional stage for initi-
ation of treatment, the optimal corticosteroid type, regimen and
dose, strategies for prevention of osteoporosis, and the age for dis-
continuation of corticosteroid treatment still need to be clarified
with RCTs. This will require national and international collabora-
tion, standardised and comparable protocols of assessment, timely
publication of studies and the facility of sharing anonymised in-
dividual patient data. While previous studies have focused mainly
on muscle strength, walking, and motor aspects, studies are now
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beginning to address respiratory, cardiac, and quality of life is-
sues; this review or separate Cochrane reviews will examine these
outcomes in future. The Quality Standards Subcommittee of the
American Academy of Neurology and the Practice Committee of
the ChildNeurology Society emphasised the need for studies to be
long term to evaluate the effect of corticosteroids on ambulation,
respiratory function, cardiac function, and quality of life. There is
a need to identify and evaluate strategies to prevent the predictable
adverse effects of long-term corticosteroid treatment, particularly
excessive weight gain, osteoporosis, and growth retardation. The
incorporation of patient and caregiver evaluations of the beneficial
and adverse effects of treatment, as additional outcome measures,
should be considered. The impact of corticosteroid therapy on
quality of life of the patient and the family, in relation both to
benefits and adverse effects, should also be evaluated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Angelini 1994
Methods Randomised double-blind trial. Randomisation followed 2:1 scheme
Participants 28 boys with DMD, all ambulant at entry into the trial
DMD proven by dystrophin or DNA studies
Mean age:
• deflazacort 98.65 ± 13.70 months
• placebo 96.55 ± 15.96 months
Interventions Deflazacort 2 mg/kg on alternate days for 2 years (n = 17) or placebo (n = 11)
Outcomes Age at loss of ambulation, age at loss of ability to rise from floor, MRC index from 4
muscles
Monitoring of: weight and height every 2 months; blood pressure; WBC; RBC and
haematocrit; plasma glucose; CPK and ions. ECG and x-rays of chest and hand for bone
age at beginning and end of treatment. Assessment for cataracts every 2 years
Declarations of interest Not stated
Funding sources A grant from Telethon, Italy
Notes Dates: not reported
Location: Italy
Ethical approval and consent procedures not described
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated to be randomised “randomization
followed a 2:1 scheme. At the beginning
of the trial the patients in each arm of
the study, both in the drug and placebo
group, were similar for motor function. At
the beginning of trial, the two groups had
the same age, MRC index, and functional
grades”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placbo-controlled
On balance, judged to be of low risk
although “Blinding and maintenance of
blindingduring trial was possible since only
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Angelini 1994 (Continued)
the coordinator, but not the examiner, had
the key of randomization. It is possible that,
during prolonged treatment, blinding was
destroyed by the appearance of side effects
of the drug”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Blinding and maintenance of blinding
during trial was possible since only the co-
ordinator, but not the examiner, had the
key of randomization. It is possible that,
during prolonged treatment, blinding was
destroyed by the appearance of side effects
of the drug”
Incomplete outcome data (attrition bias)
All outcomes
High risk “During the 4 years of our study (1 year
of natural history and 3 years of actual
drug administration trial) lack of compli-
ance was seen in 5 placebo and 4 drug-
treated patients” and 11 deflazacort and 6
placebo participants dropped out for other
reasons. Authors state “lack of significance
in some tests may be due to dropout of
DMD patients”
Selective reporting (reporting bias) Unclear risk Data reporting comprehensive in tables at
6, 12 and 24 months, but not specified in
detail in methods
Other bias Low risk None identified
Beenakker 2005
Methods Randomised, double-blind, placebo-controlled, cross-over trial
Participants 17 ambulant boys with DMD, mean age 6.29 (SD 0.92) years
Inclusion criteria: boys 5 to 8 years old with clinically classic DMD, grossly elevated
serum CK, almost no dystrophin on muscle biopsy (less than 5% of fibres), able to walk
without assistance
Exclusion criteria: use of steroids within the 2 months before start of trial
Interventions Prednisolone 0.75 mg/kg/day (n = 7) or placebo (n = 10) for the first 10 days of every
month, given for 6 months, then crossed over to the alternative treatment after a 2-
month washout period
Outcomes Total muscle force measured by hand-held dynamometry, timed 9-metre run, 4-stair
climbing and rising from floor times, quality of life assessed by DUX-25, weight, blood
pressure, upper and lower extremity functional grade (Brooke 1996). Adverse events
were evaluated at each visit by physical examination, and patient and parent interview
using a standard list of steroid-related adverse events
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Beenakker 2005 (Continued)
Measurements were performed each month on days 1, 10 and 30 by a single investigator.
Quality of life was assessed at the start and end of the 6-month treatment periods
Declarations of interest Not stated
Funding sources Prinses Beatrix Fonds
Notes Ethical approval and informed parental consent obtained
Dates: not stated
Location: the Netherlands (assumed)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Low risk No information in paper. Randomisation
by pharmacist. Assessed as low risk as trial
authors provided information indicating
adequate allocation concealment to the re-
view authors for a previous version of this
review
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo-controlled, double-blind, but does
not state whether placebo and active drug
were the same in appearance or taste
Unblinding likely because of higher inci-
dence of adverse effects
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described, but adverse effectsmay have
unblinded outcome assessors in this study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 17 participants (10 placebo), 7 prednisone.
1 in placebo group unavailable for follow-
up (fracture after 10 days’ prednisone treat-
ment) and excluded from analyses
Selective reporting (reporting bias) Low risk Largely well reported although some data
missing for some outcomes e.g. quality of
life - paper indicates no difference between
groups
Adverse events well reported
Other bias Low risk Cross-over, with 6-month treatment peri-
ods. 20-day untreated period then2-month
washout between interventions. Authors
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tested for a period effect
Bonifati 2000
Methods Double-blind, randomised, multicentre, equivalence study
Participants 19 boys with DMD (1 not included in evaluations as he received both drugs, each for 6
months)
Inclusion criteria: diagnosis confirmed by dystrophin immunohistochemistry, age over
5 years, preserved ability to ambulate independently, and no previous steroid therapy.
No patient had any recognised contraindication to steroid therapy
• Deflazacort: mean age 8.6 years (range 5.3 to 14.6 years)
• Prednisone: mean age 7.5 years (range 5.1 to 10 years)
(Natural history controls not considered in this review)
Interventions Deflazacort or equivalent dose of prednisone
Deflazacort (0.9 mg/kg/day) (n = 8)
Prednisone (0.75 mg/kg/day) (n = 11)
Duration of treatment: 1 year
Outcomes Muscle strength evaluated byMRC scale in 4 muscles, 2 in the right upper limb (deltoid
and triceps) and 2 in the right lower limb (iliopsoas and quadriceps femoris); the summed
MRC score was used in comparing the 2 groups in statistical analyses
Functional tests: gait (walk for 10 metres), rising from a chair and from the floor, and
climbing 4 steps. Sum of the grades in the functional scores calculated. Lower score =
better performance
At baseline and 3-monthly thereafter: biochemical and neurological screening (serum
CK, glucose, electrolytes, haematocrit, complete blood count); height, weight and BP
monitoring for corticosteroid side effects. Occurrence of cushingoid features, acne, hir-
sutism evaluated clinically
Parents were asked to report behavioural changes, insomnia, anorexia, increased appetite,
and GI problems
X-ray of left hand for bone age and eye examination for cataract conducted at baseline
and after 1 year of corticosteroid treatment
Time points reported 3, 6, 9 and 12 months (graphically)
Declarations of interest Not stated
Funding sources Telethon (grant number 916C)
Notes Dates: not stated
Children were recruited from 2 neuromuscular centres (Pavia and Padua, Italy)
Informed consent obtained
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk ”The two groups were randomized and
stratified on the basis of age and disease
severity“ - precise method unclear
There was some baseline imbalance ”The
absolute values of scores appeared better
in the deflazacort group, but the difference
did not reach statistical significance. This
type of response could be related to slightly
less severe baseline values“
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Neither the treating physician nor the pa-
tient’s family knew whether a child was on
prednisone or deflazacort“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Report suggests the outcome assessor was
the treating physician, who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk One dropout in prednisone group. Paper
does not discuss how this was managed;
however we consider this unlikely to repre-
sent an important risk of bias
Selective reporting (reporting bias) High risk Efficacy data reported without measures of
variability graphically. Trial authors did not
respond to request for raw data
Adverse events fully reported
Other bias Low risk None identified
Brooke 1996
Methods Randomised, double-blind, placebo-controlled trial with 4 arms
Participants 196 boys with DMD randomised
Interventions Initially:
• prednisone 0.75 mg/kg/day
• deflazacort 0.9 mg/kg/day
• deflazacort 1.2 mg/kg/day
• placebo
After 3 months the placebo group was re-randomised to one of the other interventions
Outcomes Primary outcome measures:
• Average muscle score
• Weight
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Time points: 3 months, end of 12 months’ treatment (not stated whether other time
points were measured)
”Features of steroid toxicity were rated as none, mild, moderate and severe“
Declarations of interest Not stated
Funding sources Muscular Dystrophy Association Canada and Nordic Merrell Dow Research
Notes No other study characteristics reported - abstract only
Dates: not stated
Location: Canada (assumed)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised, methods not de-
scribed in abstract
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information other than stated to be
double-blind. Placebo-controlled (placebo
not described)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided
Selective reporting (reporting bias) High risk Available as abstract only
Other bias Unclear risk No other bias identified, but the abstract
presented little information by which to
form a judgement. Participants in the
placebo group were randomly assigned to
other deflazacort or prednisone groups af-
ter 3 months
Bäckman 1995
Methods Randomised double-blind, cross-over trial
Participants 37 boys with DMD (22 ambulant and 15 wheelchair-dependent at entry to the trial), 4
boys with Becker muscular dystrophy (all ambulant)
DMD established by positive Gower sign, pseudohypertrophy of calf muscles, CK 10
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times upper limit of reference value (dystrophin was measured in 26 boys, all had none)
; BMD diagnostic criteria not stated (all 4 had reduced dystrophin)
Mean ageDMD(years): ambulant, 7.8 +/- 2.1 (range 4.0 to 10.9), wheelchair-dependent
12.5 years +/- 3.3 (range 8.0 to 19.4)
Mean age BMD (years): 9.6 +/- 3.4 (range 6.1 to 13.8 years)
Interventions Prednisolone 0.35 mg/kg/day given for 6 months, then crossed over to placebo, or vice
versa
Outcomes MRC score on 26 muscle groups, myometry on 24 muscle groups, modified Brooke and
Scott scores, hand-grip,
timed 4-stair test and 10-metre walk test. Additionally, the maximum height the boy
could achieve with a single step and lowest height from which it was possible to rise
from a chair unaided, weight gain, and laboratory tests. Patients were evaluated before
treatment and every 3rd month afterwards
Parents were asked to report signs and symptoms ”possibly related to treatment“ at end
of study
Declarations of interest Not stated
Funding sources Grants from Sven Johansson Foundation
Notes Dates: not stated
Location: university hospital and rehabilitation centre in Sweden
Local ethics committee approval obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but method of
randomisation not described
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Both prednisolone and placebo were ad-
ministered as white powder in gelatin cap-
sules of the same weight“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as “double-blind” - investigator
was also outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 withdrawal (weight gain and slight car-
diac insufficiency) of a wheelchair-depen-
dent boy. 2 deaths: 1 pneumonia and 1 car-
diac arrhythmia during appendectomy; re-
port does not say from which group
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Selective reporting (reporting bias) Unclear risk No protocol. Outcomes not fully specified
but are reported as listed
Other bias Low risk None identified. Student’s t-test used to re-
veal any learning or carry-over effects fol-
lowing cross-over - none identified
Escolar 2011
Methods Randomised, double-blind, placebo-controlled, multicentre, international, prospective,
equivalence trial
Participants 64 participants
Ambulant, steroid-naïve boys with a confirmed diagnosis of DMD, age 4 to 10 years
(“confirmed diagnosis” not defined)
Mean age 7.3 years, median age 7.2 years
Inclusion criteria: ”evidence of muscle weakness by clinical or functional assessment and
the ability to provide a reproducible unilateral quantitative muscle testing (QMT) biceps
score within 15% of the first assessment”
Exclusion criteria:
• history of significant concomitant illness or significant impairment of renal or
hepatic function, or other contraindication to steroid therapy
• symptomatic DMD carrier
• positive purified protein derivative test (for tuberculosis)
• lack of prior exposure to chickenpox or immunisation
• use of carnitine, glutamine, coenzyme Q10, other amino acids or any herbal
medications within the last 3 months
• history of symptomatic cardiomyopathy
• prior attainment of quota for the age group in which the patient belongs
Child Behaviour Checklist scores for aggressive behaviour and externalising
• mean externalising score weekend
• mean aggressive score weekend
Interventions Weekend-only oral prednisone: 5 mg/kg on Saturday and 5 mg/kg on Sunday, plus a
daily placebo
Daily dose group: daily prednisone 0.75mg/kg/day, plus placeboonSaturday andSunday
32 participants in each group
Concomitant medications allowed during the study included vitamin D, calcium, rani-
tidine, and Tums. Participants were advised to follow a high protein, low carbohydrate,
low fat diet
Criteria for dose reduction:
1. An increase in BMI (kg/m2) greater than 10% over 3 months
2. A fasting blood sugar greater than 100 mg/dL after dietary modification
3. An increase in diastolic blood pressure greater than 10 mm Hg over upper limit of
normal for age
4. An increase in systolic blood pressure greater than15 mm Hg since last visit, after
1 month of low sodium diet
5. Otherwise non-manageable side effects
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Compliance checks done by pill counts and review of medication diaries
Outcomes 8 visits total
2 screening visits (baseline)
Month 1, 3, 6, 9, 12 (the DEXA and ophthalmology assessments baseline and month
12 visits only)
Post-study visit - within 1 month of month 12
Efficacy:
• Muscle strength: QMT arm score, lb; QMT leg score, lb; QMT elbow flexors, lb;
QMT elbow extensors, lb; QMT knee flexors, lb; QMT knee extensors, lb; QMT grip
score, lb; manual muscle testing score
• Timed tests (log seconds): 10-metre walk; 4-stair climb; supine to standing
• Pulmonary function: forced vital capacity % predicted; forced expiratory volume
in 1 second % predicted; maximal voluntary ventilation and maximal inspiratory
pressure
• Mobility function scales: Brooke upper extremity; Vignos lower extremity
Adverse effects:
Anthropometrics: BMI in kg/m2; height in cm; weight in kg
Vitals:
• systolic BP, mmHg
• diastolic BP, mmHg
• blood glucose mg/dL
DEXA: lumbar spine Z scores
ChildBehaviorChecklist: total problems; internalising; externalising; anxious/depressed;
somatic complaints; withdrawn/depressed; attention problems; aggressive behaviour
Analysis: The average of QMT scores from 2 screening visits and 2 x 12 month visits i.
e. change from baseline to 12 months
The equivalence limit was defined using the baseline data and choosing an equivalence
limit of approximately 1 SD or less of the baseline distribution
For each endpoint, the observed difference from baseline (+SD) and the 95% confidence
limits of the differences in changes between treatments were calculated
Declarations of interest Full disclosures listed in report. Several authors have received honoraria or are on advisory
committees for pharmaceutical companies but none seems to have direct role in this
study or drug
Funding sources Muscular Dystrophy Association, General Clinical Research Center (GCRC), and the
National Institutes of Health
Notes “Recruitment took place over 3 years beginning November 2003; last participant com-
pleting November 2007
Location: multicentre, US
Approved by the Institutional Review Board at each institution. Written informed con-
sent obtained from parents or caregivers
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “Eligible participants were randomized by
the CINRG Coordinating Center within
site and equal-sized age stratum (4-6 years,
7-10 years) using a randompermuted block
randomization scheme (block sizes 2 and
4)”
“CBCL T scores of aggressive behavior and
externalizing were the only significant dif-
ferences at baseline and were not believed
to be clinically meaningful; thus, the ran-
domization procedure was successful”
Allocation concealment (selection bias) Low risk Communication from trial author (D Es-
colar): “At enrollment the randomization
database is accessed to obtain and consume
the next preallocated enrollment slot that
will designate the patient’s random group
assignment. The enrollee’s PIN number is
added to the consumed record in the ran-
domization database as documentation of
that assignment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial au-
thor provided information: “Blinded were
participants, physicians, clinical evaluators,
coordinators and central medical monitor/
research team. Unblinded: research phar-
macist“
Double-blind. Trial authors confirmed
”capsules identical in appearance and taste“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial au-
thor provided information: ”Blinded were
participants, physicians, clinical evaluators,
coordinators and central medical monitor/
research team. Unblinded: research phar-
macist“
Double-blind. Trial authors confirmed
”capsules identical in appearance and taste“
Each treatment group had similar out-
comes e.g. improvements in strength, in-
crease in BMI so it would be difficult to
predict treatment group from individual re-
sults
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6 participants withdrew before the end of
the study (4 in the weekend-only group and
2 in the daily group). Study flow chart in-
dicates that all 32 participants starting trial
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in each group were analysed
Unclear whether analysis took dropouts
into account
Selective reporting (reporting bias) High risk Outcomes measured at 3-month intervals
but report only includes data for 12-month
time point in tables
Other bias Low risk None identified
Griggs 1991
Methods Randomised, double-blind trial with 2 treatment groups and 1 placebo group
Participants 99 boys with DMD, age range 5 to 15 years. Mean age (SD) years; placebo group 9.55
(± 2.44); 0.3 mg/kg 9.63 (± 2.53); 0.75 mg/kg 9.36 years (± 2.88)
70 of the 99 subjects were ambulant, either independently or in calipers, at entry to the
study; 48 of the 67 in the prednisone groups and 22 of the 32 in the placebo group were
ambulant
Interventions Prednisone 0.75 mg/kg/day for 6 months (n = 34) or prednisone 0.3 mg/kg/day (n =
33) for 6 months or placebo for 6 months (n = 32)
Outcomes Muscle strength reported as muscle strength score, based on grading of 34 muscle groups
on 10-point modified MRC score, lifting weights, timed 9-metre walk, climbing 4
stairs and rising from lying to standing, leg functional grades, and pulmonary function
tests (forced vital capacity, maximum voluntary ventilation, and maximum expiratory
pressure) (Brooke 1981; Mendell 1989)
Assessments tookplace on2 consecutive days on initial admission, afterwhich prednisone
was started. Reassessment as outpatients at 10 days, 1, 2, 3, and 6 months
Participants were examined and parents interviewed for side effects at both visits before
initiation of treatment and at 1, 2, 3, and 6 months of treatment
Declarations of interest Not stated
Funding sources Supported by the Muscular Dystrophy Association and National Institutes of Health
Notes Multicentre national trial (five centres, one in Canada, four in United States)
Dates: not stated
Ethical approval and informed consent obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised. No further infor-
mation
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Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Gelatin capsules…containing powdered
prednisone…or placebo were prepared and
dispensed from the pharmacy“
Placebo was the same weight as the drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “There were independent roles for clin-
ical evaluators involved in assessment of
strength and function, and principal inves-
tigators, who assessed side effects”
“the improvement in strength at 10 days
occurred prior to the onset of demonstra-
ble side effects, excluding observable dif-
ferences between treatment and placebo
groups as a potentially unblinding factor”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appear to be no dropouts. Some partici-
pants did not contribute data for some out-
comes because of disability
We made the assumption that any missing
data are missing at random
Selective reporting (reporting bias) Low risk Average muscle strength chosen “a priori”
as primary outcome. Reporting compre-
hensive for 6-month data. Interim mea-
surements other than for the primary out-
come not reported
Other bias Low risk None identified
Authors state that “variables were evaluated
individually with no correction for mul-
tiple comparisons. Such correction would
not materially affect the conclusions, since
the uncorrected P values were very small
Hu 2015
Methods Prospective, randomised, placebo-controlled
Participants 73 boys with DMD who were independently ambulant; age 4 to 12 years
66 randomised (7 excluded: 3 screen failures, 3 refused to participate in the trial, 1 was
noncompliant)
• prednisone: mean age 7.73, SD ± 2.09, n = 36
• placebo mean age 7.56, SD ± 2.15, n = 30
Diagnosis based initially on clinical history and neuromuscular findings, later confirmed
by dystrophin gene testing or muscle biopsy
Exclusions:
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• severe or moderate learning difficulties or behavioural problems
• previous corticosteroid treatment
• non-ambulant
• severe to moderate learning difficulties
• female sex or the family’s unwillingness to participate
Interventions Daily prednisone: 0.75 mg/kg/day in white gelatin capsules (n = 36), for 1 year
Placebo: white gelatin capsules of same weight containing wheat flour (n = 30), for 1
year
Allowed co-interventions: vitamin D, calcium, ranitidine, and an over the counter
antacid; high protein, low carbohydrate, low fat diet. Respiratory, cardiac and rehabili-
tation interventions given to both groups
Outcomes Measured at initiation of prednisone treatment, 6 and 12 months
Outcomes:
• muscle strength (lower limb muscles (right hip flexion and right knee extension)
assessed on expanded MRC scale (10-point scale, Brooke 1983)
• time (in seconds; absolute values at given time points) required to:
◦ walk 10 metres
◦ climb 4 standard steps
◦ stand from supine (Gowers’ time)
• patient and carer quality of life measured using the Chinese version of the
Pediatric Quality of life Inventory (PedsQL) 3.0 Neuromuscular Module. Items were
rated on a 5-point scale and transformed linearly to a 100-point scale (higher = better).
Score = sum of items/number of items answered
• adverse events (time points unclear - at the beginning and the during study):
weight, height, BMI and diastolic BP
• other adverse events are only reported for the prednisone group
Declarations of interest No conflict of interest declaration provided
Funding sources Research Project of Chongqing Municipal Health Bureau and Medical Innovation
Project of Fujian Province
Notes Recruitment between December 2010 and December 2012; 1 year follow-up
Location: Children’s Hospital, Chongqing Medical University, China (SW China)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were randomized into pred-
nisone and placebo groups according to
a random number table.” Baseline imbal-
ances assessed - none identified
Allocation concealment (selection bias) Unclear risk Not mentioned
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo and prednisone were both white
gelatin capsules; some possibility of un-
blinding due to adverse events but, on bal-
ance, judged to be of low risk
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Each outpatient visit included independent
clinical and side effect evaluations obtained
by a clinical evaluator and the principal in-
vestigator, respectively
Outcome assessors likely to be blinded to
the intervention; some possibility of un-
blinding due to adverse events
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8 dropouts (not included in analyses):
• at 6-month follow-up: 2 lost to
follow-up and 1 dropped out due to
economic hardship
• at 12-month follow-up, 2 lost to
follow-up and 3 dropped out due to loss
of ambulation
The lost-to-follow-up rates were 5.56%,
13.89%, and 3.33%, 10.00% in the pred-
nisone and placebo groups at the 6- and
12-month time-points, respectively
Report states “There were no statistical dif-
ferences between the participants who were
lost to follow-up and included in the main
aspects of age, gender and condition”
Selective reporting (reporting bias) Low risk Efficacy outcomes and adverse event mea-
surements (height, weight, BMI, and dias-
tolic BP) described inmethods and fully re-
ported at 6 and 12 months. Other adverse
events partially reported - high risk for ad-
verse events
Other bias Low risk None identified
Karimzadeh 2012
Methods Single-blind, randomised clinical trial
Participants 34 participants (17 in each group)
Participants met these 5 diagnostic criteria for DMD:
• muscular weakness onset under the age of 5
• male
• proximal muscle weakness
• greater than 40-fold increase in CK at the beginning of symptoms
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• confirmation by muscle biopsy to prove dystrophin deficiency or genetic
evaluation to confirm dystrophin gene deletion
• Deflazacort group: mean age 7.1 ± 1.98
• Prednisone group: mean age 7.37 ± 1.27
Interventions Deflazacort group: 0.9 mg/kg in a single dose daily. Reduced to 0.5 mg/kg if complica-
tions occurred; exclusion if complications not controllable at that dose
Prednisone group: 0.75 mg/kg in a single dose daily as 50 mg tablets. Reduced to 0.3
mg/kg in the event of complications with discontinuation if still complications
Treatment continued for 18 months (some participants had dosage reduction at 1 year
Co-interventions: 500 mg calcium and 400 IU vitamin D
Outcomes Movement function measured every 3months, using 1-3 grading (accomplished without
assistance, accomplished with assistance, not able to accomplish the task) of:
• climbing four 17 cm stairs
• sit to stand
• 10-metre walk
• change in height every 3 months
• weight measured every 3 months
• measurement of blood pressure every 3 months and comparing it with the
standard blood pressure chart for children
• check for glucosuria every 3 months
• eye examination for cataract
• orthopaedic examination for scoliosis
• annual spirometry and vital lung capacity as an index for respiratory function
(abnormal defined as vital capacity less than 80% of normal based on age and gender)
• annual cardiac evaluation: measurement of ejection fraction (abnormal defined as
less than 55% normal based on age and gender)
Declarations of interest ”Not declared“
Funding sources Grant from the pediatric neurologic research centre of Shahid Beheshti University of
Medical Sciences
Notes Dates: enrolment 23 September 2008 to 21 March 2009
Location: Iran
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk ”The patients were treated alternatively by
prednisone or deflazacort“
Appears to be quasi-randomised
Allocation concealment (selection bias) High risk Unlikely with this method of randomisation
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind. Paper does not specify who was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Single-blind. Paper does not specify who was
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 8 cases who did not continue therapy, 3
were on deflazacort and 5 on prednisone. At 1
year a further 4 dropouts occurred in the pred-
nisone group because of uncontrollable weight
gain. Dropouts at 1 year were boys with worse
outcomes
Selective reporting (reporting bias) High risk Data were not reported for every time point
Other bias Low risk None identified
Mendell 1989
Methods Randomised, double-blind, placebo-controlled trial with 3 groups
Participants 103 boys with DMD aged 5 to 15 years, mean (SD) age:
• prednisone 0.75 mg/day: 9.16 (2.95)
• prednisone 1.5 mg/day: 9.16 (2.95)
• placebo: 8.99 (2.64)
85 of the participants were ambulant, either independently or in calipers, at entry to the
study; 55 of the 69 in the prednisone groups and 30 of the 33 in the placebo group were
ambulant
Interventions Prednisone 0.75 mg/kg/day (n = 33) or prednisone 1.5 mg/kg/day (n = 34) or placebo (n
= 36) for 6 months. One boy in the 1.5 mg/kg group was not treated because of baseline
hypertension
Outcomes Muscle strength reported as muscle strength score, based on grading of 34 muscle groups
on 10-point modified MRC score, lifting weights, timed 9-metre walk, climbing 4 stairs
and rising from lying to standing, leg functional grades, and forced vital capacity (Brooke
1981; Mendell 1989)
Declarations of interest Not stated
Funding sources Grants from the Muscular Dystrophy Association and the National Institutes of Health
Notes Multicentre national trial
Dates: not stated
Location: USA (4 centres)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomized”
“No significant differences were seen be-
tween the three patient groups in any base-
line values”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Gelatin capsules (No. 3, Eli Lilly) con-
taining powdered prednisone or placebo
were prepared and dispensed from a sin-
gle pharmacy...Placebo was administered
in a gelatin capsule that weighed 240 mg
and contained powdered lactose, and pred-
nisone in a capsule that held the appropri-
ate dose and enough lactose so that the cap-
sule weighed 240 mg”
Some possibility of unblinding as cushin-
goid appearance present in 4 participants
in each corticosteroid group at 1 month
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Implied: “The clinical evaluationswere car-
ried out by clinical evaluators who did not
inquire about side effects”
“The examination for side effects was per-
formed by the principal investigators in an
area separate from that of the clinical eval-
uation”
Some possibility of unblinding as cushin-
goid appearance apparent in 4 participants
in each corticosteroid group at 1 month
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants dropped out: 2 in the low
dose prednisone group required surgery,
and a participant on placebo was removed
by parents after analysis of the drug to
find out its composition. Another placebo
group participant stopped taking medica-
tion because of “adverse events” but com-
pleted all required visits
Selective reporting (reporting bias) Low risk Reporting appears complete
Other bias Low risk None identified
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Methods Randomised, parallel-group, controlled trial
Participants 19 participants with DMD
(16 of the 19 participants were ambulant at entry to the study; 8 of the 10 boys in the
prednisolone group and 8 of the 9 boys in the control group were ambulant)
Inclusion criteria: onset of weakness under 5 years, CK at least 10 times upper limit of
normal
Exclusion criteria: findings suggestive of other diagnoses
Interventions • Prednisolone 0.75 mg/kg/day for 6 months (n = 10) or
• vitamin (not further specified) (n = 9)
Both groups received physiotherapy
Outcomes Muscle strength score, 30-ft walking, lying to standing time, 4-stair climbing times,
functional scores (Brooke 1981). Trial authors state ”any adverse events were noted
during evaluation“
Outcomes evaluated at 0, 1, 2, and 6 months following start of therapy. After 6 months,
a full evaluation was repeated on 2 occasions separated by 1 to 7 days
Declarations of interest Not stated
Funding sources Not stated
Notes Dates: not stated
Location: Dhaka, Bangladesh
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised but method not
described
Allocation concealment (selection bias) Low risk Assessed as low risk as trial authors pro-
vided information indicating adequate al-
location concealment to the review authors
for a previous version of this review
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Control group received vitamin - unlikely
to be matched
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report does notmentiondropouts; the trial
author reported one dropout in response to
the Cochrane authors’ request for an earlier
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version of this review
Selective reporting (reporting bias) High risk Outcomes not clearly defined in methods.
Results reported at endof treatment but not
at interim time points. Adverse events are
notmentioned in results althoughmethods
state that data were collected
Other bias Low risk None identified
Todorovic 1998
Methods Randomised controlled trial
Participants 34 boys (5 to 17 years) with DMD
Interventions Prednisone 2 mg/kg alternate days (high dose) versus placebo. Abstract does not state
number of participants in each group
Outcomes Mean follow-up 20 months
Change in muscle function assessed by myometry, MRC score, motor ability score, and
walking times for ambulant boys, prolongation of ambulation, side effects
Declarations of interest Not stated
Funding sources Not stated
Notes Dates: not stated
Location: not stated
Reported in an abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, with no further details
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo said to be used and ‘blinded’ with no further
information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
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Todorovic 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) High risk Results not comprehensively reported in abstract. No
known full report
Other bias Unclear risk None identified, but insufficient information to make a
judgement
BMI: body mass index
BP: blood pressure
CK: creatine kinase
CPK: creatine phosphokinaseDEXA: dual energy x-ray absorptiometry
DMD: Duchenne muscular dystrophy
DNA: deoxyribonucleic acid
ECG: electrocardiogram
MRC: Medical Research Council
QMT: quantitative muscle testing
RBC: red blood cell
SD: standard deviation
WBC: white blood cell
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahlander 2003 Retrospective study; published as abstract only
Alman 2004 Non-randomised study
Angelini 1995 Non-randomised study; published as abstract only
Angelini 2007 Review article
Angelini 2012 A review of corticosteroid treatment; not a clinical study
Aviles 1982 Non-randomised study; published as abstract only
Balaban 2005 Non-randomised study
Biggar 2001 Non-randomised study
Biggar 2004 Non-randomised study
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(Continued)
Biggar 2006 Non-randomised study
Bonifati 2006 Non-randomised study
Bothwell 2003 Retrospective case note review and telephone interview study
Brooke 1987 Non-randomised open study
Campbell 2003 Systematic online review of deflazacort in Duchenne muscular dystrophy
Connolly 2002 Non-randomised study; historical controls
Daftary 2007 Non-randomised study
de Groot 2002 Non-randomised cohort study
DeSilva 1987 Non-randomised study
Drachman 1974 Non-randomised open study
Dubowitz 2002 Non-randomised open study
Dubrovsky 1999 Non-randomised study; published as abstract only
Fenichel 1991a Three randomised groups (prednisone 0.75 mg/kg/day versus prednisone 1.5 mg/kg/day versus placebo) from
previous Mendell 1989 study were all put on alternate-day prednisone, without breaking the randomisation code.
There was no washout period between the two studies. All patients went on to alternate-day prednisone treatment
and there was no contemporary placebo control group
Fenichel 1991b Open study on previous cohort of patients from Mendell 1989 and Fenichel 1991a
Flanigan 2012 Not randomised or quasi-randomised
Griggs 1993 Randomised study with prednisone group compared with azathioprine. No placebo group
Griggs 2013 Study discussing different practices in corticosteroid regimen used. No outcome measures assessed
Henricson 2013 Not randomised or quasi-randomised. Prospective cohort study
Houde 2008 Not randomised or quasi-randomised. Retrospective cohort study
Kinali 2002 Non-randomised; case-series of 4 patients
Kinali 2007 Non-randomised study
King 2007 Non-randomised study
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(Continued)
Markham 2005 Non-randomised study
Mayhew 2013 Not randomised or quasi-randomised
Mazzone 2013 Not randomised or quasi-randomised
McAdam 2012 A review of 7 studies
Merlini 2003 Non-randomised; open, parallel-group study
Mesa 1991 Non-randomised, double-blind controlled study
”Two groups of 14 patients each were formed after an initial evaluation designed to balance the scores and
composition of the groups“
Pandya 2001 Non-randomised, long-term cohort follow-up of patients from clinical investigation of DMD therapeutic trials
(Griggs 1991; Mendell 1989) at University of Rochester. Published as abstract only
Parreira 2007 Non-randomised
Pradhan 2006 Randomised, open study of deflazacort versus prednisolone. In addition to a very high dropout rate in the
prednisolone group (24/44 participants dropped out because of adverse effects), treatment was stopped in a further
five patients because of no improvement in power. No intention-to-treat analysis performed
Reitter 1995 Not stated to be randomised
Resende 2001 Non-randomised, cohort study; published as abstract only
Ricotti 2013 Not randomised. Prospective, longitudinal observational study
Sansome 1993 Non-randomised open study
Schara 2001 Non-randomised study
Schram 2013 Retrospective cohort review
Siegel 1974 Non-randomised study. Clinically matched double-blind evaluation
Silva 2012 Longitudinal study primarily designed to assess the outcomemeasure tool. Compared quality of life scores between
different age groups but no comparison between different corticosteroid regimens or with any control
Silversides 2003 Non-randomised study; retrospective cohort study
Simon 2011 Not randomised; no comparison of corticosteroid with control or other group
Takeuchi 2013 Not randomised; retrospective cohort study
Tunca 2001 Non-randomised cohort study; published as abstract only
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(Continued)
Vasanth 1996 Interim results of a randomised study of prednisone, ayurvedic medicine, and placebo, published as an abstract.
Further unpublished data were provided by colleagues at Dr Vasanth’s Instituition as she had died. Study design
was modified during the trial with amalgamation of the placebo control group with the ayurvedic treatment
group. At completion of the study, prednisone group was compared with ayurvedic drug treatment group (See
Table 2 for more details)
Wong 2002 Review of previous studies
Yilmaz 2004 Non-randomised study
Characteristics of studies awaiting assessment [ordered by study ID]
ACTRN12605000075684
Methods Randomised, blinded, parallel-group, phase III controlled trial
Participants Diagnosis of Duchenne muscular dystrophy, ambulant, steroid naïve, aged 4 to 10 years
No exclusion criteria
Interventions Daily low-dose (0.75mg/kg/day) prednisone to high-dose prednisone over 2 days (10 mg/kg/week)
Outcomes Primary:
• muscle strength measured at the start of the trial, and 1,3,6,9 and 12 months after starting prednisone
Secondary:
• ”minimum“ adverse events
Notes First enrollment: 1 July 2005
Target sample size: 140
Primary sponsor: TheChildren’sHospital atWestmead, Australia; Cooperative InternationalNeuromuscularResearch
Group, USA listed as a collaborative group
Bello 2015
Methods Longitudinal, multicentre, observational
Participants 340 participants
Interventions Prednisone, prednisolone, or deflazacort (14 different regimens)
Outcomes ”Assessments obtained every 3 months for 1 year, at 18 months, and annually thereafter included: clinical history;
anthropometrics; goniometry; manual muscle testing; quantitative muscle strength; timed function tests; pulmonary
function; and patient-reported outcomes/ health-related quality-of-life instruments“
Notes Average follow-up 3.8 ± 1.8 years
For consideration for the Discussion
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Pane 2015
Methods Observational. Longitudinal, multicentre, cohort study
Participants 96 ambulant participants with genetically proven DMD
Interventions Various: no steroids, or intermittent or daily regimens of prednisone or deflazacort
Outcomes 6-metre walk test
North Star Ambulatory Assessment
Notes For consideration for the Discussion
Characteristics of ongoing studies [ordered by study ID]
CTRI/2009/091/000738
Trial name or title A clinical trial to compare the two ways of giving steroids (daily versus intermittent) in ambulatory patients
with Duchenne muscular dystrophy
Methods Randomised, parallel-group, open-label, active controlled trial
Participants Patients with DMD, 5 to 10 years old meeting the European Neuromuscular Centre DMD diagnostic criteria
(Emery 1997)
Inclusion criteria:
• onset of proximal muscle weakness before 5 years of age
• 10-fold elevation in serum CK
• dystrophic muscle biopsy
• absent or minimal dystrophin on muscle biopsy or DMD mutation in the dystrophic gene, or both
Exclusion criteria:
• at least 7 days corticosteroid use within 2 months of the start of the trial
• non-ambulatory
• unable to rise from the floor without assistance
• contraindications to corticosteroid use
Interventions • Intervention: prednisolone 0.75 mg/kg/day once daily 10 days/month for 6 months
• Control intervention: prednisolone 0.75 mg/kg/day once daily for 6 months
Outcomes Primary outcome:
• muscle strength measured by MMT score and isokinetic muscle testing at 6 months
Secondary outcomes:
• timed functional capacities at 3 and 6 months
• muscular dystrophy-specific functional rating score at 3 and 6 months
• pulmonary function as measured by spirometry at 6 months
• adverse effects like weight gain, hypertension, excessive hair growth, cushingoid facies, infection,
cataract at 3 and 6 months
Starting date First enrollment 20 January 2009
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CTRI/2009/091/000738 (Continued)
Contact information Sheffali Gulati, Department of Pediatrics, AIIMS 110029 New Delhi, Delhi, India
Notes Location: India
Supported by All India Institute of Medical Sciences (AIIMS). Drug supplied by pharmaceutical company
Status unclear
Guglieri 2015
Trial name or title Finding the optimum regimen for Duchenne muscular dystrophy (FOR-DMD)
Methods Randomised, safety/efficacy, parallel assignment, double-blind
Participants Boys with DMD ages 4 to 7 years
Interventions Daily prednisone (0.75 mg/kg/day); intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off ), daily
deflazacort (0.9 mg/kg/day)
Outcomes Primary:
3-dimensional (multivariate) outcome consisting of the following 3 components (each averaged over month
3, 6, 12, 18, 24, 30, and 36 visits):
• time to stand from lying (log-transformed)
• forced vital capacity
• participant/parent global satisfaction with treatment, as measured by the Treatment Satisfaction
Questionnaire for Medication
Secondary
• The North Star Ambulatory Assessment (NSAA): 17-item timed function tests to evaluate motor
ability in ambulant children with DMD. Total score = sum of all graded items. ”Of primary interest will be
the average value of these outcomes over all post-baseline visits over the three year follow-up period“
• 6-minute walk test: once during the screening period (1 to 3 months prior to baseline), at baseline
(month 0), and at months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60
• Range of motion (goniometry): once during the screening period (1 to 3 months prior to baseline), at
baseline, and at months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60). Range of motion at the ankle joint in
dorsiflexion measured in degrees from plantigrade
• Regimen tolerance at months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60, defined as completing 3 to 5
years of follow-up on study medication with no deviation from the initially prescribed dosage level
(increases in dosage band to accommodate growth and weight gain allowed)
• Adverse event profile at months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60. The occurrence and
severity of the following predictable adverse events (i.e. known side effects of corticosteroids) will be
recorded. Behavior problems, bone fractures, cataracts, cushingoid features, GI symptoms, hypertension,
immune/adrenal suppression, slow growth (height restriction), skin changes, weight gain, diabetes
• Child self report and carer quality of life, at months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60.
Measured by child self report and by proxy (parent(s)/guardian(s)) report for all children. Generic Peds
Quality of life (23 questions) neuromuscular disease-specific module (25 questions). The average values of
these outcomes over all post-baseline assessments during the 3-year follow-up period will be of primary
interest
• Cardiac function every 2 years to the age of 10 years, and annually thereafter or at the onset of cardiac
signs and symptoms and the year 3 visit. Monitored by trans-thoracic echocardiogram and 12-lead ECG.
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Guglieri 2015 (Continued)
The findings will be categorised as: normal; abnormal but not clinically significant; abnormal; and clinically
significant. The earliest definite, echo-detectable impairment of left ventricular function is defined as
ejection fraction < 55%, fractional shortening < 28%, or both. Monitored 12-lead ECG. If ECG shows any
impaired left ventricular function or evidence of regional motion abnormalities (posterior wall), the interval
between evaluations will be reduced and treatment initiated
Starting date January 2013
Contact information Kimberley Hart: kim hart@urmc.rochester.edu, University of Rochester, MN, USA
Notes Estimated study completion date: August 2019
International, multicentre: 40 centres (USA, Canada, UK, Germany, and Italy)
NCT01603407
DMD: Duchenne muscular dystrophy; ECG: electrocardiogram; GI: gastrointestinal
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D A T A A N D A N A L Y S E S
Comparison 1. Corticosteroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in MRC index (%)
after 6 months of treatment -
deflazacort 2 mg/kg alternate
days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 MRC - Average muscle score
after 6 months of treatment -
prednisone
3 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 0.3 mg/kg/day 1 61 Mean Difference (IV, Random, 95% CI) 0.34 [0.17, 0.51]
2.2 0.75 mg/kg/day 3 147 Mean Difference (IV, Random, 95% CI) 0.52 [0.33, 0.71]
2.3 1.5 mg/kg/day 1 65 Mean Difference (IV, Random, 95% CI) 0.45 [0.23, 0.67]
3 Change in MRC index (%)
after 24 months of treatment -
deflazacort 2 mg/kg alternate
days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
4 Lower limb muscle strength
grade after 6 months of
treatment - prednisone
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Hip flexion (right) 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Knee extension (right) 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Lower limb muscle strength
grade after 12 months of
treatment - prednisone
1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Hip flexion (right) 1 58 Mean Difference (IV, Random, 95% CI) 1.27 [0.74, 1.80]
5.2 Knee extension (right) 1 58 Mean Difference (IV, Random, 95% CI) 1.23 [0.71, 1.75]
6 Time taken to rise from floor
after 6 months of treatment -
prednisone
5 Mean Difference (Random, 95% CI) Subtotals only
6.1 0.75 mg/kg for 1st 10 days
every month
1 Mean Difference (Random, 95% CI) -1.08 [-2.51, 0.35]
6.2 0.3 mg/kg/ daily 1 Mean Difference (Random, 95% CI) -1.59 [-3.75, 0.57]
6.3 0.75 mg/kg daily 4 Mean Difference (Random, 95% CI) -2.28 [-3.12, -1.44]
6.4 1.5 mg/kg daily 1 Mean Difference (Random, 95% CI) -2.74 [-3.98, -1.50]
7 Change in time taken to rise
from floor after 6 months of
treatment - deflazacort 2 mg/kg
alternate days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
8 Time taken to rise from floor
after 12 months of treatment
(daily prednisone 0.75
mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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9 Change in time taken to rise
from floor after 24 months of
treatment - deflazacort 2 mg/kg
alternate days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
10 9-metre walking/running time
after 6 months of treatment -
prednisone
4 Mean Difference (Random, 95% CI) Subtotals only
10.1 0.75 mg/kg for 1st 10
days every month
1 Mean Difference (Random, 95% CI) -0.68 [-1.15, -0.21]
10.2 0.3 mg/kg daily 1 Mean Difference (Random, 95% CI) -1.18 [-2.65, 0.29]
10.3 0.75 mg/kg daily 3 Mean Difference (Random, 95% CI) -2.73 [-3.97, -1.50]
10.4 1.5 mg/kg daily 1 Mean Difference (Random, 95% CI) -2.64 [-4.45, -0.83]
11 Timed walk (assumed in
seconds) - after 6 months of
treatment - deflazacort 2 mg/kg
alternate days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
12 10-metre walking time 6
months post-treatment (daily
prednisone 0.75 mg/kg)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
13 10-metre walk time 1
year post-treatment (daily
prednisone 0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
14 Timed walk (assumed in
seconds) - after 24 months of
treatment - deflazacort 2 mg/kg
alternate days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
15 Lifting weight (kg) after
6 months of treatment -
prednisone
2 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 0.3 mg/kg/day 1 39 Mean Difference (IV, Random, 95% CI) 0.38 [0.13, 0.63]
15.2 0.75 mg/kg/day 2 94 Mean Difference (IV, Random, 95% CI) 0.75 [0.50, 0.99]
15.3 1.5 mg/kg/day 1 57 Mean Difference (IV, Random, 95% CI) 0.96 [0.52, 1.40]
16 Four-stair climbing time
after 6 months of treatment -
prednisone
5 Mean Difference (Random, 95% CI) Subtotals only
16.1 0.75 mg/kg for 1st 10
days every month
1 Mean Difference (Random, 95% CI) -1.93 [-3.56, -0.30]
16.2 0.3 mg/kg daily 1 Mean Difference (Random, 95% CI) -2.68 [-4.06, -1.30]
16.3 0.75 mg/kg daily 4 Mean Difference (Random, 95% CI) -3.09 [-4.33, -1.85]
16.4 1.5 mg/kg daily 1 Mean Difference (Random, 95% CI) -3.05 [-4.41, -1.69]
17 Timed function: stair climb
after 6 months of treatment -
deflazacort 2 mg/kg alternate
days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
18 Four-stair climbing time after
12 months of treatment (daily
prednisone 0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
19 Change in timed stair climb
after 24 months of treatment -
deflazacort 2 mg/kg alternate
days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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20 Dynamometry - total muscle
force after 6 months of
treatment - prednisone
1 Mean Difference (Random, 95% CI) Subtotals only
21 Leg function grade after
6 months of treatment -
prednisone
2 Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 0.3 mg/kg/day 1 58 Mean Difference (IV, Random, 95% CI) -0.39 [-0.79, 0.01]
21.2 0.75 mg/kg/day 2 129 Mean Difference (IV, Random, 95% CI) -0.41 [-0.73, -0.09]
21.3 1.5 mg/kg/day 1 68 Mean Difference (IV, Random, 95% CI) -0.49 [-0.93, -0.05]
22 Forced vital capacity after
6 months of treatment -
prednisone
2 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 0.3 mg/kg/day 1 59 Mean Difference (IV, Random, 95% CI) 0.16 [0.05, 0.27]
22.2 0.75 mg/kg/day 2 127 Mean Difference (IV, Random, 95% CI) 0.17 [0.10, 0.24]
22.3 1.5 mg/kg/day 1 62 Mean Difference (IV, Random, 95% CI) 0.14 [0.05, 0.23]
23 Quality of life after six months
of treatment (daily prednisone
0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
23.1 Child self report 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
23.2 Parent proxy-report 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
24 Quality of life after 12 months
of treatment (daily prednisone
0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
24.1 Child self report 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
24.2 Parent proxy-report 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
25 Mean % weight gain -
prednisone - daily dose regimen
2 Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 0.3 mg/kg/day 1 56 Mean Difference (IV, Random, 95% CI) 4.21 [0.76, 7.66]
25.2 0.75 mg/kg/day 2 126 Mean Difference (IV, Random, 95% CI) 9.27 [6.87, 11.68]
25.3 1.5 mg/kg/day 1 67 Mean Difference (IV, Random, 95% CI) 8.78 [5.46, 12.10]
26 Weight gain - prednisone -
intermittent, given 1st 10 days
every month
1 Mean Difference (Random, 95% CI) Subtotals only
27 Mean % weight gain -
deflazacort 2 mg/kg alternate
days
1 Mean Difference (IV, Random, 95% CI) Subtotals only
28 Body weight at 6 months
(prednisone 0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
29 Body weight at 12 months
(prednisone 0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
30 BMI at 6 months (daily
prednisone 0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
31 BMI at 12 months (daily
prednisone 0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
32 Excessive hair growth -
prednisone
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
32.1 0.3 mg/kg/day 1 65 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.18, 3.00]
32.2 0.75 mg/kg/day 2 135 Risk Ratio (M-H, Random, 95% CI) 2.60 [1.47, 4.60]
32.3 1.5 mg/kg/day 1 69 Risk Ratio (M-H, Random, 95% CI) 2.32 [1.16, 4.64]
33 Behavioural changes -
prednisone
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
33.1 0.3 mg/kg/day 1 65 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.67, 1.56]
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33.2 0.75 mg/kg/day 2 135 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.94, 2.06]
33.3 1.5 mg/kg/day 1 69 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.92, 2.24]
34 Cushingoid appearance -
prednisone
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
34.1 0.3 mg/kg/day 1 65 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.60, 2.17]
34.2 0.75 mg/kg/day 2 135 Risk Ratio (M-H, Random, 95% CI) 2.37 [1.53, 3.67]
34.3 1.5 mg/kg/day 1 69 Risk Ratio (M-H, Random, 95% CI) 4.36 [2.04, 9.33]
35 Acne - prednisone 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
35.1 0.3 mg/kg/day 1 65 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.18, 3.00]
35.2 0.75 mg/kg/day 2 135 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.96, 3.32]
35.3 1.5 mg/kg/day 1 69 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.84, 3.73]
36 Increased appetite - prednisone 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
36.1 0.3 mg/kg daily 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 0.75 mg/kg daily 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37 Height at 6 months (daily
prednisone 0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
38 Height at 12 months (daily
prednisone 0.75 mg/kg/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 2. Weekend-only versus daily prednisone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Muscle strength (change from
baseline to 12 months)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 MMT score 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 QMT arm score, lb 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 QMT leg score, lb 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 QMT elbow flexors, lb 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.5 QMT elbow extensors, lb 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.6 QMT knee flexors, lb 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.7 QMT knee extensors, lb 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.8 QMT grip score, lb 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Functional outcome measures
(change from baseline to 12
months)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Time taken to rise from
the floor (Gowers’ time) (log
seconds)
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 10-metre walking time
(log seconds)
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Four-stair climb (log
seconds)
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Change in mobility function
(lower extremity score - Vignos)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Change in mobility function
(upper extremity score -
Brooke)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
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5 FVC % predicted 1 Mean Difference (IV, Random, 95% CI) Totals not selected
6 FEV1 % predicted 1 Mean Difference (IV, Random, 95% CI) Totals not selected
7 Maximal inspiratory pressure 1 Mean Difference (IV, Random, 95% CI) Totals not selected
8 Maximal voluntary ventilation 1 Mean Difference (IV, Random, 95% CI) Totals not selected
9 Weight (BMI kg/m2) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
10 Weight (kg) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
11 Child Behavior Checklist:
total problems (higher = more
severe)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
12 Child Behavior Checklist:
internalising
1 Mean Difference (IV, Random, 95% CI) Totals not selected
13 Child Behavior Checklist:
externalising
1 Mean Difference (IV, Random, 95% CI) Totals not selected
14 Child Behavior Checklist:
anxious/depressed
1 Mean Difference (IV, Random, 95% CI) Totals not selected
15 Child Behavior Checklist:
somatic complaints
1 Mean Difference (IV, Random, 95% CI) Totals not selected
16 Child Behavior Checklist:
withdrawn/depressed
1 Mean Difference (IV, Random, 95% CI) Totals not selected
17 Child Behavior Checklist:
attention problems
1 Mean Difference (IV, Random, 95% CI) Totals not selected
18 Child Behavior Checklist:
aggressive behaviour
1 Mean Difference (IV, Random, 95% CI) Totals not selected
19 Osteoporosis: lumbar spine Z
scores (DEXA)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
20 Height (m) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
21 Mean growth in cm 1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 3. Deflazacort versus prednisone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight gain (%) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 At 1 year 2 43 Mean Difference (IV, Random, 95% CI) -9.52 [-14.91, -4.12]
2 Adverse events at six months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Cushingoid appearance 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Appetite increase 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Behavioural changes 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Gastric symptoms 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Hirsutism 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events at 1 year 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Cushingoid appearance 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Appetite increase 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Behavioural changes 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Gastric symptoms 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Hirsutism 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Corticosteroids versus placebo, Outcome 1 Change in MRC index (%) after 6
months of treatment - deflazacort 2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 1 Change in MRC index (%) after 6 months of treatment - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 16 -0.78 (6.5) 10 -2.75 (3.22) 1.97 [ -1.79, 5.73 ]
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Corticosteroids versus placebo, Outcome 2 MRC - Average muscle score after 6
months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 2 MRC - Average muscle score after 6 months of treatment - prednisone
Study or subgroup Steroid Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 0.3 mg/kg/day
Griggs 1991 31 5.82 (0.06) 30 5.48 (0.47) 100.0 % 0.34 [ 0.17, 0.51 ]
Subtotal (95% CI) 31 30 100.0 % 0.34 [ 0.17, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.93 (P = 0.000084)
2 0.75 mg/kg/day
Griggs 1991 34 6 (0.46) 30 5.48 (0.47) 43.5 % 0.52 [ 0.29, 0.75 ]
Mendell 1989 30 6.23 (0.36) 35 5.8 (0.52) 46.8 % 0.43 [ 0.21, 0.65 ]
Rahman 2001 10 3.88 (0.58) 8 2.92 (0.67) 9.8 % 0.96 [ 0.37, 1.55 ]
Subtotal (95% CI) 74 73 100.0 % 0.52 [ 0.33, 0.71 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.79, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 5.32 (P < 0.00001)
3 1.5 mg/kg/day
Mendell 1989 30 6.25 (0.4) 35 5.8 (0.52) 100.0 % 0.45 [ 0.23, 0.67 ]
Subtotal (95% CI) 30 35 100.0 % 0.45 [ 0.23, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.94 (P = 0.000082)
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Analysis 1.3. Comparison 1 Corticosteroids versus placebo, Outcome 3 Change in MRC index (%) after 24
months of treatment - deflazacort 2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 3 Change in MRC index (%) after 24 months of treatment - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 9 -2.78 (7.23) 4 -9.38 (9.44) 6.60 [ -3.79, 16.99 ]
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Corticosteroids versus placebo, Outcome 4 Lower limb muscle strength grade
after 6 months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 4 Lower limb muscle strength grade after 6 months of treatment - prednisone
Study or subgroup Prednisone Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Hip flexion (right)
Hu 2015 34 6.88 (0.95) 29 6.24 (0.83) 0.64 [ 0.20, 1.08 ]
2 Knee extension (right)
Hu 2015 34 7.26 (0.86) 29 6.55 (0.91) 0.71 [ 0.27, 1.15 ]
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Analysis 1.5. Comparison 1 Corticosteroids versus placebo, Outcome 5 Lower limb muscle strength grade
after 12 months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 5 Lower limb muscle strength grade after 12 months of treatment - prednisone
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Hip flexion (right)
Hu 2015 31 6.84 (0.99) 27 5.57 (1.07) 100.0 % 1.27 [ 0.74, 1.80 ]
Subtotal (95% CI) 31 27 100.0 % 1.27 [ 0.74, 1.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.67 (P < 0.00001)
2 Knee extension (right)
Hu 2015 31 7.16 (0.96) 27 5.93 (1.05) 100.0 % 1.23 [ 0.71, 1.75 ]
Subtotal (95% CI) 31 27 100.0 % 1.23 [ 0.71, 1.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.63 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 1.6. Comparison 1 Corticosteroids versus placebo, Outcome 6 Time taken to rise from floor after
6 months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 6 Time taken to rise from floor after 6 months of treatment - prednisone
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 0.75 mg/kg for 1st 10 days every month
Beenakker 2005 -1.08 (0.73) 100.0 % -1.08 [ -2.51, 0.35 ]
Subtotal (95% CI) 100.0 % -1.08 [ -2.51, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 0.3 mg/kg/ daily
Griggs 1991 -1.59 (1.104) 100.0 % -1.59 [ -3.75, 0.57 ]
Subtotal (95% CI) 100.0 % -1.59 [ -3.75, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
3 0.75 mg/kg daily
Griggs 1991 -3.67 (1.0366) 15.9 % -3.67 [ -5.70, -1.64 ]
Hu 2015 -1.62 (0.8119) 24.8 % -1.62 [ -3.21, -0.03 ]
Mendell 1989 -2.02 (0.5113) 53.3 % -2.02 [ -3.02, -1.02 ]
Rahman 2001 -3.63 (1.7164) 6.1 % -3.63 [ -6.99, -0.27 ]
Subtotal (95% CI) 100.0 % -2.28 [ -3.12, -1.44 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 3.33, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 5.32 (P < 0.00001)
4 1.5 mg/kg daily
Mendell 1989 -2.74 (0.6351) 100.0 % -2.74 [ -3.98, -1.50 ]
Subtotal (95% CI) 100.0 % -2.74 [ -3.98, -1.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.31 (P = 0.000016)
Test for subgroup differences: Chi2 = 3.35, df = 3 (P = 0.34), I2 =11%
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Analysis 1.7. Comparison 1 Corticosteroids versus placebo, Outcome 7 Change in time taken to rise from
floor after 6 months of treatment - deflazacort 2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 7 Change in time taken to rise from floor after 6 months of treatment - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 12 1.08 (6.11) 7 3.14 (4.18) -2.06 [ -6.70, 2.58 ]
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Corticosteroids versus placebo, Outcome 8 Time taken to rise from floor after
12 months of treatment (daily prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 8 Time taken to rise from floor after 12 months of treatment (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hu 2015 27 7.42 (3.19) 23 9.63 (2.85) -2.21 [ -3.88, -0.54 ]
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Corticosteroids versus placebo, Outcome 9 Change in time taken to rise from
floor after 24 months of treatment - deflazacort 2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 9 Change in time taken to rise from floor after 24 months of treatment - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 7 2.14 (3.24) 3 7 (5) -4.86 [ -11.01, 1.29 ]
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Corticosteroids versus placebo, Outcome 10 9-metre walking/running time
after 6 months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 10 9-metre walking/running time after 6 months of treatment - prednisone
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 0.75 mg/kg for 1st 10 days every month
Beenakker 2005 -0.68 (0.24) 100.0 % -0.68 [ -1.15, -0.21 ]
Subtotal (95% CI) 100.0 % -0.68 [ -1.15, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
2 0.3 mg/kg daily
Griggs 1991 -1.18 (0.7497) 100.0 % -1.18 [ -2.65, 0.29 ]
Subtotal (95% CI) 100.0 % -1.18 [ -2.65, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
3 0.75 mg/kg daily
Griggs 1991 -2.14 (0.7006) 54.5 % -2.14 [ -3.51, -0.77 ]
Mendell 1989 -2.87 (0.9779) 33.3 % -2.87 [ -4.79, -0.95 ]
Rahman 2001 -5.03 (1.7444) 12.1 % -5.03 [ -8.45, -1.61 ]
Subtotal (95% CI) 100.0 % -2.73 [ -3.97, -1.50 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 2.44, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 4.33 (P = 0.000015)
4 1.5 mg/kg daily
Mendell 1989 -2.64 (0.9218) 100.0 % -2.64 [ -4.45, -0.83 ]
Subtotal (95% CI) 100.0 % -2.64 [ -4.45, -0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
Test for subgroup differences: Chi2 = 12.50, df = 3 (P = 0.01), I2 =76%
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Analysis 1.11. Comparison 1 Corticosteroids versus placebo, Outcome 11 Timed walk (assumed in
seconds) - after 6 months of treatment - deflazacort 2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 11 Timed walk (assumed in seconds) - after 6 months of treatment - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 14 -1.57 (2.21) 9 1.44 (2.01) -3.01 [ -4.76, -1.26 ]
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Corticosteroids versus placebo, Outcome 12 10-metre walking time 6 months
post-treatment (daily prednisone 0.75 mg/kg).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 12 10-metre walking time 6 months post-treatment (daily prednisone 0.75 mg/kg)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hu 2015 34 9.78 (1.83) 29 10.72 (1.38) -0.94 [ -1.73, -0.15 ]
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Corticosteroids versus placebo, Outcome 13 10-metre walk time 1 year post-
treatment (daily prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 13 10-metre walk time 1 year post-treatment (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hu 2015 31 9.55 (2.16) 27 11.26 (1.86) -1.71 [ -2.74, -0.68 ]
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Corticosteroids versus placebo, Outcome 14 Timed walk (assumed in
seconds) - after 24 months of treatment - deflazacort 2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 14 Timed walk (assumed in seconds) - after 24 months of treatment - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 9 0 (2.4) 3 0.67 (0.58) -0.67 [ -2.37, 1.03 ]
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Corticosteroids versus placebo, Outcome 15 Lifting weight (kg) after 6
months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 15 Lifting weight (kg) after 6 months of treatment - prednisone
Study or subgroup Steroid Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 0.3 mg/kg/day
Griggs 1991 21 1.64 (0.11) 18 1.26 (0.54) 100.0 % 0.38 [ 0.13, 0.63 ]
Subtotal (95% CI) 21 18 100.0 % 0.38 [ 0.13, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0033)
2 0.75 mg/kg/day
Griggs 1991 22 2.04 (0.53) 18 1.26 (0.54) 53.3 % 0.78 [ 0.45, 1.11 ]
Mendell 1989 26 1.88 (0.06) 28 1.17 (0.96) 46.7 % 0.71 [ 0.35, 1.07 ]
Subtotal (95% CI) 48 46 100.0 % 0.75 [ 0.50, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 6.01 (P < 0.00001)
3 1.5 mg/kg/day
Mendell 1989 29 2.13 (0.71) 28 1.17 (0.96) 100.0 % 0.96 [ 0.52, 1.40 ]
Subtotal (95% CI) 29 28 100.0 % 0.96 [ 0.52, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.28 (P = 0.000019)
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Analysis 1.16. Comparison 1 Corticosteroids versus placebo, Outcome 16 Four-stair climbing time after 6
months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 16 Four-stair climbing time after 6 months of treatment - prednisone
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 0.75 mg/kg for 1st 10 days every month
Beenakker 2005 -1.93 (0.83) 100.0 % -1.93 [ -3.56, -0.30 ]
Subtotal (95% CI) 100.0 % -1.93 [ -3.56, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.020)
2 0.3 mg/kg daily
Griggs 1991 -2.68 (0.704) 100.0 % -2.68 [ -4.06, -1.30 ]
Subtotal (95% CI) 100.0 % -2.68 [ -4.06, -1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.81 (P = 0.00014)
3 0.75 mg/kg daily
Griggs 1991 -4.21 (0.8077) 27.4 % -4.21 [ -5.79, -2.63 ]
Hu 2015 -1.68 (0.6941) 31.0 % -1.68 [ -3.04, -0.32 ]
Mendell 1989 -3.18 (0.7543) 29.1 % -3.18 [ -4.66, -1.70 ]
Rahman 2001 -3.93 (1.5482) 12.5 % -3.93 [ -6.96, -0.90 ]
Subtotal (95% CI) 100.0 % -3.09 [ -4.33, -1.85 ]
Heterogeneity: Tau2 = 0.80; Chi2 = 6.27, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 4.89 (P < 0.00001)
4 1.5 mg/kg daily
Mendell 1989 -3.05 (0.6959) 100.0 % -3.05 [ -4.41, -1.69 ]
Subtotal (95% CI) 100.0 % -3.05 [ -4.41, -1.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.38 (P = 0.000012)
Test for subgroup differences: Chi2 = 1.46, df = 3 (P = 0.69), I2 =0.0%
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Analysis 1.17. Comparison 1 Corticosteroids versus placebo, Outcome 17 Timed function: stair climb after
6 months of treatment - deflazacort 2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 17 Timed function: stair climb after 6 months of treatment - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 15 -0.33 (5.69) 8 2.63 (4.14) -2.96 [ -7.02, 1.10 ]
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Corticosteroids versus placebo, Outcome 18 Four-stair climbing time after 12
months of treatment (daily prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 18 Four-stair climbing time after 12 months of treatment (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hu 2015 27 7.15 (3.12) 25 8.78 (2.1) -1.63 [ -3.07, -0.19 ]
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Corticosteroids versus placebo, Outcome 19 Change in timed stair climb after
24 months of treatment - deflazacort 2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 19 Change in timed stair climb after 24 months of treatment - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 8 3.63 (6.52) 3 3 (1.73) 0.63 [ -4.29, 5.55 ]
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Corticosteroids versus placebo, Outcome 20 Dynamometry - total muscle
force after 6 months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 20 Dynamometry - total muscle force after 6 months of treatment - prednisone
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Beenakker 2005 99.22 (42.65) 99.22 [ 15.63, 182.81 ]
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Analysis 1.21. Comparison 1 Corticosteroids versus placebo, Outcome 21 Leg function grade after 6
months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 21 Leg function grade after 6 months of treatment - prednisone
Study or subgroup Steroid Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 0.3 mg/kg/day
Griggs 1991 29 4.07 (0.76) 29 4.46 (0.8) 100.0 % -0.39 [ -0.79, 0.01 ]
Subtotal (95% CI) 29 29 100.0 % -0.39 [ -0.79, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
2 0.75 mg/kg/day
Griggs 1991 34 4.19 (0.74) 29 4.46 (0.8) 57.3 % -0.27 [ -0.65, 0.11 ]
Mendell 1989 31 3.25 (1.04) 35 3.85 (0.82) 42.7 % -0.60 [ -1.06, -0.14 ]
Subtotal (95% CI) 65 64 100.0 % -0.41 [ -0.73, -0.09 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.18, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 2.52 (P = 0.012)
3 1.5 mg/kg/day
Mendell 1989 33 3.36 (1.02) 35 3.85 (0.82) 100.0 % -0.49 [ -0.93, -0.05 ]
Subtotal (95% CI) 33 35 100.0 % -0.49 [ -0.93, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.030)
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Analysis 1.22. Comparison 1 Corticosteroids versus placebo, Outcome 22 Forced vital capacity after 6
months of treatment - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 22 Forced vital capacity after 6 months of treatment - prednisone
Study or subgroup Steroid Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 0.3 mg/kg/day
Griggs 1991 29 1.64 (0.27) 30 1.48 (0.16) 100.0 % 0.16 [ 0.05, 0.27 ]
Subtotal (95% CI) 29 30 100.0 % 0.16 [ 0.05, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0058)
2 0.75 mg/kg/day
Griggs 1991 34 1.67 (0.29) 30 1.48 (0.16) 38.2 % 0.19 [ 0.08, 0.30 ]
Mendell 1989 29 1.68 (0.16) 34 1.52 (0.2) 61.8 % 0.16 [ 0.07, 0.25 ]
Subtotal (95% CI) 63 64 100.0 % 0.17 [ 0.10, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 4.81 (P < 0.00001)
3 1.5 mg/kg/day
Mendell 1989 28 1.66 (0.16) 34 1.52 (0.2) 100.0 % 0.14 [ 0.05, 0.23 ]
Subtotal (95% CI) 28 34 100.0 % 0.14 [ 0.05, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.06 (P = 0.0022)
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Analysis 1.23. Comparison 1 Corticosteroids versus placebo, Outcome 23 Quality of life after six months of
treatment (daily prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 23 Quality of life after six months of treatment (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Child self report
Hu 2015 23 64.92 (14.58) 15 54.05 (16.43) 10.87 [ 0.64, 21.10 ]
2 Parent proxy-report
Hu 2015 34 63.46 (15.1) 29 53.49 (17.03) 9.97 [ 1.96, 17.98 ]
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Analysis 1.24. Comparison 1 Corticosteroids versus placebo, Outcome 24 Quality of life after 12 months of
treatment (daily prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 24 Quality of life after 12 months of treatment (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Child self report
Hu 2015 24 67.38 (16.2) 17 51.33 (14.87) 16.05 [ 6.46, 25.64 ]
2 Parent proxy-report
Hu 2015 31 65.33 (16.53) 27 50.91 (16.67) 14.42 [ 5.85, 22.99 ]
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Analysis 1.25. Comparison 1 Corticosteroids versus placebo, Outcome 25 Mean % weight gain - prednisone
- daily dose regimen.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 25 Mean % weight gain - prednisone - daily dose regimen
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 0.3 mg/kg/day
Griggs 1991 27 11.11 (7.01) 29 6.9 (6.07) 100.0 % 4.21 [ 0.76, 7.66 ]
Subtotal (95% CI) 27 29 100.0 % 4.21 [ 0.76, 7.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
2 0.75 mg/kg/day
Griggs 1991 32 15.78 (7.47) 29 6.9 (6.07) 50.1 % 8.88 [ 5.48, 12.28 ]
Mendell 1989 30 16.67 (7.55) 35 7 (6.27) 49.9 % 9.67 [ 6.26, 13.08 ]
Subtotal (95% CI) 62 64 100.0 % 9.27 [ 6.87, 11.68 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 7.55 (P < 0.00001)
3 1.5 mg/kg/day
Mendell 1989 32 15.78 (7.47) 35 7 (6.27) 100.0 % 8.78 [ 5.46, 12.10 ]
Subtotal (95% CI) 32 35 100.0 % 8.78 [ 5.46, 12.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.19 (P < 0.00001)
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Analysis 1.26. Comparison 1 Corticosteroids versus placebo, Outcome 26 Weight gain - prednisone -
intermittent, given 1st 10 days every month.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 26 Weight gain - prednisone - intermittent, given 1st 10 days every month
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Beenakker 2005 0.84 (0.45) 0.84 [ -0.04, 1.72 ]
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Analysis 1.27. Comparison 1 Corticosteroids versus placebo, Outcome 27 Mean % weight gain - deflazacort
2 mg/kg alternate days.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 27 Mean % weight gain - deflazacort 2 mg/kg alternate days
Study or subgroup Deflazacort Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Angelini 1994 11 26.59 (12.16) 5 25.5 (15.04) 1.09 [ -13.92, 16.10 ]
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Corticosteroids versus placebo, Outcome 28 Body weight at 6 months
(prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 28 Body weight at 6 months (prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hu 2015 34 23.09 (4.15) 29 21.93 (3.91) 1.16 [ -0.83, 3.15 ]
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Analysis 1.29. Comparison 1 Corticosteroids versus placebo, Outcome 29 Body weight at 12 months
(prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 29 Body weight at 12 months (prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg] N Mean(SD)[kg] IV,Random,95% CI IV,Random,95% CI
Hu 2015 31 24.61 (3.78) 27 22.87 (4.19) 1.74 [ -0.33, 3.81 ]
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Analysis 1.30. Comparison 1 Corticosteroids versus placebo, Outcome 30 BMI at 6 months (daily
prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 30 BMI at 6 months (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
Hu 2015 34 16.11 (2.05) 29 15.76 (1.92) 0.35 [ -0.63, 1.33 ]
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Analysis 1.31. Comparison 1 Corticosteroids versus placebo, Outcome 31 BMI at 12 months (daily
prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 31 BMI at 12 months (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
Hu 2015 31 17.02 (2.13) 27 16.17 (2.09) 0.85 [ -0.24, 1.94 ]
Test for subgroup differences: Not applicable
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Analysis 1.32. Comparison 1 Corticosteroids versus placebo, Outcome 32 Excessive hair growth -
prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 32 Excessive hair growth - prednisone
Study or subgroup Prednisone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 0.3 mg/kg/day
Griggs 1991 3/33 4/32 100.0 % 0.73 [ 0.18, 3.00 ]
Subtotal (95% CI) 33 32 100.0 % 0.73 [ 0.18, 3.00 ]
Total events: 3 (Prednisone), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 0.75 mg/kg/day
Mendell 1989 17/33 8/36 67.5 % 2.32 [ 1.16, 4.64 ]
Griggs 1991 14/34 4/32 32.5 % 3.29 [ 1.21, 8.96 ]
Subtotal (95% CI) 67 68 100.0 % 2.60 [ 1.47, 4.60 ]
Total events: 31 (Prednisone), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
3 1.5 mg/kg/day
Mendell 1989 17/33 8/36 100.0 % 2.32 [ 1.16, 4.64 ]
Subtotal (95% CI) 33 36 100.0 % 2.32 [ 1.16, 4.64 ]
Total events: 17 (Prednisone), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
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Analysis 1.33. Comparison 1 Corticosteroids versus placebo, Outcome 33 Behavioural changes - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 33 Behavioural changes - prednisone
Study or subgroup Prednisone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 0.3 mg/kg/day
Griggs 1991 19/33 18/32 100.0 % 1.02 [ 0.67, 1.56 ]
Subtotal (95% CI) 33 32 100.0 % 1.02 [ 0.67, 1.56 ]
Total events: 19 (Prednisone), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
2 0.75 mg/kg/day
Griggs 1991 31/34 18/32 61.9 % 1.62 [ 1.17, 2.24 ]
Mendell 1989 16/33 16/36 38.1 % 1.09 [ 0.66, 1.81 ]
Subtotal (95% CI) 67 68 100.0 % 1.39 [ 0.94, 2.06 ]
Total events: 47 (Prednisone), 34 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.77, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 1.67 (P = 0.094)
3 1.5 mg/kg/day
Mendell 1989 21/33 16/36 100.0 % 1.43 [ 0.92, 2.24 ]
Subtotal (95% CI) 33 36 100.0 % 1.43 [ 0.92, 2.24 ]
Total events: 21 (Prednisone), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
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Analysis 1.34. Comparison 1 Corticosteroids versus placebo, Outcome 34 Cushingoid appearance -
prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 34 Cushingoid appearance - prednisone
Study or subgroup Prednisone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 0.3 mg/kg/day
Griggs 1991 13/33 11/32 100.0 % 1.15 [ 0.60, 2.17 ]
Subtotal (95% CI) 33 32 100.0 % 1.15 [ 0.60, 2.17 ]
Total events: 13 (Prednisone), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
2 0.75 mg/kg/day
Griggs 1991 24/34 11/32 69.5 % 2.05 [ 1.21, 3.47 ]
Mendell 1989 18/33 6/36 30.5 % 3.27 [ 1.48, 7.24 ]
Subtotal (95% CI) 67 68 100.0 % 2.37 [ 1.53, 3.67 ]
Total events: 42 (Prednisone), 17 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 3.85 (P = 0.00012)
3 1.5 mg/kg/day
Mendell 1989 24/33 6/36 100.0 % 4.36 [ 2.04, 9.33 ]
Subtotal (95% CI) 33 36 100.0 % 4.36 [ 2.04, 9.33 ]
Total events: 24 (Prednisone), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.80 (P = 0.00014)
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Analysis 1.35. Comparison 1 Corticosteroids versus placebo, Outcome 35 Acne - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 35 Acne - prednisone
Study or subgroup Prednisone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 0.3 mg/kg/day
Griggs 1991 3/33 4/32 100.0 % 0.73 [ 0.18, 3.00 ]
Subtotal (95% CI) 33 32 100.0 % 0.73 [ 0.18, 3.00 ]
Total events: 3 (Prednisone), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 0.75 mg/kg/day
Griggs 1991 9/34 4/32 33.3 % 2.12 [ 0.72, 6.20 ]
Mendell 1989 12/33 8/36 66.7 % 1.64 [ 0.77, 3.50 ]
Subtotal (95% CI) 67 68 100.0 % 1.78 [ 0.96, 3.32 ]
Total events: 21 (Prednisone), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.068)
3 1.5 mg/kg/day
Mendell 1989 13/33 8/36 100.0 % 1.77 [ 0.84, 3.73 ]
Subtotal (95% CI) 33 36 100.0 % 1.77 [ 0.84, 3.73 ]
Total events: 13 (Prednisone), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
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Analysis 1.36. Comparison 1 Corticosteroids versus placebo, Outcome 36 Increased appetite - prednisone.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 36 Increased appetite - prednisone
Study or subgroup Favours prednisone Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 0.3 mg/kg daily
Griggs 1991 19/33 12/32 1.54 [ 0.90, 2.62 ]
2 0.75 mg/kg daily
Griggs 1991 23/34 12/32 1.80 [ 1.09, 2.99 ]
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Analysis 1.37. Comparison 1 Corticosteroids versus placebo, Outcome 37 Height at 6 months (daily
prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 37 Height at 6 months (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[cm] N Mean(SD)[cm] IV,Random,95% CI IV,Random,95% CI
Hu 2015 34 116.81 (12.01) 29 117.69 (12.23) -0.88 [ -6.89, 5.13 ]
Test for subgroup differences: Not applicable
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Analysis 1.38. Comparison 1 Corticosteroids versus placebo, Outcome 38 Height at 12 months (daily
prednisone 0.75 mg/kg/day).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 1 Corticosteroids versus placebo
Outcome: 38 Height at 12 months (daily prednisone 0.75 mg/kg/day)
Study or subgroup Prednisone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[m] N Mean(SD)[m] IV,Random,95% CI IV,Random,95% CI
Hu 2015 31 118.02 (11.37) 27 120.64 (11.98) -2.62 [ -8.66, 3.42 ]
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Weekend-only versus daily prednisone, Outcome 1 Muscle strength (change
from baseline to 12 months).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 1 Muscle strength (change from baseline to 12 months)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 MMT score
Escolar 2011 27 4 (24.3) 27 -0.6 (23.2) 4.60 [ -8.07, 17.27 ]
2 QMT arm score, lb
Escolar 2011 27 0.7 (1.7) 30 1.3 (2.4) -0.60 [ -1.67, 0.47 ]
3 QMT leg score, lb
Escolar 2011 27 2.2 (3.7) 30 2.1 (3.4) 0.10 [ -1.75, 1.95 ]
4 QMT elbow flexors, lb
Escolar 2011 27 0.9 (1.9) 30 1.3 (2.7) -0.40 [ -1.60, 0.80 ]
5 QMT elbow extensors, lb
Escolar 2011 27 0.5 (1.7) 30 1.4 (2.5) -0.90 [ -2.00, 0.20 ]
6 QMT knee flexors, lb
Escolar 2011 27 2.5 (3.5) 30 1.1 (3.8) 1.40 [ -0.50, 3.30 ]
7 QMT knee extensors, lb
Escolar 2011 27 1.8 (4.6) 30 3 (4.3) -1.20 [ -3.52, 1.12 ]
8 QMT grip score, lb
Escolar 2011 27 2.5 (2.4) 30 4.2 (3.4) -1.70 [ -3.22, -0.18 ]
-10 -5 0 5 10
Favours daily Favours weekend
115Corticosteroids for the treatment of Duchenne muscular dystrophy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Weekend-only versus daily prednisone, Outcome 2 Functional outcome
measures (change from baseline to 12 months).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 2 Functional outcome measures (change from baseline to 12 months)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Time taken to rise from the floor (Gowers’ time) (log seconds)
Escolar 2011 21 -0.05 (0.3) 25 -0.2 (0.3) 0.15 [ -0.02, 0.32 ]
2 10-metre walking time (log seconds)
Escolar 2011 27 0.1 (0.4) 29 0.1 (0.4) 0.0 [ -0.21, 0.21 ]
3 Four-stair climb (log seconds)
Escolar 2011 26 -0.06 (0.3) 29 -0.06 (0.5) 0.0 [ -0.22, 0.22 ]
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Analysis 2.3. Comparison 2 Weekend-only versus daily prednisone, Outcome 3 Change in mobility function
(lower extremity score - Vignos).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 3 Change in mobility function (lower extremity score - Vignos)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 28 0.6 (1.4) 30 0.5 (1.4) 0.10 [ -0.62, 0.82 ]
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Analysis 2.4. Comparison 2 Weekend-only versus daily prednisone, Outcome 4 Change in mobility function
(upper extremity score - Brooke).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 4 Change in mobility function (upper extremity score - Brooke)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 28 -0.1 (0.4) 30 0.2 (0.5) -0.30 [ -0.53, -0.07 ]
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Analysis 2.5. Comparison 2 Weekend-only versus daily prednisone, Outcome 5 FVC % predicted.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 5 FVC % predicted
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 15 5 (15.7) 16 0.6 (24) 4.40 [ -9.79, 18.59 ]
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Analysis 2.6. Comparison 2 Weekend-only versus daily prednisone, Outcome 6 FEV1 % predicted.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 6 FEV1 % predicted
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 15 2 (22.5) 16 -4 (20.4) 6.00 [ -9.15, 21.15 ]
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Analysis 2.7. Comparison 2 Weekend-only versus daily prednisone, Outcome 7 Maximal inspiratory
pressure.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 7 Maximal inspiratory pressure
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 23 9 (12) 19 9 (13) 0.0 [ -7.63, 7.63 ]
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Analysis 2.8. Comparison 2 Weekend-only versus daily prednisone, Outcome 8 Maximal voluntary
ventilation.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 8 Maximal voluntary ventilation
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 12 2 (6) 15 -2 (9) 4.00 [ -1.68, 9.68 ]
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Analysis 2.9. Comparison 2 Weekend-only versus daily prednisone, Outcome 9 Weight (BMI kg/m2).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 9 Weight (BMI kg/m2)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 28 17.8 (3.3) 30 19.6 (4.2) -1.80 [ -3.74, 0.14 ]
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Analysis 2.10. Comparison 2 Weekend-only versus daily prednisone, Outcome 10 Weight (kg).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 10 Weight (kg)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 28 28.2 (8.5) 30 30.7 (11) -2.50 [ -7.54, 2.54 ]
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Analysis 2.11. Comparison 2 Weekend-only versus daily prednisone, Outcome 11 Child Behavior Checklist:
total problems (higher = more severe).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 11 Child Behavior Checklist: total problems (higher = more severe)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 26 49 (10) 28 48 (10) 1.00 [ -4.34, 6.34 ]
-20 -10 0 10 20
Favours weekend Favours daily
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Analysis 2.12. Comparison 2 Weekend-only versus daily prednisone, Outcome 12 Child Behavior Checklist:
internalising.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 12 Child Behavior Checklist: internalising
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 26 52 (9) 28 48 (9) 4.00 [ -0.80, 8.80 ]
-20 -10 0 10 20
Favours weekend Favours daily
Analysis 2.13. Comparison 2 Weekend-only versus daily prednisone, Outcome 13 Child Behavior Checklist:
externalising.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 13 Child Behavior Checklist: externalising
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 26 50 (11) 28 51 (10) -1.00 [ -6.62, 4.62 ]
-10 -5 0 5 10
Favours weekend Favours daily
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Analysis 2.14. Comparison 2 Weekend-only versus daily prednisone, Outcome 14 Child Behavior Checklist:
anxious/depressed.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 14 Child Behavior Checklist: anxious/depressed
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 26 47 (8) 29 48 (7) -1.00 [ -4.99, 2.99 ]
-10 -5 0 5 10
Favours weekend Favours daily
Analysis 2.15. Comparison 2 Weekend-only versus daily prednisone, Outcome 15 Child Behavior Checklist:
somatic complaints.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 15 Child Behavior Checklist: somatic complaints
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 26 50 (7) 29 48 (9) 2.00 [ -2.24, 6.24 ]
-10 -5 0 5 10
Favours weekend Favours daily
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Analysis 2.16. Comparison 2 Weekend-only versus daily prednisone, Outcome 16 Child Behavior Checklist:
withdrawn/depressed.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 16 Child Behavior Checklist: withdrawn/depressed
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 26 50 (9) 29 46 (7) 4.00 [ -0.30, 8.30 ]
-10 -5 0 5 10
Favours weekend Favours daily
Analysis 2.17. Comparison 2 Weekend-only versus daily prednisone, Outcome 17 Child Behavior Checklist:
attention problems.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 17 Child Behavior Checklist: attention problems
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 26 48 (10) 30 46 (6) 2.00 [ -2.40, 6.40 ]
-10 -5 0 5 10
Favours weekend Favours daily
123Corticosteroids for the treatment of Duchenne muscular dystrophy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.18. Comparison 2 Weekend-only versus daily prednisone, Outcome 18 Child Behavior Checklist:
aggressive behaviour.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 18 Child Behavior Checklist: aggressive behaviour
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 26 48 (9) 29 47 (8) 1.00 [ -3.52, 5.52 ]
-10 -5 0 5 10
Favours weekend Favours daily
Analysis 2.19. Comparison 2 Weekend-only versus daily prednisone, Outcome 19 Osteoporosis: lumbar
spine Z scores (DEXA).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 19 Osteoporosis: lumbar spine Z scores (DEXA)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 25 -0.88 (0.85) 28 -1.33 (0.91) 0.45 [ -0.02, 0.92 ]
-1 -0.5 0 0.5 1
Favours daily Favours weekend
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Analysis 2.20. Comparison 2 Weekend-only versus daily prednisone, Outcome 20 Height (m).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 20 Height (m)
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 28 124 (11) 30 123 (11) 1.00 [ -4.67, 6.67 ]
-20 -10 0 10 20
Favours daily Favours weekend
Analysis 2.21. Comparison 2 Weekend-only versus daily prednisone, Outcome 21 Mean growth in cm.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 2 Weekend-only versus daily prednisone
Outcome: 21 Mean growth in cm
Study or subgroup Weekend Daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Escolar 2011 28 6.6 (2.93) 30 4.1 (2.93) 2.50 [ 0.99, 4.01 ]
-10 -5 0 5 10
Favours daily Favours weekend
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Analysis 3.1. Comparison 3 Deflazacort versus prednisone, Outcome 1 Weight gain (%).
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 3 Deflazacort versus prednisone
Outcome: 1 Weight gain (%)
Study or subgroup Deflazacort Prednisone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 At 1 year
Bonifati 2000 9 9 (11.88) 8 21.3 (11.88) 22.7 % -12.30 [ -23.61, -0.99 ]
Karimzadeh 2012 14 12.95 (9.23) 12 21.65 (6.68) 77.3 % -8.70 [ -14.84, -2.56 ]
Subtotal (95% CI) 23 20 100.0 % -9.52 [ -14.91, -4.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.46 (P = 0.00054)
-50 -25 0 25 50
Favours deflazacort Favours prednisone
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Analysis 3.2. Comparison 3 Deflazacort versus prednisone, Outcome 2 Adverse events at six months.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 3 Deflazacort versus prednisone
Outcome: 2 Adverse events at six months
Study or subgroup Deflazacort Prednisone Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cushingoid appearance
Bonifati 2000 2/9 3/8 0.59 [ 0.13, 2.70 ]
2 Appetite increase
Bonifati 2000 2/9 6/8 0.30 [ 0.08, 1.07 ]
3 Behavioural changes
Bonifati 2000 4/9 4/8 0.89 [ 0.32, 2.43 ]
4 Gastric symptoms
Bonifati 2000 1/9 2/8 0.44 [ 0.05, 4.02 ]
5 Hirsutism
Bonifati 2000 5/9 4/8 1.11 [ 0.45, 2.75 ]
0.001 0.01 0.1 1 10 100 1000
Favours deflazacort Favours prednisone
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Analysis 3.3. Comparison 3 Deflazacort versus prednisone, Outcome 3 Adverse events at 1 year.
Review: Corticosteroids for the treatment of Duchenne muscular dystrophy
Comparison: 3 Deflazacort versus prednisone
Outcome: 3 Adverse events at 1 year
Study or subgroup Deflazacort Prednisone Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cushingoid appearance
Bonifati 2000 5/9 4/8 1.11 [ 0.45, 2.75 ]
2 Appetite increase
Bonifati 2000 3/9 6/8 0.44 [ 0.16, 1.22 ]
3 Behavioural changes
Bonifati 2000 6/9 5/8 1.07 [ 0.53, 2.17 ]
4 Gastric symptoms
Bonifati 2000 1/9 1/8 0.89 [ 0.07, 12.00 ]
5 Hirsutism
Bonifati 2000 5/9 3/8 1.48 [ 0.51, 4.31 ]
0.01 0.1 1 10 100
Favours deflazacort Favours prednisone
A D D I T I O N A L T A B L E S
Table 1. Excluded non-randomised studies
Study ID Design No. of
patients
Age (years) Regimen Treatment
period
Outcome Adverse
events
Drachman
1974
Open 14 4 to 10.5 Pred-
nisone 2 mg/
kg/day for 3
months, then
two-
thirds dose on
alternate days
3 weeks to 28
months
Improvement Adverse events
in 4 patients
Siegel 1974 Double-blind 14 6 to 9 Prednisone 5
mg/kg on al-
ternate days
24 months No benefit
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Table 1. Excluded non-randomised studies (Continued)
Brooke 1987 Open 33 5 to 15 Prednisone 1.
5 mg/kg/day
6 months Improvement 6 dropouts
DeSilva 1987 Open 16 3 to 10 Pred-
nisone 2 mg/
kg/day for 3
months, then
two-
thirds dose on
alternate days
1 to 11
months
Walking pro-
longedby 2 yrs
Excessive
weight gain
in 12 patients;
cataracts in 2
Fenichel
1991b
Open 92 5 to 15 Prednisone 0.
75 mg/kg/day
2 yrs Sta-
bilisation for 2
yrs Prednisone
0.56 mg/kg/
day least effect
dose
Cataracts in
10 patients;
glycosuria in
10 patients;
significant
weight gain
Mesa 1991 Double-blind 28 5 to 11 DFZ1mg/kg/
day
9 months Improved up
to 6 months,
then stable
35% cushin-
goid;
no significant
weight gain
Sansome 1993 Open 32 6 to 14 Pred-
nisolone 0.75
mg/kg/day for
10 days/
months (given
10 days on, 20
days off )
From 6 to 18
months
Strength im-
proved at 6
months; slow
decline at 18
months
Fewer adverse
events, but
26% of boys
had more than
20% weight
gain
Biggar 2001 Open 30 7 to 15 DFZ 0.9 mg/
kg/day
3.8 (+/- SD 1.
5) yrs
Ambulation
prolonged
FVC pre-
served: mean
% predicted
FVC 72%
inDFZgroup;
35% in non-
treated group
Cataracts in
30%
Dubowitz
2002
Open 2 3 yrs 10
months
Prednisolone
0.75 mg/
kg/day (given
10 days on, 10
days off )
5 yrs Stabilisation
of motor func-
tion for up to
5 yrs
Irritability in 1
patient
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Table 1. Excluded non-randomised studies (Continued)
Connolly
2002
Open, histori-
cal controls
20 treated 5 to 10 Prednisolone
5 mg/kg twice
weekly
(every Friday
and Saturday).
22 (+/- 1.5)
months
Improved
strength over 6
to 12 months
in majority
Irritability in
6. 2 stopped, 4
reduced pred-
nisone dose
Merlini 2003 Open, paral-
lel-
group, double
consent
5 treated, 3
control
2 to 4 Prednisone
0.75 mg/
kg for 2 weeks,
then 1.25 mg/
kg on alternate
days
47 to 63
months
Ability to
rise from floor
prolonged;
stairs and 10-
metre walking
time similar
Growth rate
decline; irri-
tability requir-
ing niaprazine
in 1 patient
Kinali 2002 Open 4 (including 2
patients from
Dubowitz
2002)
3
yrs 10 months
to 4.5 yrs
Prednisolone
0.75 mg/
kg/day (given
10 days on, 10
days off )
2.5 yrs to over
5 yrs
Stabilisation
of motor func-
tion for up to
5 yrs; loss of
ambulation in
1 boy at age 9
yrs, after 5 yrs
of treatment
Bone mineral
den-
sity on DEXA
scans at 1 to
6 yrs of treat-
ment was nor-
mal
Silversides
2003
Retrospective
cohort study;
patients refus-
ing treatment
formed
control group
33 (21
treated)
8.4 (+/-2) DFZ
Start: 0.9 mg/
kg/day
(grad-
ual decrease in
dose with age)
At 18
yrs: 0.59 +/-0.
15 mg/kg/day
5.1 (+/- 2.4)
yrs
Walking pro-
longed, 48%
ambulant at
14 +/- 2 yrs of
age
Mean % pre-
dicted FVC:
83% in
treated, 41%
control group
Cardiomy-
opathy:
5% of DFZ vs
58% of con-
trols
Marked retar-
dation
of height gain;
weight gain
similar to con-
trols; cataracts
in
50% (asymp-
tomatic)
Aviles 1982
(Published as
abstract only)
Open - - Prednisone
3 mg/kg on al-
ternate days.
- - -
Dubrovsky
1999
(published as
abstract only)
Open 30 (compared
to 59 age-
matched con-
trols)
7 to 21 yrs DFZ
0.5 to 1 mg/
kg/day.
2 yrs to 9 yrs FVC sig-
nificantly pre-
served in
DFZ-treated
group
Not described
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Table 1. Excluded non-randomised studies (Continued)
Tunca 2001
(published as
abstract only)
Open 66 (com-
pared with 22
historical con-
trols)
2.5 to 11 yrs Prednisolone
0.75mg/kg on
alternate days;
Vit D
0.5 to 5
(mean 2.75)
yrs
Mean age at
loss
of ambulation
- prednisolone
10 yrs, con-
trols 7.69 yrs);
no scoliosis at
a mean age of
11 .7 yrs
Not described
Pandya 2001
(published as
abstract only)
Open 13 inde-
pendently am-
bulant
patients from
clinical Inves-
tigation group
of Duchenne
Dystrophy
(CIDD) stud-
ies
Prednisone
0.75 mg/kg/
day,
gradually
decreased over
time
10 yrs Mean age of
loss of ambu-
lation pro-
longed to 14.5
yrs
Not described
Resende 2001
(published as
abstract only)
Open 36 Not described DFZ1mg/kg/
day
15 treated for
12 to 43
months
11 of the 15
boys am-
bulant beyond
10 yrs
GI distur-
bances and de-
pression need-
ing discontin-
u-
ation of treat-
ment in 1 pa-
tient; cataracts
in 2 patients
deGroot 2002
(published as
abstract only)
Open 18 4.5 to 9 yrs Prednisolone
0.75 mg/
kg/day (given
10 days on,10
days off )
Not described ”Func-
tional ability
improved“
”Osteo-
porosois 2 -3
SDat the start,
but did not
change under
treatment“
Ahlander
2003 (pub-
lished as ab-
stract only)
Retrospective
review
43 (15 not
treated)
Prednisone 0.
35 mg/kg/day
Up to 7.5 yrs Authors per-
ceived
a prolongation
of walking by
0.9 yrs, but the
patient groups
compared are
from different
eras and there
may be con-
Behavioural
problems;
weight
gain; dyspep-
sia; growth re-
tardation
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Table 1. Excluded non-randomised studies (Continued)
founding fac-
tors
Biggar 2006 Open co-
hort study; pa-
tients declin-
ing treatment
formed com-
parison (con-
trol) group
40 treated, 34
not treated
10 to 18 yrs DFZ 0.9 mg/
kg/day
Mean of 5.5
yrs
DFZ-treated
boys were able
to rise
from supine to
standing walk
10 metres
with-
out aids, 3 to
5 yrs longer
than boys not
treated
At 18 yrs, only
4/40 treated
boys had scol-
iosis greater
than 20
degrees, com-
pared to 30/34
untreated boys
At 18 yrs, 4/40
boys treated
with DFZ had
cardiac
left ventricular
ejection frac-
tion of < 45%,
com-
pared with 20/
34 untreated
boys
Two of the 40
DFZ-treated
boys died
by 18 yrs of
age, compared
with 12/34
boys in the un-
treated group
DFZ-treated
boys were sig-
nifi-
cantly shorter,
but did not
have excessive
weight gain
22/40 treated
boys had
asymptomatic
cataracts
Biggar 2004 De-
scription and
comparison of
2 cohorts in
open study of
2 DFZ proto-
cols, in 2 dif-
56 boys
started on
DFZ
30 boys on
DFZ
4 to 8 yrs
6 to 8 yrs
DFZ 0.6 mg/
kg/day for 1st
20 days every
month, Vit D
880 iu & Ca
1000 mg daily
4 yrs +
4 yrs +
At 15 yrs of
age 25% able
towalk 10me-
tres
No cataracts
Cataracts in
30%. Shorter
in height than
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Table 1. Excluded non-randomised studies (Continued)
ferent centres:
1. Naples pro-
tocol (ret-
rospective); 2.
Toronto pro-
tocol (Biggar
2001 cohort)
DFZ 0.9 mg/
kg/day, Vit D
1000 iu & Ca
750 mg daily
At 15 yrs of
age 77% able
towalk 10me-
tres
the Naples
study cohort
Yilmaz 2004 Prospective
cohort study
with historical
controls
66 treated
22 controls
6.8 ± 2.1 Prednisolone
0.75 mg/kg
given on alter-
nate days,
Vit D 600 to
1200 iu daily
2.75 ± 1.1 yrs No scoliosis >
24° in pred-
nisolone-
treated group
at end of study
(mean age 10.
8±1.2 yrs)
7/22 in the
historical con-
trols had sco-
liosis > 45°
aged 11.7±0.8
yrs
Duration of
follow-up lim-
ited with
young mean
age at end of
study
Scoliosis
appears post-
poned as com-
pared to
historical con-
trols, but po-
ten-
tial for wors-
ening in pu-
bertal growth
spurt in early
teens remains
Alman 2004 Prospective
cohort study
(same co-
hort as Biggar
2001)
54
(30 treated)
7 to 10 DFZ Start: 0.
9 mg/kg/day
(grad-
ual decrease in
dose with age)
7.3 (5 to 8) yrs Scoliosis > 20°
de-
veloped in 5/
30DFZ group
versus 16/24
in non-treated
Symp-
tomatic stress
fractures in 3/
30 in DFZ
group
Cataracts in
33% of DFZ
group
Balaban 2005 Retrospective
review
n = 49
18 pred-
nisone-treated
12 DFZ-
treated
19 no drug
treatment
12 to 15 Prednisone
start-
ing dose: 0.75
mg/kg/day
DFZ starting
dose:
0.9 mg/kg/
day
Corti-
costeroid ther-
apy for > 2 yrs
before loss of
ambulation
Mean du-
ration of treat-
ment was 5.
49 yrs and 5.
85 yrs in pred-
nisone and
Similar bene-
fit for walking
in both pred-
nisone and
DFZ- treated
groups,
with approxi-
mate prolon-
gation
of walking of
2 yrs as com-
Dose decrease
required
in prednisone
group because
of excessive
weight gain
DFZ
dose decreased
in 3 boys be-
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Table 1. Excluded non-randomised studies (Continued)
DFZ-treated
groups,
respectively
pared to non-
treated control
group
Markedly de-
creased
need for sco-
liosis surgery
in DFZ and
prednisone
groups
cause of hy-
pertension,
behavioural
changes and
vertebral frac-
ture
Schara 2001 Retrospective
review
19 DFZ-
treated boys
9 to 18 DFZ starting
dose 0.9 mg/
kg/day
More than 2
yrs
All DFZ-
treated boys
were able to
walk indepen-
dently during
the study pe-
riod to a mean
age of 13 yrs
(range 9.4 to
18.11 yrs)
Fourteen of
the 19 DFZ-
treated boys
developed
cataracts; one
pa-
tient’s progres-
sive cataracts
lead to im-
plantation
of lenses af-
ter 56 months
into the treat-
ment
King 2007 Retrospective
review
n = 143
75 prednisone
or DFZ-
treated boys
68 non-
treated (or
briefly treated,
and
therefore con-
sidered appro-
priate as con-
trols)
mean 16.9
(6 to 30 yrs)
Daily dose
prednisone or
DFZ
Average
”steroid“ dose
at last clinic re-
view 0.55 mg/
kg/day (range
0.1 - 0.78)
Corticos-
teroid-treated
boys
were given Ca
carbonate 350
mg
3 times daily,
or a calcium
tablet with vit
D
(750 to 1200
mg) daily
Mean 8 yrs (+/
-5.2 yrs, range
0.5 to 18 yrs)
Treated
boys walked 3.
3 yrs longer
than the un-
treated group
Lower preva-
lence (31%
ver-
sus 91%) and
severity (Cobb
angle 11 ver-
sus 33 ) in the
corticos-
teroid-treated
as opposed to
the non-
treated boys
Verte-
bral compres-
sion frac-
tures reported
in 32% of the
treated group
(none
in the steroid-
naïve group)
Long-
bone fractures
were 2.6 times
greater in cor-
ticosteroid-
treated
patients
Eight of the 75
treated boys
discontin-
ued corticos-
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Table 1. Excluded non-randomised studies (Continued)
teroid treat-
ment because
of adverse ef-
fects. Another
2boys stopped
treatment as
it was thought
that the maxi-
mum ben-
efit had been
achieved
Daftary 2007 Retrospective,
case-control
study
n = 35
10 prednisone
or DFZ-
treated
25 non-
treated
7 to 21 yrs
in the treated
group
Prednisone 0.
75 mg/kg/day
and DFZ at 0.
9 mg/kg/day,
were the start-
ing doses
8.2 yrs
(range 1 yr to
14 yrs)
IRLS model
suggested that
the corticos-
teroid-treated
group had
higher peak
cough flow
values (27 L/
min higher
than the non-
treated group
(95% CI 2 to
52 L/min; P =
0.0328)
Longi-
tudinal effect
on peak cough
flow could not
be assessed be-
cause of the
study design
Not reported
Kinali 2007 Retro-
spective study
analysing pre-
dictive factors
for scoliosis in
DMD
n = 123
37
prednisolone-
treated
All boys 17
yrs or older at
time of study
Pred-
nisolone 0.75
mg/kg/day, 10
consecutive
days/month
(Prednisolone
started at
mean age of 9.
5 yrs (range 7.
7 to 12.4)
Median 1 yr
(range
2 months to 9
yrs)
There was
a positive re-
lationship be-
tween age at
scoliosis onset
(later) and du-
ration (longer)
of pred-
nisolone treat-
ment (r = 0.
44, P = 0.01, n
= 36)
There was no
Not reported
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Table 1. Excluded non-randomised studies (Continued)
re-
lationship be-
tween severity
of scoliosis at
17 yrs and du-
ration of pred-
nisolone treat-
ment (P = 0.
64)
Parreira 2007 Prospective
single
(treated)
cohort study
n = 32 Age at start
of treatment: 5
yrs 8 months
to 8 yrs 8
months
Prednisolone
0.
75 mg/kg/day
in an intermit-
tent course of
10 days on, 10
days off
or
DFZ 1 mg/
kg/day
14 months Focus of the
study was to
select an as-
sessment pro-
tocol which
could be ap-
plied in outpa-
tient settings
8 boys
stopped walk-
ing during the
study period
Muscle
strength MRC
score
decreased over
time, but there
was some
functional im-
provement in
lift-
ing weights, 9-
metre walking
time
2 withdrew
from
treatment and
2 took it irreg-
ularly
Markham
2005
Retrospective
review
n = 111
Prednisone-
treated n = 29
DFZ-treated
n = 19
3 to 11 yrs
Treated 11 ± 4
yr
Non-treated
12 ± 5 yr
Not described Mean
length of treat-
ment was 3 ±
2.5 yr
Article focuses
on cardiac
outcome and
presents cross-
sectional
echocardio-
graphic data
The shorten-
ing frac-
tion was lower
in the non-
Not described
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Table 1. Excluded non-randomised studies (Continued)
treated group
than
in the corti-
costeroid-
treated group
(30% ± 7% vs
36% ± 5%; P
< 0.001)
In comparison
with the corti-
costeroid-
treated
boys, the non-
treated boys
older than 10
yrs
were 15 times
more likely to
have a short-
ening fraction
less than 28%
(P < 0.01)
Houde 2008 Retrospective
cohort study
(patients de-
clining to take
corticosteroid
or used for less
than 6months
formed the
control group)
37 treated
42 untreated
Mean 13.1 +/-
3.2 yrs treated
group
Mean 9.5 +/
-2.9 yrs un-
treated group
DFZ started at
0.9 mg/kg
Ad-
justed accord-
ing to evolu-
tion or side ef-
fects (max 1
mg/kg)
Mean dose
at most recent
visit 0.69 +/-
0.22 mg/kg
Mean
treatment 66
months
Walking pro-
longed:
mean age loss
of ambulation
11.
5 years treated
versus 9.6 yrs
control
Muscle
strength
improved:
63% of nor-
mal in DFZ
group versus
32% of nor-
mal in control
group
FVC
improved:
66%DFZver-
sus 48% con-
trol
Cardiomy-
All fractures:
43%DFZver-
sus 26% con-
trol
At least 1 limb
fracture:
24%DFZver-
sus 26% con-
trol
Vertebral frac-
tures:
20%DFZver-
sus 0% con-
trol
Decline in
bone density:
Z-score
-1.8 after 1 yr
DFZ and -4.5
after 7 yrs
Weight excess:
62%DFZver-
sus 55% con-
137Corticosteroids for the treatment of Duchenne muscular dystrophy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Excluded non-randomised studies (Continued)
opathy
reduced:
present in
32%DFZver-
sus 58% con-
trol
Scoliosis
reduced:
present in
27%DFZver-
sus 67% con-
trol (43% of
whom
required
surgery)
trol
Mean height
gain:
3 times
as much in
controls versus
DFZ group
Cataracts:
developed in
49% of DFZ
group (1 re-
quired
surgery)
Henricson
2013
Prospective
cohort
study over 12
months of 3
groups:
GC-
naïve (treated
< 1 month to-
tal or never),
current GC
users,
past GC users
(treated
in past for >
1 month but
not currently
receiving GC)
340 total
82 GC-naïve
210 current
GC
48 past GC
Age range 2 to
28 yrs
Not specified As-
sessments per-
formed over a
12-month pe-
riod
Better upper
and lower ex-
tremity func-
tion in current
GC group ver-
sus GC-naïve
P < 0.001
Bet-
ter functional
milestones in
GC users ver-
sus GC-naïve
P = 0.0022
No significant
differences in
MMT scores
al-
though rate of
decline slower
than com-
pared with
historical GC-
naïve controls
Re-
quirement for
surgical spinal
stabili-
sation reduced
in GC group
versus GC-
naïve between
Fractures:
no significant
differences be-
tween groups
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Table 1. Excluded non-randomised studies (Continued)
ages 13 to 15
yrs P = 0.013
Better FVC in
GC-
treated versus
GC- naïve in
ages 10 to 15
yrs
Takeuchi
2013
Ret-
rospective co-
hort study of
prednisolone-
treated (cur-
rent and past)
versus steroid-
naïve
553 total
242
prednisolone-
treated, 311
steroid-naïve
Age range > 5
to < 40
Prednisolone
(no data on
dose, regimen
or duration)
Review of reg-
istry
data compiled
from July
2009 to June
2012
Increased age
at loss of am-
bulation:
steroid-
naïve median
10.1 yrs
prednisolone-
treated 11.0
yrs
Not examined
Ricotti 2013 Prospec-
tive longitudi-
nal observa-
tional study
360 Age range
3 to 15 yrs
Daily ver-
sus intermit-
tent GC regi-
mens
Mean du-
ration of treat-
ment 4 yrs
In-
creased age at
loss of ambu-
lation for daily
regimen:
median 12 yrs
intermittent
versus 14.5 yrs
daily
Slower decline
inNSAA score
after age 7 for
daily versus in-
termittent reg-
imen
No difference
in respira-
tory or cardiac
outcomes be-
tween groups
Cushin-
goid features:
33% daily ver-
sus 15% inter-
mittent
Hyperactivity:
23% daily ver-
sus 15% inter-
mittent
GI symptoms:
14% daily ver-
sus 6% inter-
mittent
Hypertension:
22% daily ver-
sus 5% inter-
mittent
Ex-
cessive weight
gain in both
groups but
greatest in-
crease in over-
all BMI and
shorter
heights seen in
daily regimen
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Table 1. Excluded non-randomised studies (Continued)
Low bone
min-
eral density z
scores < 2.5 in
8% daily ver-
sus 5% inter-
mittent
Vertebral frac-
tures:
8% daily ver-
sus 4% inter-
mittent
BMI: body mass index; Ca: calcium; CI: confidence interval; DEXA: dual energy x-ray absorptiometry; DFZ: deflazacort; FVC: forced
vital capacity; GC: glucocorticosteroid; GI: gastrointestinal; IRLS: iteratively reweighted least squares; MMT:manual muscle testing;
MRC: Medical Research Council; NSAA: North Star Ambulatory Assessment; SD: standard deviation; vit D: vitamin D; yr: year;
Table 2. Excluded randomised studies
Study ID Design No. of
patients
Age (years) Regimen Treatment
period
Outcome Adverse
events
Fenichel
1991a
Double-blind 103 5 to 15 yrs Prednisone 1.
25 mg/kg/al-
ternate day
Prednisone 2.
5 mg/kg alter-
nate day
6 months Improved at 3
months
Similar
adverse events
on daily and
alternate day
regimens
Griggs 1993 Randomised 107 5 to 15 yrs Prednisone 0.
75 mg/kg/day
Aza-
thiaoprine 2.5
mg/kg/day
18 months
12 months
Strength and
function im-
proved
No additional
benefit of
azathioprine
Pradhan 2006 Open con-
trolled study
with par-
ticipants ran-
domised in 2:
1
proportion, to
prednisolone
(+ multivi-
tamins) treat-
ment group or
control (mul-
tivitamins
67
(44 in pred-
nisolone treat-
ment group)
(23 in control
group)
Mean ages 8.8
and 8.1 yrs in
prednisolone
and con-
trol groups, re-
spectively
Participants
were enrolled
into the study
when they had
started falling
several times
Pred-
nisolone 0.75
mg/kg daily
2 yrs or longer
un-
til completely
wheelchair-
dependent
Of the 44 par-
ticipants
in the pred-
nisolone treat-
ment group,
24 dropped
out because of
adverse effects
and treatment
was stopped in
a fur-
ther 5 partic-
24 of the 44
patients in the
prednisolone
group
dropped out
because of ad-
verse effects;
14 dropped
out because of
excessive
weight gain,
12 within the
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Table 2. Excluded randomised studies (Continued)
only)
Note: Data
from only a
subgroup (15/
44) of partic-
ipants in the
prednisolone-
treated group
who
did not drop
out because of
adverse effects
and improved,
were used for
comparison
with the con-
trol group
during the day
and had ap-
preciable diffi-
culty in rising
from the floor
(Gowers’ sign
time of more
than 10 sec-
onds)
ipants because
of no improve-
ment
in power. Of
the remaining
19, only 15
participants in
the treatment
group
could be fol-
lowed up reg-
ularly for 2 yrs
and then up
to wheelchair-
de-
pendent stage;
data from only
these 15 par-
ticipants was
used for com-
parison
with the con-
trol group
In
this subgroup
of 15 partici-
pants from the
prednisolone
group,
the mean age
of becoming
wheelchair-
dependent
was 169 ± 9
months com-
pared to 132
± 8 months
in the control
group
3 months of
start-
ing treatment;
4 dropped out
because of tu-
berculosis and
2 because of
recurrent in-
fections
Reitter 1995
(Data
reported
in Dubowitz
2000)
Double-blind 100 5 until ambu-
lant
Prednisone 0.
75 mg/kg/day
DFZ 0.9 mg/
kg/day
2 yrs Muscle func-
tion stabilised
Excessive
weight gain in
prednisolone
group;
cataracts in
27% of DFZ
group
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Table 2. Excluded randomised studies (Continued)
Vasanth 1996
(published as
abstract only)
RCT
of prednisone,
ayurvedic
drug and
placebo
28 Not reported Prednisone
1 mg/kg/day
7 months Stability
in prednisone
group; deteri-
oration in the
other two
groups
”mild weight
gain“ in pred-
nisolone
group
Vasanth 1996
(unpublished
data provided
by Dr AB Taly
National
Insti-
ture of Men-
tal Health &
Neuro-
Sciences, Ban-
galore)
Randomised,
non-blinded
trial compar-
ing pred-
nisone with
a combination
of ayurvedic
drugs (partici-
pants who had
been given
placebo in the
initial part of
the study, were
put
on ayurvedic
drug
treatment)
128
(32 on pred-
nisone treat-
ment, and 96
on ayurvedic
drug
treatment)
Not reported Prednisone
1 mg/kg/day
2 yrs
(2-yr follow-
up data avail-
able for only
18/32 partic-
ipants in the
pred-
nisone group
and 29/96 in
the ayurvedic
treatment
group)
Strength and
func-
tion not statis-
tically differ-
ent in the 2
groups at 2 yrs
Of the boys
who lost walk-
ing
ability, mean
age of loss of
ambulation in
13 boys in the
prednisone
group was 11.
88 (SD 2.7)
yrs and 10.97
(SD 2.2) yrs in
the 42 boys in
the ayurvedic
treatment
group
”Most
children had
weight gain
and developed
striae“
DFZ: deflazacort: RCT: randomised controlled trial; SD: standard deviation; yr: year
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A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Disease Group Specialized Register (CRS) search strategy
#1 duchenne [REFERENCE] [STANDARD]
#2 MeSH DESCRIPTOR Adrenal Cortex Hormones Explode All [REFERENCE] [STANDARD]
#3 prednisone or prednisolone or deflazacort [REFERENCE] [STANDARD]
#4 steroid or steroids or corticosteroid or corticosteroids or glucocorticoid [REFERENCE] [STANDARD]
#5 steroid or steroids or corticosteroid or corticosteroids or glucocorticoid [REFERENCE] [STANDARD]
#6 #2 or #3 or #4 or #5 [REFERENCE] [STANDARD]
#7 #1 and #6 [REFERENCE] [STANDARD]
#8 (#1 and #6) AND (INREGISTER) [REFERENCE] [STANDARD]
Appendix 2. CENTRAL search strategy
#1 (duchenne NEAR dystrophy)
#2 steroid OR corticosteroid OR prednisone OR prednisolone OR deflazacort OR ”adrenal cortex hormone“ OR ”adrenal cortex
hormones“
#3 (#1 AND #2)
Appendix 3. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) <1946 to February Week 1 2016>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (405759)
2 controlled clinical trial.pt. (90039)
3 randomized.ab. (302966)
4 placebo.ab. (154812)
5 drug therapy.fs. (1817824)
6 randomly.ab. (214567)
7 trial.ab. (312188)
8 groups.ab. (1358843)
9 or/1-8 (3445960)
10 exp animals/ not humans.sh. (4184674)
11 9 not 10 (2934178)
12 Duchenne muscular dystrophy/ or (Duchenne$ adj3 Dystrophy).tw. (8530)
13 (steroid$ or corticosteroid$).mp. (332729)
14 Adrenal Cortex Hormones/ (56962)
15 PREDNISONE/ or Prednisone.tw. (45973)
16 PREDNISOLONE/ or Prednisolone.tw. (38806)
17 DEFLAZACORT/ or deflazacort.mp. (457)
18 or/13-17 (419754)
19 11 and 12 and 18 (234)
20 remove duplicates from 19 (231)
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Appendix 4. EMBASE (OvidSP) search strategy
Database: Embase <1980 to 2016 Week 07>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (46034)
2 double-blind procedure.sh. (126073)
3 single-blind procedure.sh. (21489)
4 randomized controlled trial.sh. (392427)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1220611)
6 trial.ti. (192615)
7 or/1-6 (1367162)
8 (animal/ or nonhuman/ or animal experiment/) and human/ (1439993)
9 animal/ or nonanimal/ or animal experiment/ (3483059)
10 9 not 8 (2890621)
11 7 not 10 (1258007)
12 limit 11 to embase (1039155)
13 Duchenne Muscular Dystrophy/ (11290)
14 13 or (duchenne* adj3 dystrophy).mp. (13716)
15 (steroid$ or corticosteroid$).mp. (545220)
16 Corticosteroid Therapy/ (34287)
17 PREDNISONE/ or Prednisone.mp. (142485)
18 PREDNISOLONE/ or Prednisolone.mp. (109310)
19 deflazacort.mp. or DEFLAZACORT/ (1949)
20 or/15-19 (710093)
21 12 and 14 and 20 (126)
22 remove duplicates from 21 (124)
Appendix 5. CINAHL Plus (EBSCOhost) search strategy
Tuesday, February 2016 8:48:54 AM
S27 S18 and S26
S26 S19 and S25
S25 S20 or S21 or S22 or S23 or S24
S24 deflazacort
S23 (”prednisolone“) or (MH ”Prednisolone“)
S22 (”prednisone“) or (MH ”Prednisone“)
S21 (MH ”Adrenal Cortex Hormones“)
S20 (steroid* or corticosteroid*)
S19 (Duchenne and dystrophy) or (MH ”Duchenne Muscular Dystrophy“)
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17
S17 ABAB design*
S16 TI random* or AB random*
S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial
or sham? or dummy) )
S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or
experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) )
S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) )
S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind*
or mask*) )
S11 PT (”clinical trial“ or ”systematic review“)
S10 (MH ”Factorial Design“)
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S9 (MH ”Concurrent Prospective Studies“) or (MH ”Prospective Studies“)
S8 (MH ”Meta Analysis“)
S7 (MH ”Solomon Four-Group Design“) or (MH ”Static Group Comparison“)
S6 (MH ”Quasi-Experimental Studies“)
S5 (MH ”Placebos“)
S4 (MH ”Double-Blind Studies“) or (MH ”Triple-Blind Studies“)
S3 (MH ”Clinical Trials+“)
S2 (MH ”Crossover Design“)
S1 (MH”RandomAssignment“) or (MH”RandomSample“) or (MH”Simple RandomSample“) or (MH”StratifiedRandomSample“)
or (MH ”Systematic Random Sample“)
Appendix 6. LILACS (IAHx) search strategy
(Duchenne) and (prednisone or prednisolone or deflazacort or steroid or steroids or corticosteroid or corticosteroids or glucocorticoid
or ”adrenal cortex hormone“ or ”adrenal cortex hormones“) and ((PT:”Randomized Controlled Trial“ or ”Randomized Controlled
trial“ or ”Ensayo Clínico Controlado Aleatorio“ or ”Ensaio Clínico Controlado Aleatório“ or PT:”Controlled Clinical Trial“ or ”Ensayo
Clínico Controlado“ or ”Ensaio Clínico Controlado“ or ”Random allocation“ or ”Distribución Aleatoria“ or ”Distribuição Aleatória“
or randon$ or Randomized or randomly or ”double blind“ or ”duplo-cego“ or ”duplo-cego“ or ”single blind“ or ”simples-cego“ or
”simples cego“ or placebo$ or trial or groups) AND NOT (B01.050$ AND NOT (humans or humanos or humanos)))
Appendix 7. Trials registers search strategy
Duchenne AND steroids
F E E D B A C K
Feedback from Luca Bello, Postdoctoral Fellow, University of Padua, Italy, 16 May 2016
Summary
Results from a 2015 paper by Bello et al. are not included in this review. In this study, the authors report that in a large observational
study of 340 boys with Duchenne muscular dystrophy (DMD) (CINRG Duchenne Natural History Study), participants treated ≥
1 year with glucocorticoids (GCs) while ambulatory (n = 252/340) showed a 3-year median delay in loss of ambulation (LoA) (p <
0.001). Participants aged 2 to 28 years at baseline were recruited in 20 CINRG centers in the USA, Canada, Argentina, Sweden, Italy,
Israel, India, and Australia. Average dose was lower for daily prednisone or prednisolone (0.56 mg/kg/day, 75% of recommended) than
daily deflazacort (0.75 mg/kg/day, 83% of recommended, p<0.001), and non-daily treatment was more common for prednisone or
prednisolone (37%) than deflazacort (3%). In a Cox regression analysis adjusted for dose and regimen, deflazacort was associated with
a lower yearly risk of LoA than prednisone or prednisolone (HR 0.294 ± 0.053 vs. 0.490 ± 0.08, p=0.003). In participants treated
with a daily regimen, a later median LoA was observed with deflazacort compared to prednisone or prednisolone (13.9 years vs. 11.2
years). Deflazacort showed higher frequencies of reported growth delay (p<0.001), Cushingoid appearance (p=0.002), and cataracts
(p<0.001), but not of weight gain. Although this was a non-randomized, observational study, at risk of bias from potential differences
in standards of care because of geographical location and age, we feel that the important results described therein should have been
included in this review, along with those of other large observational studies.
Do you have any affiliation with or involvement in any organisation with a financial interest in the subject matter of your
comment?
I was the first author of the paper mentioned in my comment, which was written during a research fellowship at Children’s National
Medical Center in Washington DC. I also write on behalf of the other authors of said paper.
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Reply
The 2015 paper by Bello et al was published after the initial literature and trial search was conducted for this review in February 2015.
Cochrane practice requires that searches for all relevant databases be run (or re-run) within 12 months before publication of the review
or review update. The completion date of this review was very close to this timeframe (within one month). As such a late update search
was performed, we included all new RCTs identified within the year that met the inclusion criteria. The observational study by Bello
was noted and given its large size was of interest. However, as a non-randomized study it did not meet our inclusion criteria and the
conclusions of the study mirrored those of earlier long-term observational studies that were already discussed. As the study provided
supporting evidence to already presented data it was not included at such a late editorial stage. However, it is of interest to future
updates and we have listed the study and another non-randomised study identified in the final search as ‘Studies awaiting classification’
for consideration when the review is next updated.
Contributors
Emma Matthews and co-authors, Rosaline Quinlivan (Cochrane Neuromuscular Co-ordinating Editor), Brian Dickie (Cochrane
Neuromuscular Feedback Editor)
WH A T ’ S N E W
Last assessed as up-to-date: 16 February 2016.
Date Event Description
26 May 2016 Amended Two observational studies added to those awaiting assessment. For consideration
in future update
26 May 2016 Feedback has been incorporated Feedback incorporated 26 May 2016
H I S T O R Y
Protocol first published: Issue 3, 2002
Review first published: Issue 2, 2004
Date Event Description
16 February 2016 New citation required and conclusions have changed Review authors expanded the scope of the review at
this update to include comparisons of corticosteroids
and dosing regimens.We included three trials compar-
ing different corticosteroids or dosing regimens and
one new published trial comparing corticosteroid and
placebo. We included two previously excluded ab-
stracts thatmet selection criteria, as this is current prac-
tice
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(Continued)
16 February 2016 New search has been performed Search updated to February 2016. Tony Swan and
Mike Pike withdrew from authorship; Ruth Brassing-
ton joined the authors. Review authors updated the
methodology and assessed all studies using the current
Cochrane ’Risk of bias’ tool. We added ’Summary of
findings’ tables
26 May 2008 Amended Converted to new review format.
14 November 2007 New citation required and conclusions have changed We updated the searches of the Neuromuscular Dis-
ease Trials Register (August 2006), MEDLINE (July
2007), EMBASE (August 2006), CINAHL (August
2006) and LILACS (August 2006). We identified one
randomised controlled trial which fulfilled the inclu-
sion criteria. Another new randomised controlled trial
was identified, but did not meet the inclusion criteria,
and is described in this update. Twelve new non-ran-
domised studies were identified, and are tabulated and
discussed in this update
C O N T R I B U T I O N S O F A U T H O R S
AM wrote the first draft of the original review, selected studies, assessed methodological quality and extracted the data, which the
Review Group Co-ordinator checked. TK selected studies and assessed their quality. AS gave statistical advice and helped with inference
of data. All four authors (AM, TK, MP, AS) approved the final text.
For this update EM, AM and TK selected new studies. EM and RB assessed risk of bias, extracted data and drafted additional sections
of the review. RB entered outcome data into RevMan, which EM checked. FJ provided statistical advice. TK and AM provided advice
and commented on the draft.
D E C L A R A T I O N S O F I N T E R E S T
Dr Emma Matthews has no conflicts of interest.
Dr Ruth Brassington is Managing Editor of Cochrane Neuromuscular, of which The National Institute for Health Research (NIHR)
is the largest single funder. The NIHR provided an incentive award to Cochrane Neuromuscular for the updating of this review (see
Acknowledgements). A grant from the Motor Neurone Disease Association to Cochrane Neuromuscular contributed to her salary in
2011-2015. She has no financial conflicts of interest. She withdrew from the later stages of the editorial process of this review.
Dr Thierry Kuntzer has no conflicts of interest.
Fatima Jichi has no known conflicts of interest.
Dr Adnan Y Manzur, at the time of preparation and submission of the protocol for this review was the principal investigator of a
proposed UK multicentre trial of prednisolone in Duchenne muscular dystrophy. However, this trial was not funded. Currently, Dr
Manzur is the lead clinician of the UK North Star Clinical Network for Neuromuscular Disorders. The clinicians on this clinical
network have a consensus on approach to use of corticosteroids (prednisolone) and plans for future collaboration to audit and modify
clinical practice in line with available evidence.
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S O U R C E S O F S U P P O R T
Internal sources
• Ruth Brassington, UK.
Employed as Managing Editor of Cochrane Neuromuscular by University College London Hospitals (UCLH) NHS Foundation
Trust. Her work on this review was supported by NIHR under its Cochrane Incentive Award scheme (award number 13/175/49) and
through Cochrane Review Group Infrastructure funding to Cochrane Neuromuscular
• Fatima Jichi, UK.
UCL School of Life & Medical Sciences, Joint Research Office, University College London, London, UK
External sources
• Emma Matthews, UK.
This work was supported by NIHR under its Cochrane Incentive Award scheme (award number 13/175/49)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Tony Swan and Mike Pike withdrew from authorship at this 2016 update; Ruth Brassington joined as an author.
At this update, we extended the scope of the review to include comparisons of corticosteroids and of dosing regimens. We added
quality of life and pulmonary function as outcome measures at a previous update and updated the methods in this version of the review
accordingly. We revised the objectives to reflect this change and to better reflect specified outcomes.
We added additional adverse events to those specifically listed in the Types of outcomes.
We updated the methods section according to Methodological Expectations of Cochrane Intervention Reviews (MECIR) guidance.
We used the current Cochrane ’Risk of bias’ tool and included ’Summary of findings’ tables. We extended the searches to clinical trials
registries.
We used a random-effects meta-analysis throughout, regardless of the presence of heterogeneity.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [administration & dosage; adverse effects; ∗therapeutic use]; Glucocorticoids [administration & dosage;
adverse effects; ∗therapeutic use]; Muscle Strength [∗drug effects]; Muscular Dystrophy, Duchenne [∗drug therapy]; Prednisolone
[therapeutic use]; Prednisone [therapeutic use]; Pregnenediones [administration&dosage; therapeutic use];Quality of Life; Randomized
Controlled Trials as Topic; Walking
MeSH check words
Humans; Male
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